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Abstract 
 
Variability in blood pressure (BP) may influence ischaemic stroke outcomes in addition 
to mean BP. However, how best to measure BP variability (BPV) and whether different 
measurements are equivalent is unknown, as is whether treatment can reduce BPV. 
This thesis aimed to investigate relationships between BP and BPV measurements 
from different devices in patients with ischaemic cerebrovascular disease, 
relationships between BPV and stroke severity, and whether antihypertensive 
medications can reduce BPV. 
 
Three trials that recruited patients following an ischaemic cerebrovascular event 
provided data. Correlations and limits of agreement between mean BP and BPV from 
different measurement devices were assessed. Relationships between baseline BPV 
and stroke severity were investigated, along with differences in baseline BPV in those 
treated with calcium channel blockers (CCB) or renin-angiotensin system inhibitors. A 
feasibility trial was developed to compare the effects of these medication classes on 
reduction of BPV post stroke. 
 
BP from daytime ambulatory monitoring was significantly lower than home BP 
monitoring and BPV values from different devices were unrelated. There was an 
inverse relationship between baseline BPV and stroke severity, with BPV increased in 
lacunar infarction. There was no difference in baseline BPV with the medication 
regimens specified above. Recruitment to the feasibility trial was insufficient due to 
patient ineligibility, but a reduction in BPV over three month follow-up was 
demonstrated.  
 
In patients with ischaemic cerebrovascular disease, BP and BPV recorded using 
different devices are not equivalent. Work to standardise BPV measurement and 
establish if any method is clinically superior is required. Treatment to reduce BPV may 
particularly benefit certain stroke patients, yet establishing that it is possible to target 
BPV, and doing so improves outcomes, is prerequisite. The feasibility trial in this thesis 
requires modification to be scaled up, but a definitive trial could be successful if 
recruitment were improved.
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INTERACT-2 Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage 
Trial (second) 
IST-3  Third International Stroke Trial 
LACS  Lacunar stroke 
LIFE  Losartan Intervention For Endpoint reduction in hypertension (trial) 
MAP  Mean arterial pressure 
MH  Masked hypertension 
MI  Myocardial infarction 
MiND-B Motor Neuron Disease Behavioural Instrument 
MMD  Maximum-minimum difference 
MoCA  Montreal Cognitive Assessment 
MRC  Medical Research Council (trial) 
MRI  Magnetic resonance imaging 
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mRS  Modified Rankin score 
NHS  National Health Service 
NIHSS  National Institutes of Health Stroke Scale 
NINDS  National Institute of Neurological Disorders and Stroke 
NNUH  Norfolk and Norwich University Hospital 
OCSP  Oxford Community Stroke Project classification 
OR  Odds ratio 
PACS  Partial anterior circulation stroke 
PATS  Post-stroke Antihypertensive Treatment Study 
POCS  Posterior circulation stroke 
PROGRESS Perindopril Protection Against Recurrent Stroke Study 
RCT  Randomised controlled trial 
RR  Relative risk 
SBP  Systolic blood pressure 
SCAST  Scandinavian Candesartan Acute Stroke Trial 
SD  Standard deviation 
SHEP  Systolic Hypertension in the Elderly Program(trial) 
SITS-ISTR Safe Implementation of Thrombolysis in Stroke – International Stroke 
Thrombolysis Register 
SPRINT  Systolic Blood Pressure Intervention Trial 
SPS3  Secondary Prevention of Small Subcortical Strokes (trial) 
TACS  Total anterior circulation stroke 
TIA  Transient ischaemic attack 
TOAST  Trial of Org 10172 in Acute Stroke Treatment 
VA  Veterans Association 
VIM  Variation independent of the mean 
WCH  White coat hypertension 
WHO  World Health Organisation 
X-CELLENT Natrilix SR Versus Candesartan and Amlodipine in the Reduction of 
Systolic Blood Pressure in Hypertensive Patients (trial) 
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1 Introduction 
 
Stroke is an important health issue both globally and in the UK [1, 2]. The last 20-30 
years have seen several major advances in stroke care, such as the creation of 
specialist stroke units and the development of acute reperfusion treatment strategies 
[3-5]. However, in spite of these developments stroke remains a major cause of 
morbidity and mortality [2, 6]. Raised blood pressure (BP) is recognised to be one of 
the major modifiable risk factors for stroke, with extensive evidence demonstrating 
that treatment aimed at reducing BP confers a reduced risk of both first episode and 
recurrent stroke [7, 8]. Furthermore, it is suggested that the relationship between BP 
and cardiovascular risk is linear (at least to a lower threshold of 115/75mmHg) [9], but 
with regard to stroke the relationship may not be this straightforward. 
 
Raised BP (>140/90mmHg) is frequently demonstrated in the hours to days following a 
cerebrovascular event [10], yet usually falls without specific intervention in the 
subsequent days to weeks [11]. The exact mechanism underlying this observation is 
uncertain and it is likely a multifactorial process. Interestingly, trials that have 
investigated intervening to reduce BP in the acute phase of ischaemic stroke have not 
demonstrated any benefit from such intervention in terms of mortality or stroke 
recovery, with limited data suggesting that doing so may be harmful [11]. This 
observation may relate to one of the proposed mechanisms underlying the rise in BP 
seen in acute stroke. Cerebral autoregulation allows the adjustment of cerebral blood 
flow (CBF) to match metabolic demand [12]. However, cerebral autoregulation is 
dysfunctional following stroke [13], leading to an increased dependence on systemic 
BP for the maintenance of adequate CBF. In this context it could be hypothesised that 
rapid changes in systemic BP levels (i.e. BP variability (BPV)), rather than simply the 
absolute BP level, may be the most important factor. 
 
There is a growing body of evidence examining the prognostic importance of BPV, with 
the majority of data suggesting that increased BPV is an independent risk factor for 
cardiovascular death, coronary heart disease events, and stroke events in addition to 
mean BP [14]. Further work focusing on BPV following ischaemic stroke indicates 
associations between increased BPV and both adverse stroke outcomes [15], and the 
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risk of stroke recurrence [16]. However, there is inconsistency in the approach to 
defining BPV in the literature due to variability being measured over different 
timescales and calculated using multiple techniques [17]. This inconsistency is 
underscored by a lack of data directly comparing different measures of BPV and 
uncertainty regarding which is most relevant. Furthermore, much of the evidence 
regarding the clinical importance of BPV in relation to stroke risk and outcomes has 
come from post hoc analysis of existing trial data. Whilst some of this evidence 
suggests that it may be possible and desirable to reduce BPV in patients with stroke, 
this has not been adequately investigated. Consequently, the role of BPV in acute 
stroke and secondary prevention is a subject of current interest and debate. 
 
The first part of this thesis will concentrate on the measurement of BPV using different 
techniques, and the relationships between these different techniques and durations of 
BP recording, in patients with a recent cerebrovascular event. In chapter four, different 
out-of-office BP measurement techniques will be compared for their equivalence. 
Chapter five will then go on to investigate differences in variability from beat-to-beat 
BP measurements compared with other short and medium-term variability measures. 
The second part of the thesis will investigate the potential of BPV as a therapeutic 
target following an ischaemic cerebrovascular event. In chapter six the relationships 
between BPV and stroke severity will be investigated and whether any subgroup of 
stroke patients in particular might benefit from treatment intended to reduce BPV will 
be discussed. Chapters seven and eight will then explore if there are differences in the 
effect on BPV between commonly used antihypertensive medication classes, the 
former using a cross-sectional analysis of trial data and the latter presenting a 
feasibility trial comparing two different antihypertensive medication classes. 
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2 Background 
 
2.1 Stroke 
 
2.1.1 Definition 
 
Stroke is defined as the presence of rapidly developing focal neurological dysfunction 
of presumed vascular origin [18-20]. This incorporates events due to cerebral 
infarction (which account for over 80% of strokes), primary intracerebral haemorrhage 
(ICH), and subarachnoid haemorrhage [18, 21]. Historically, the definition has also 
included reference to symptom duration. The World Health Organisation (WHO) 
definition, widely used for the last 40 years, states that symptoms should persist for 
over 24 hours or result in death to qualify as stroke [20], with episodes of focal 
neurological deficit resolving before 24 hours traditionally being classified as transient 
ischaemic attack (TIA) [22, 23]. However, the increased use of neuroimaging in the 
investigation of acute stroke and TIA has challenged this notion. Firstly, although non-
contrast computed tomography (CT) is highly sensitive for detecting acute 
haemorrhage, up to 60% of patients with cerebral infarction will have no acute 
ischaemic changes on imaging in the first few hours after onset [24]. Secondly, 
between 30-50% of patients whose symptoms resolve within 24 hours will have 
evidence of restricted diffusion lesions consistent with acute infarction on magnetic 
resonance imaging (MRI) [25]. Consequently, revised ‘tissue-based’ classifications of 
both stroke and TIA have been proposed. They define TIA as a transient episode of 
neurological dysfunction of vascular origin without any acute abnormality on 
neuroimaging [18, 23, 25], whereas stroke is an acute focal neurological deficit with 
radiological evidence of acute infarction or non-traumatic haemorrhage consistent 
with the symptoms, or a clear clinical syndrome of infarction without acutely abnormal 
imaging [24]. Modern definitions also acknowledge that stroke and TIA can affect the 
spinal cord or retina as well as cerebral tissue.  
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2.1.2 Epidemiology 
 
Cerebrovascular disease is a major global health issue. Statistics from the WHO show 
that in 2008 30% of deaths worldwide were attributable to cardiovascular disease, of 
which a third were caused by cerebrovascular disease [1]. In the UK stroke is the fourth 
most common cause of death, accounting for 7% of deaths annually [2], with a 
reported age-standardised incidence of 115-160 events per 100,000 population per 
year [2, 26]. Over 1.2 million people are living with the effects of stroke and over 50% 
of stroke survivors remain dependent on others for assistance with their activities of 
daily living after discharge from hospital [2, 19], making it the third leading cause of 
disability [6]. Consequently, stroke represents a significant burden to the UK economy 
costing around £1.7 billion per annum to the National Health Service (NHS) directly, 
with additional costs, for example of lost productivity, meaning that the overall cost is 
nearer to £9 billion annually [2].  
 
The epidemiology of stroke in the UK has changed in the last 40-50 years. A study of 
stroke incidence in Oxfordshire between 1981 and 2004 demonstrated a decline in 
age-specific incidence in the region of 30% [26]. However, this reduction may have 
plateaued, with the 2010 Global Burden of Disease Study indicating a slower decline of 
approximately 20% in the 20 years since 1990 and little change from 2005 to 2010 
[27]. This change in incidence reflects significant reductions in major cardiovascular 
risk factors in the population, such as smoking rates and hypertension, driven by 
improvements in primary cardiovascular preventative treatments [6, 26]. Stroke 
mortality has also decreased, falling by around 45% from 1990 to 2013, and this is due 
in part to the reduced incidence [6]. However, it is also due to significant 
improvements in acute stroke care, including the introduction of specialist ‘stroke 
units’ for the provision of multidisciplinary care and rehabilitation [3], faster access to 
specialist stroke physician and therapist assessments [28], and the introduction of 
reperfusion therapies for acute ischaemic stroke (initially thrombolysis and more 
recently mechanical thrombectomy) [4, 5]. In contrast, as more people are surviving 
stroke, the disease prevalence has increased by around 30% during this period [27]. 
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The successful impact of advances in acute care and primary prevention strategies are 
mirrored by changes in secondary prevention. Data from the Oxfordshire incidence 
study indicates that in stroke patients with previous TIA significantly greater 
proportions were on secondary prevention treatment in 2004 compared to 1981. This 
includes antihypertensives (around 60% compared to 35%), antiplatelets (around 60% 
compared to 5%), and lipid-lowering medication (around 35% compared to 0%) [26]. 
Estimates of the risk of recurrent stroke are lower in more recent cohorts compared to 
those from over 20 years ago and, whilst this may in part be attributable to 
methodological issues such as the definition of recurrent events, it also demonstrates 
the efficacy of more widespread secondary prevention [29]. Nevertheless, recurrent 
events remain common, with the risk of stroke in the three months following a TIA 
approaching 20% and roughly a 25% cumulative risk of recurrent stroke in the five 
years following a first event [2, 29]. Furthermore, recurrent events tend to be more 
severe, with a mortality rate nearly double that of first events and an increased risk of 
poor functional outcome at 90 days [30, 31]. As a result of this, and the fact that the 
reperfusion therapies are not viable for all patients with acute stroke (around 10% of 
patients in the UK receive thrombolysis [21, 28]), there remains room for improvement 
in the treatment and prevention of stroke and a need for further research to drive this 
improvement. 
 
2.1.3 Pathophysiology 
 
In cases of cerebral infarction there is vessel obstruction leading to reduced blood flow 
which lasts sufficiently long to cause irreversible damage. Multiple mechanisms can 
lead to the obstruction and can be divided according to the Trial of Org 10172 in Acute 
Stroke Treatment (TOAST) classification (Table 1) [32]. Interruption of the blood supply 
results in insufficient oxygen and glucose delivery required for cell metabolism. This 
triggers a cascade of events, including cell membrane disruption characterised by 
potassium efflux and calcium influx, release of glutamate and other toxic substances 
(e.g. free radicals), inflammation with cytotoxic oedema, localised acidosis, and 
ultimately cell necrosis [33, 34]. There may be additional early or late cell damage 
secondary to apoptotic mechanisms triggered by inflammatory cytokines [33]. The 
degree of damage is dependent on the level of reduction in blood flow, with the 
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Table 1: Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification of acute 
ischaemic stroke [32]. 
Classification Criteria 
Large artery 
atherosclerosis 
Clinical findings of a cortical, brainstem, or cerebellar deficit. 
Normal neuroimaging/imaging showing a lesion >1.5cm in 
diameter consistent with symptoms. 
Evidence of occlusion in pre-cerebral arteries (e.g. carotid 
stenosis). 
Cardio-embolism 
As above with evidence of a high-risk source of cardio-
embolism, such as atrial fibrillation or left ventricular 
thrombus. 
Small artery 
occlusion (lacunar) 
Clinical lacunar syndrome. 
Normal neuroimaging/imaging showing a subcortical lesion 
<1.5cm in diameter. 
No evidence of large vessel or cardio-embolic disease. 
Supported by a history of hypertension or diabetes. 
Other determined 
cause 
Other confirmed abnormality on testing, such as vasculitis or 
hypercoagulable state. 
Undetermined 
cause 
One of the following: 
 two or more causes identified; 
 no cause identified; 
 incomplete investigation. 
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lowest flow found in the infarcted core (which is irreversibly damaged) and higher (but 
still abnormal) flows in the surrounding tissue known as the ischaemic penumbra [35]. 
Collateral blood supply to the penumbra contributes to blood flow to this area and 
cells within this region, despite being dysfunctional, remain viable for a short period. 
Salvage of the ischaemic penumbra by restoring perfusion is a key aim in the acute 
treatment of ischaemic stroke.  
 
The mechanism in ICH differs to ischaemic stroke. The most common cause of acute 
bleeding is rupture of a small vessel lipohyalinotic aneurysm secondary to chronic 
hypertensive vascular damage [34, 36, 37]. Other potential causes include, but are not 
limited to, chronic vascular damage due to cerebral amyloid angiopathy, structural 
pathologies like arteriovenous malformation, cavernous haemangioma, or saccular 
aneurysm, and the use of anticoagulant medications [37]. Following the acute bleed 
there is a similar inflammatory and cytotoxic cascade as in ischaemic stroke, but the 
mechanical impact of tissue oedema and the developing haematoma is probably the 
greater source of neuronal damage. Whether there is salvageable penumbral tissue in 
ICH is debated [37]. Currently the immediate goals of treatment are to arrest the 
bleeding and reduce haematoma expansion. 
 
2.2 The Relationship between Stroke and Blood Pressure 
 
2.2.1 Historical Aspects 
 
Hypertension has been recognised as a risk factor for cardiovascular disease for almost 
100 years, yet the medical community did not immediately accept the necessity of its 
treatment. Shortly after the development of the sphygmomanometer in the late 19th 
century American insurance companies began including BP measurement in their 
assessments [38]. By the mid-1920’s they had published reports that linked above 
average BP values with an increased risk of death. In 1928 the term ‘malignant 
hypertension’ was coined for a syndrome of very high BP (>200/100mmHg) and 
retinopathy which was noted to lead to death within months from heart failure, stroke 
or kidney failure unless treatment to lower BP was instigated [39]. However, it would 
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be another 30 years before attitudes to the treatment of so-called ‘benign 
hypertension’ would comprehensively shift. A key event in this process was the 
discovery of chlorothiazide in the late 1950’s [40]. This was the first effective oral 
antihypertensive not hampered by excessive side effects and its discovery started to 
shift the risk-benefit balance in favour of treatment. The second key event was the 
publication, beginning with reports from the Framingham Heart Study [41], of robust 
observational data demonstrating a strong correlation between raised BP and 
subsequent complications such as heart disease, stroke, and kidney failure.  
 
2.2.2 Primary Prevention - Observational Studies 
 
The observational evidence linking hypertension to cardiovascular disease is now 
substantial and the consistency of the evidence strongly suggests a causal relationship. 
Pooled analysis of the data, amounting to over 400,000 participants with an average 
follow-up period of 10 years, demonstrated that in patients with no previous history of 
cardiovascular disease the relationship between BP and cardiovascular risk is direct, 
continuous and linear [9]. Further pooled analysis incorporating additional data 
amounting to nearly one million participants corroborated this [42]. The relationship is 
stronger for stroke than ischaemic heart disease (IHD) or other vascular disease, with a 
reduction in BP of 10/5mmHg conveying a reduction in first ever stroke risk of 
approximately 30% [9, 43]. Although it has been demonstrated that this is not 
consistent across age groups, with larger hazard ratios (HR) for raised BP seen in 
patients under 60 years old compared to those over 80 years old [42], the greater 
incidence of stroke in older age groups means that the absolute benefit of lowering BP 
in these patients is at least similar, if not greater [43]. Interestingly, there does not 
appear to be a threshold at which lower BP is not associated with lower cardiovascular 
risk, although data for BP below 115/75mmHg is limited [9, 42, 43].  
 
2.2.3 Primary Prevention - Randomised Controlled Trials (RCT) 
 
Building on the observational evidence, multiple large and robust RCT have confirmed 
that BP reduction results in a decreased primary cardiovascular risk, in particular 
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stroke risk. Two of the earliest landmark RCT were the Veterans Association (VA) Co-
operative Study and the Hypertension Detection and Follow-up Program (HDFP) study 
[44]. The VA Co-operative Study was the first randomised, placebo controlled, double 
blind trial investigating the treatment of hypertension. 143 men with diastolic BP (DBP) 
between 115-129mmHg and 380 men with DBP between 90-114mmHg were 
randomised to treatment with hydrochlorothiazide (plus reserpine and hydralazine 
added stepwise if necessary) or placebo [45, 46]. For the group with severe 
hypertension the trial was terminated early [45]. After two years follow-up BP in the 
treatment group fell by 43/29.7mmHg and there were only two recorded severe 
complications compared to no change in BP and 27 severe complications in the 
placebo group. The results for the group with mild-moderate hypertension after a total 
of five years follow-up were also positive, but more modest [46]. These results were 
subsequently corroborated by the HDFP study which randomised 10,500 patients with 
DBP between 90-104 mmHg to stepped care or treatment as usual [47]. The stepped 
care group received standardised treatment (diuretic plus reserpine, hydralazine and 
guanethedine added in sequence if necessary) to lower DBP to <90mmHg. Deaths from 
cardiovascular disease were 26% lower in the intervention group, demonstrating the 
benefit of treating patients with mild-moderate diastolic hypertension. The Systolic 
Hypertension in the Elderly Program (SHEP) trial addressed the question of the 
importance of isolated raised systolic BP (SBP) [48]. In this study 4736 patients with 
SBP >160mmHg but DBP <90mmHg were randomised to treatment (chlorthalidone ± 
atenolol) or placebo. Although some patients in the placebo group also received 
antihypertensive therapy with other agents during the trial, over the five-year follow-
up there was a greater reduction in SBP and a 36% lower risk of stroke in the 
intervention group. Systematic review of the major RCT confirms that lowering BP is 
beneficial for reducing the risk of primary cardiovascular disease, especially stroke 
(Tables 2-3) [7, 43, 49]. Furthermore, it is likely that BP reduction is the important 
factor irrespective of the particular therapy used to achieve it [43, 49], although 
whether antihypertensive medicines really are equivalent in relation to stroke will be 
discussed further in this thesis. 
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Table 2: Risk of stroke in selected randomised controlled trials evaluating 
antihypertensive medications vs. placebo [43]. 
Study 
Treatment Arm Placebo Arm Relative Risk ([RR] 
95% confidence 
interval (CI)) 
Events Total Events Total 
ACTION 82 3825 108 3840 0.63 (0.37 to 1.09) 
ACTIVE 1 379 4518 411 4498 0.71 (0.43 to 1.19) 
ADVANCE 215 5569 218 5571 0.96 (0.69 to 1.35) 
ANBPS 13 1721 22 1706 0.59 (0.30 to 1.16) 
Coope 20 419 39 465 0.57 (0.34 to 0.96) 
EUROPA 98 6110 102 6108 0.92 (0.53 to 1.60) 
EWPHE 32 416 48 424 0.68 (0.44 to 1.04) 
FEVER 177 4841 251 4870 0.41 (0.23 to 0.71) 
HDFP 102 5485 158 5455 0.64 (0.50 to 0.82) 
HYVET 51 1933 69 1912 0.79 (0.62 to 1.00) 
MRC older 101 2183 134 2213 0.76 (0.59 to 0.98) 
MRC young 60 8700 109 8654 0.55 (0.40 to 0.75) 
NAVIGATOR 105 4631 132 4675 0.43 (0.17 to 1.08) 
PREVENT 5 417 5 408 0.98 (0.29 to 3.35) 
SHEP 105 2365 162 2371 0.65 (0.51 to 0.83) 
STOP H 30 812 55 815 0.55 (0.35 to 0.85) 
Syst-China 45 1253 59 1141 0.63 (0.41 to 0.97) 
Syst-Eur 47 2398 77 2297 0.58 (0.41 to 0.84) 
TRANSCEND 112 2954 136 2972 0.63 (0.33 to 1.18) 
VA 6 254 23 257 0.26 (0.11 to 0.64) 
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Table 3: Relative risk of stroke per 10mmHg reduction in systolic blood pressure in 
selected randomised controlled trials evaluating intensive vs. less intensive blood 
pressure targets [7]. 
Study 
Intensive BP Target 
Arm 
Control Arm Relative Risk (95% 
CI) 
Events Total Events Total 
ABCD-H 9 237 9 233 0.97 (0.21 to 4.35) 
ACCORD 36 2362 62 2371 0.69 (0.52 to 0.92) 
BBB 8 1064 11 1064 0.75 (0.33 to 1.71) 
HOT 200 12,526 94 6264 1.22 (0.56 to 2.64) 
JATOS 52 2212 49 2206 1.06 (0.71 to 1.58) 
SPRINT 62 4678 70 4683 0.91 (0.70 to 1.19) 
VALISH 16 1545 23 1534 0.49 (0.15 to 1.60) 
 
BP denotes blood pressure; 95% CI, 95% confidence interval.
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2.2.4 Secondary Prevention 
 
It is reported that 50-60% of strokes can be attributed to uncontrolled hypertension, 
making this the most important modifiable risk factor for cerebrovascular disease [49, 
50]. So far I have concentrated on the primary prevention of stroke, but given that 
there are over 20,000 recurrent strokes annually in the UK lowering BP should also 
improve secondary prevention [18, 21]. This view is supported by observational data 
that shows an association between higher BP in the 12 months post-stroke and a 
greater risk of recurrence, and conversely that antihypertensive treatment is 
associated with lower rates of recurrence [50]. Fewer RCT have investigated BP 
lowering for secondary prevention, but both the Post-stroke Antihypertensive 
Treatment Study (PATS) and the Perindopril Protection Against Recurrent Stroke Study 
(PROGRESS) demonstrated a reduced risk of recurrent stroke in the region of 30% with 
intervention compared to placebo [51, 52]. A recent meta-analysis of secondary 
prevention RCT confirmed these reports (Table 4 and Figure 1) and also demonstrated 
that intensive BP lowering is beneficial for secondary prevention [8]. Patients were 
stratified according to the achieved level of SBP (<130mmHg, 130-140mmHg, or 
>140mmHg) and DBP (<85mmHg, 85-90mmHg, or >90mmHg). The risk of recurrent 
stroke was smallest for those in the lowest categories of SBP and DBP, linearly 
increasing with achieved BP level. This analysis supports the findings of the Secondary 
Prevention of Small Subcortical Strokes (SPS3) trial which was a dedicated RCT 
designed to assess the impact of intensive BP lowering on recurrent events after 
lacunar stroke in 3020 patients [53]. SPS3 reported a trend towards reduced rates of 
recurrent stroke in the group treated to target SBP <130mmHg, indicating that 
intensive BP lowering for secondary prevention is likely to be beneficial (Figure 2). 
 
2.2.5 Current Guidelines 
 
It is clear that treatment to lower BP has a beneficial effect on stroke risk (Figure 3) 
and this is reflected in guidelines, with some advocating intensive treatment to a 
target BP of <130/80mmHg [18, 54]. However, this is not a consensus 
recommendation. For example, the American Stroke Association (ASA) and the 
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Table 4: Risk of recurrent stroke in trials of antihypertensive medication vs. placebo. 
Data adapted from the meta-analysis by Katsanos et al. 2017 [8]. 
Study 
Treatment Arm Placebo Arm 
Risk Ratio (95% CI) 
Events Total Events Total 
Carter et al. 7 49 11 48 0.62 (0.26 to 1.47 
Dutch TIA 52 732 62 741 0.85 (0.60 to 1.21 
HOPE 13 500 23 513 0.58 (0.30 to 1.13) 
HSCSG 37 233 42 219 0.83 (0.55 to 1.24) 
Liu et al. 67 762 147 758 0.45 (0.35 to 0.59) 
Marti Masso 
and Lozano 
20 170 18 94 0.61 (0.34 to 1.10) 
PATS 159 2841 217 2824 0.73 (0.60 to 0.89) 
PRoFESS 880 10146 934 10186 0.95 (0.87 to 1.03) 
PROGRESS 307 3051 420 3054 0.73 (0.64 to 0.84) 
SCOPE 5 97 14 97 0.36 (0.13 to 0.95) 
TEST 74 372 69 348 1.00 (0.75 to 1.35) 
Total 1621 18953 1957 18882 0.73 (0.62 to 0.87) 
 
95% CI denotes 95% confidence interval.
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Figure 1: Meta-analysis of the effects of antihypertensive therapy following stroke on 
the risk of fatal and non-fatal recurrence [10].  
 
 
Figure 2: Probability of recurrent stroke, myocardial infarction (MI), or vascular death 
after randomisation in the intensive blood pressure target and standard blood 
pressure target arms of SPS3 [53]. 
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Figure 3: Standardised effects of a 10mmHg reduction in systolic blood pressure on 
cardiovascular outcomes incorporating data from primary and secondary prevention 
trials, and trials of intensive blood pressure lowering. Adapted from Ettehad et al. 2016 
[7]. RR denotes relative risk; 95% CI, 95% confidence interval. 
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European Society of Hypertension (ESH) are more cautious. Firstly, they note that trials 
drawing conclusions about intensive BP targets have not always successfully lowered 
BP beyond standard recommendations [55]. However, this criticism is not true of more 
recent trials, including SPS3 and the Systolic Blood Pressure Intervention Trial (SPRINT), 
which both achieved their pre-stated intensive BP reduction, and successfully showed 
an associated reduction in cardiovascular events and mortality [53, 56]. Secondly, the 
ASA and ESH cite a post-hoc analysis of PROGRESS which suggested that the 
effectiveness of secondary prevention diminished in line with baseline BP level, such 
that participants with baseline SBP <120mmHg gained no additional benefit from 
antihypertensive therapy [55, 57]. However, a meta-analysis of the benefit of 
antihypertensive treatment stratified by baseline BP level, incorporating a mixture of 
low and high-risk hypertensive subjects, contradicts this position [58]. This uncertainty 
relates to the debate about whether the relationship between BP and secondary 
stroke risk is linear or ‘J’ shaped, the latter implying that overly aggressive BP reduction 
could be harmful [59]. This idea has some logical basis given that autoregulatory 
mechanisms to maintain organ perfusion have both a lower and higher functional limit 
and that these limits can shift in the presence of chronic vascular disease [60, 61]. 
Further research into these issues is required and dedicated ongoing trials, such as the 
Stroke in Hypertension Optimal Treatment trial (ESH-CHL-SHOT [62]), should help to 
establish the optimum BP target for secondary stroke prevention. 
 
2.3 Blood Pressure in the Acute Phase of Stroke 
 
2.3.1 The Acute Hypertensive Response 
 
It is common for patients with an acute stroke (either infarct or ICH) to have BP 
>140/90mmHg, with between 60-84% of acute stroke patients found to have BP above 
this threshold within 24 hours of symptom onset [10, 63, 64]. Similar rates are 
reported for patients with acute TIA [65]. Only around half of these patients will be 
known to have hypertension prior to their cerebrovascular event [10, 11], leading to 
the hypothesis that there is an ‘acute hypertensive response’ related to stroke and TIA. 
Whilst the natural history of raised BP in TIA has not been reported, observational data 
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in stroke patients demonstrates that this acutely raised BP can decline without specific 
treatment from around 24 hours to 14 days post-event [11, 63, 66]. This suggests a 
possible stroke specific cause for the observed pattern. Multiple potential mechanisms 
have been suggested, including haematoma expansion in ICH, cerebral oedema and 
raised intracranial pressure, autonomic dysfunction, and abnormal cerebral 
autoregulation [11, 13, 63, 67, 68]. Perhaps the most important of these in ischaemic 
stroke is the latter. As a consequence of disordered cerebral autoregulation, CBF 
becomes dependent on systemic BP and therefore raised BP may be necessary to 
maintain perfusion of the ischaemic penumbra, with low BP potentially causing 
cerebral hypoperfusion and infarct expansion. This idea is supported by a meta-
analysis of observational studies investigating the prognostic impact of raised BP in 
acute stroke that demonstrated raised BP is associated with worse outcomes (either 
death or dependency) [69]. Retrospective review of data from the International Stroke 
Trial corroborated this conclusion and additionally showed that low BP is also a poor 
prognostic factor [70]. Consequently, the management of BP in the acute phase of 
stroke is of clinical interest as appropriate therapeutic intervention could potentially 
improve outcomes for stroke survivors.  
 
2.3.2 Management in Patients Receiving Thrombolysis 
 
For patients who receive thrombolysis raised BP can increase the risk of haemorrhage 
as a treatment complication. Retrospective review of the Third International Stroke 
Trial (IST-3) data showed that a higher baseline BP was associated with an increased 
risk of any early adverse event with an odds ratio (OR) of 1.05 (95% CI 1.01 to 1.09, 
p=0.01) [71]. This was primarily driven by an increased risk of symptomatic ICH (OR 
1.10 [95% CI 1.02 to 1.19, p=0.01]), which was the only other statistically significant 
association. Similarly, retrospective review of the Safe Implementation of Thrombolysis 
in Stroke – International Stroke Thrombolysis Register (SITS-ISTR) found that increased 
BP (measured at baseline, 2 hours post-onset and 24 hours post-onset) was linearly 
associated with an increased risk of symptomatic ICH. Furthermore, they reported a ‘U’ 
shaped relationship between BP level and mortality and 3 month independence [64]. 
As a result of this it is accepted that BP should be lowered to ≤185/110mmHg (the 
upper BP threshold required for inclusion in the first National Institute of Neurological 
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Disorders and Stroke (NINDS) trial) prior to administering thrombolysis and this is 
recommended in stroke guidelines [18, 19, 57]. However, whether to lower BP in 
patients not eligible for thrombolysis, and if so to what target level, is controversial. 
 
2.3.3 Management in Patients not Receiving Thrombolysis 
 
Interestingly, in their review of IST-3 Berge et al. observed that receiving BP lowering 
treatment in the first 24 hours after randomisation to thrombolysis or control resulted 
in a reduced risk of poor functional outcome at six months, irrespective of whether the 
patient received alteplase or placebo (OR 0.78 [95% CI 0.65-0.93, p=0.007]) [71]. The 
decision to give BP lowering treatment was according to local protocols. Participants 
receiving antihypertensives had a higher mean baseline SBP (159.7mmHg compared to 
152.5mmHg), but after 24 hours mean SBP in the groups had converged (147.8 mmHg 
with treatment and 144.1mmHg without). BP lowering treatment was also not 
associated with the development of early neurological deterioration (END) or early 
recurrent ischaemic stroke. However, these findings have not been replicated in RCT 
specifically designed to investigate the effect of lowering BP in the acute phase of 
ischaemic stroke (Table 5).  
 
Of the large dedicated trials the Acute Candesartan Cilexitil Therapy in Stroke Survivors 
(ACCESS) trial was the first, enrolling patients with ischaemic stroke and BP 
>200/110mmHg within 6-24 hours after admission (or >180/105mmHg 24-36 hours 
after admission) [72]. The trial was stopped early due to an increased mortality rate at 
12 months in the placebo group. However, BP was not significantly lowered by the 
intervention compared to control and mortality at 12 months was a secondary 
outcome. Neither of the pre-specified primary outcomes (mortality or functional status 
at three months) were reported, partly due to the recognition that the Barthel Index 
was not a suitable measure of functional outcome. In the Controlling Hypertension and 
Hypotension Immediately Post-Stroke (CHHIPS) trial 179 patients with any stroke and 
SBP >160mmHg were randomised within 36 hours of symptom onset to labetalol, 
lisinopril or placebo [66]. There was no difference in the primary outcome of death or 
dependency (defined as a modified Rankin score (mRS) >3) at 14 days (RR 1.03 [95% CI 
0.80 to 1.33, p=0.82]) despite a definite reduction in SBP (21mmHg with intervention
  
 
Table 5: Summary of main published trials of blood pressure lowering treatment in acute ischaemic stroke. Outcome figures presented are mean 
(standard deviation (SD)) or risk (95% CI). 
Trial N Intervention Control 
Treatment 
duration 
ICH eligible Outcome 
Bath 2000 
[73] 
37 
GTN patch within 5 days of 
onset 
Placebo 12 days Yes 
Day 1 BP reduction: 
13.0/5.2mmHg with intervention 
ACCESS 
2003 [72] 
339 
Candesartan, commenced 
24-36 hours after onset 
Placebo 7 days No 
Barthel index at 3 months: 
87.0 (22.9) vs. 88.9 (19.9) 
Eames 
2005 [74] 
37 
Bendroflumethiazide 
within 96 hours of onset 
Placebo 7 days No 
BP at 7 days: 
No significant differences 
Eveson 
2007 [75] 
40 
Lisinopril within 24 hours 
of onset 
Placebo 14 days No 
Change in NIHSS1 at 14 days: 
No significant differences 
CHHIPS 
2009 [66] 
179 
Labetalol or Lisinopril 
within 36 hours of onset 
Placebo 14 days Yes 
mRS ≥4 at 2 weeks  
RR 1.03 (0.80 to 1.33)* 
PRoFESS 
2009 [76] 
1360 
Telmisartan within 72 
hours of onset 
Placebo 2.5 years No 
mRS at 30 days: 
OR 1.03 (0.84 to 1.26) 
SCAST 
2011 [77] 
2029 
Candesartan within 30 
hours of onset 
Placebo 7 days Yes 
a) death/recurrent stroke or MI: HR 1.09 (0.84 to 
1.41) 
  
 
b) mRS at 6 months: 
OR 1.13 (0.97 to 1.32) 
CATIS 2013 
[78] 
4071 
Any treatment within 48 
hours of onset to achieve 
BP <140/90mmHg 
Not 
treated 
14 days No 
mRS ≥3 at 14 days or hospital discharge: 
OR 1.00 (0.88 to 1.14) 
RIGHT 
2013 [79] 
41 
GTN patch within 4 hours 
of onset 
No GTN Single dose Yes 
Difference in SBP at 2 hours: 
-18 (30) mmHg with intervention 
ENOS 2014 
[80] 
4011 
GTN patch within 48 hours 
of onset 
No GTN 7 days Yes 
mRS at 90 days: 
OR 1.01 (0.91 to 1.13) 
1National Institutes of Health Stroke Scale (NIHSS) 
*combined active treatment groups vs. placebo 
BP denotes blood pressure; ICH, intracerebral haemorrhage; GTN, Glyceryl trinitrate; NIHSS, National Institutes of Health Stroke Scale; mRS, modified 
Rankin score; MI, myocardial infarction; SBP, systolic blood pressure.
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vs. 11mmHg with placebo, p=0.04), though the trial did not meet its recruitment 
target. The Scandinavian Candesartan Acute Stroke Trial (SCAST) employed a similar 
study design to ACCESS, but with a lower threshold BP for inclusion [77]. Two thousand 
twenty-nine patients with any stroke within 30 hours of symptom onset and with SBP 
>140mmHg were randomised to candesartan or placebo. After seven days of 
treatment mean BP in the intervention group was 5/2mmHg lower. However, this 
difference was not sustained at the six month outcome point, nor was there any 
difference in composite vascular death/non-fatal myocardial infarction (MI)/non-fatal 
stroke (HR 1.09 [95% CI 0.84 to 1.41, p=0.52]). In fact there was a non-significant trend 
towards better six month functional outcome with placebo (OR 1.17 [95% CI 1.00 to 
1.38, p=0.048]). The China Antihypertensive Trial in Acute Ischemic Stroke (CATIS) 
investigated an intensive BP target rather than a specified treatment [78], enrolling 
4071 ischaemic stroke patients with SBP 140-220mmHg within 48 hours of onset. 
Those in the intervention arm had a greater BP reduction in the first 24 hours with the 
difference sustained at seven days. Despite this, there was no difference in the primary 
outcome of death or disability (mRS ≥3) at 14 days, nor was there any difference at 
three months. Finally, the Efficacy of Nitric Oxide in Stroke (ENOS) trial investigated 
glyceryl trinitrate (GTN) as the therapeutic agent [80]. GTN is a nitric oxide donor 
which, as well as having BP lowering properties, may be neuroprotective and inhibit 
apoptosis, thereby reducing ischaemic damage. The trial enrolled 4011 patients with 
any stroke within 48 hours of symptom onset and randomised them to transdermal 
GTN or placebo. As with other trials there was a greater BP reduction with intervention 
but this did not translate to a difference in functional outcome (assessed as the 
distribution of mRS at 90 days). Systematic review of these and additional studies, 
including a total of 17,011 patients, has confirmed the findings of the individual trials 
[11].  
 
Overall, there is no evidence of benefit for lowering BP in hyperacute ischaemic stroke 
and the data from SCAST suggests it may actually be harmful to do so. However, this 
may relate to methodological factors, specifically the timing of treatment initiation. 
Whilst subgroup analysis in CATIS suggested a possible improvement in functional 
outcome in those who commenced treatment >24 hours after symptom onset [78], 
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several trials have shown the opposite. In SCAST there was a non-significant finding 
that those who received treatment <6 hours after symptom onset had an improved 
functional outcome [77]. This was also reported as a statistically significant finding in 
ENOS, where it was a pre-specified secondary outcome [80]. Furthermore, a pilot trial 
for transdermal GTN administered within four hours of stroke onset reported a one 
point favourable shift in mRS at 3 months in the intervention group [79]. Although the 
trial was not powered for this outcome it is a potentially important finding that is being 
further investigated [81]. It is also interesting to note that larger BP reductions have 
been achieved with earlier treatment initiation (mean reduction -16.0/-15.0mmHg for 
patients receiving pre-hospital treatment compared to -7.3/-4.9mmHg for those 
commencing treatment >48 hours after onset) and this may underlie the differences in 
reported outcomes [11].  
 
2.3.4 Management in Patients with Intracerebral Haemorrhage 
 
It is also hypothesised that stroke subtype may be a relevant factor in the acute 
treatment of raised BP. Hypertension is the major risk factor for primary ICH. Chronic 
hypertension is associated with degenerative changes to penetrating arterioles that 
can lead to vessel rupture and haemorrhage, such as lypohyalinosis and Bouchard 
aneurysm formation [36, 37]. Two theories about the risk related to BP immediately 
following ICH have been proposed. Firstly, raised BP may inhibit haemostasis and 
propagate haematoma expansion. Secondly, as in ischaemic stroke, there may be a 
peri-haematomal penumbra that is vulnerable to low BP [82]. The first theory is 
supported by the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage 
Trial (INTERACT) which showed less haematoma expansion 24 hours after symptom 
onset with intensive management of BP (target of SBP <140mmHg) compared to 
standard management (target SBP of <180mmHg) [83]. However, the idea of a 
vulnerable peri-haematomal penumbra is not supported by data from the 
Intracerebral Haemorrhage Acutely Decreasing Arterial Pressure Trial 
(ICH-ADAPT). Using CT perfusion imaging this trial demonstrated that relative CBF in 
the peri-haematomal region is not reduced with intensive BP reduction (SBP 
<150mmHg) compared to standard management (SBP <180mmHg) [84]. Trials of 
intensive vs. standard BP reduction in acute primary ICH are summarised in Table 6.   
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Table 6: Summary of published trials of intensive blood pressure reduction compared 
to standard blood pressure lowering (according to guideline recommendations) in 
acute intracerebral haemorrhage. 
Trial N 
Recruitment 
window 
SBP targets 
(mmHg)* 
Primary 
outcome 
Result 
Koch 2008 
[85] 
42 <8 hours 
<110 vs. 
110-130 
END (NIHSS drop 
≥2 within 48 
hours) 
No significant 
difference 
INTERACT 
2008 [83] 
404 <6 hours 
<140 vs. 
<180 
Haematoma 
growth at 24 
hours 
13.7% vs. 36.3% 
(p=0.04) 
ICH-ADAPT 
2013 [84] 
75 <24 hours 
<150 vs. 
<180 
Perihaematoma 
relative CBF at 2 
hours 
0.86 vs. 0.89 
(p=0.18) 
INTERACT-2 
2013 [86] 
2839 <6 hours 
<140 vs. 
<180 
mRS ≥3 at 3 
months 
OR 0.87 (0.75 to 
1.01), p=0.06 
ATACH-2 
2016 [87] 
1000 <4.5 hours 
110-139 vs. 
140-179 
mRS ≥4 at 3 
months 
RR 1.04 (95% CI 
0.85 to 1.27), 
p=0.72 
*Mean arterial pressure (MAP) in Koch, SBP all other trials 
SBP denotes systolic blood pressure; END, early neurological deterioration; NIHSS, 
National Institutes of Health Stroke Scale; CBF, cerebral blood flow; mRS, modified 
Rankin score; OR, odds ratio; RR, relative risk; 95% CI, 95% confidence interval. 
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The two major trials (The second Intensive Blood Pressure Reduction in Acute Cerebral 
Haemorrhage Trial (INTERACT-2) and the second Antihypertensive Treatment of Acute 
Cerebral Hemorrhage (ATACH-2)) both failed to show a benefit to morbidity and 
mortality (defined as mRS ≥3 or ≥4 respectively) at three months with intensive BP 
lowering compared to standard management [86, 87]. However, in a pre-specified 
secondary outcome, INTERACT-2 did demonstrate a significant favourable shift in mRS 
with intensive BP lowering, suggesting a benefit in terms of functional outcome for 
survivors (OR 0.87 [95% CI 0.77 to 1.00, p=0.04]) [86]. 
 
2.3.5 Guideline Recommendations 
 
Current stroke guidelines reflect the uncertainty in the evidence base. For ischaemic 
stroke the recommendations for patients receiving thrombolysis have already been 
described, but for all other patients it is felt that BP lowering treatment should only be 
started in the first 24 hours after stroke onset if there is a hypertensive emergency 
with organ damage [18, 19, 57]. Only the ASA specifically mentions an upper BP 
threshold (220/120mmHg) [57]. For patients with ICH it is felt to be safe, and possibly 
beneficial, to aim for intensive BP reduction to a target SBP <140mmHg, provided that 
treatment can be instigated within six hours [18, 88]. Rather than the lack of evidence 
being related to the timing of initiation of treatment, an alternative explanation may 
be that it is not just the absolute BP level that matters in the acute phase of stroke. 
This will be discussed further in subsequent sections of this thesis where I will consider 
the concept of BPV and its relationship with stroke outcomes. 
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2.4 Blood Pressure Monitoring 
 
2.4.1 Office Measurement 
 
Controlling BP for primary and secondary stroke prevention relies on being able to 
accurately measure BP levels and establishing at what level BP treatment is of benefit. 
Whilst distinguishing normotension and hypertension with a specific threshold value is 
somewhat arbitrary due to the normal distribution of BP within the population and the 
continuous relationship between BP and cardiovascular risk, such categorisations are 
clinically useful. Based on the evidence from major trials SBP >140mmHg and/or DBP 
>90mmHg has traditionally been accepted as the point at which treatment benefits 
significantly outweigh any risks. However, the 2017 American Heart Association (AHA) 
guidelines recommend a lower threshold, citing recent evidence from observational 
studies demonstrating increased risks of stroke and coronary heart disease at BP levels 
between 120-139/80-89mmHg [54]. Currently recommended threshold values for 
clinic and out-of-office BP measurement methods are presented in Tables 7-8. 
 
Traditionally BP measurement has been undertaken using a manual 
sphygmomanometer, referred to as ‘office’ or ‘clinic’ BP measurement (CBPM) [89]. To 
ascertain the patient’s ‘usual’ BP repeated measurements on separate occasions are 
recommended as this mitigates against the natural variation in BP attributable to 
factors like change in circadian rhythm or seasonal variation [90]. CBPM is more 
complex than it may appear and its fallibility is recognised. Limitations include poor 
technique (e.g. not allowing the patient to rest several minutes before measuring, 
incorrect cuff size, not positioning the arm level with the heart), taking single 
measurements (often due to time constraints), observer bias, and observer terminal 
digit preference [89]. Furthermore, CBPM may not accurately represent the ‘usual’ BP 
in some patients. White coat hypertension (WCH) exists when the patient’s office BP is 
consistent with a diagnosis of hypertension, yet their out-of-office BP is within the 
normal range. Conversely, masked hypertension (MH) is where office BP is within the 
normal range yet out-of-office BP is consistent with a diagnosis of hypertension. 
Neither of these phenomena can be identified by CBPM alone and both are important  
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Table 7: Definitions of normotension and hypertension based on clinic blood pressure 
measurement from current guidelines [54, 91, 92]. Blood pressure category is defined 
according to the highest value, whether systolic or diastolic. 
 NICE (2011) ESH (2018) AHA (2017) 
SBP 
(mmHg) 
DBP 
(mmHg) 
SBP 
(mmHg) 
DBP 
(mmHg) 
SBP 
(mmHg) 
DBP 
(mmHg) 
Normal <140 <90 <130 <85 <120 <80 
High normal - - 130-139 85-89 120-129 <80 
Grade 1 
hypertension 
≥140 ≥90 140-159 90-99 130-139 80-89 
Grade 2 
hypertension 
≥160 ≥100 160-179 100-109 140-159 90-99 
Grade 3 
hypertension 
≥180 ≥110 ≥180 ≥110 ≥160 ≥100 
SBP denotes systolic blood pressure; DBP, diastolic blood pressure; NICE, National 
Institute for Health and Care Excellence; ESH, European Society of Hypertension; AHA, 
American Hypertension Association. 
 
 
Table 8: Threshold values for grade 1 hypertension based on out-of-office blood 
pressure measurements from current guidelines [54, 91, 92]. 
 NICE (2011) ESH (2018) AHA (2017)* 
Home 
measurement 
≥135/85mmHg ≥135/85mmHg ≥130/80mmHg 
Daytime ABPM ≥135/85mmHg ≥135/85mmHg ≥130/80mmHg 
Night-time ABPM - ≥120/70mmHg ≥110/65mmHg 
24 hour ABPM - ≥130/80mmHg ≥125/75mmHg 
*AHA guidelines also provide out-of-office measurement threshold values for each 
grade of hypertension 
ABPM denotes ambulatory blood pressure measurement; NICE, National Institute for 
Health and Care Excellence; ESH, European Society of Hypertension; AHA, American 
Hypertension Association. 
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as they can lead to over-treatment and under-treatment respectively [93]. 
Consequently, modern hypertension guidelines recommend the additional use of out-
of-office BP measurement to improve diagnostic accuracy and for the monitoring of 
treatment response [54, 91, 92]. 
 
2.4.2 Beat-to-beat Measurement 
 
Continuous (beat-to-beat) BP measurements in the clinic/lab are also possible over 
short periods. Non-invasive methods that measure the finger arterial pressure 
waveform using a cuff with built-in plethysmograph have been available since the 
1980’s, with available validated devices including the Finometer (Finapres®), 
Portapres®, and the Task Force® Monitor [94-96]. Evaluation of these devices has 
shown that they are sufficiently accurate (Table 9), although the standard deviation 
(SD) of SBP with the Finapres® is higher than the Association for the Advancement of 
Medical Instruments’ (AAMI) acceptable limit of 8mmHg, so they may lack the required 
precision for assessment of isolated BP levels. The Finapres®, in comparison with 
invasive arterial measurements, has also been shown to accurately track sudden 
changes in BP and measure variability (defined as SD or spectral analysis) in recordings 
up to 30 minutes long [95, 97], with the Task Force Monitor® being validated against 
the Finapres® for assessment of BPV [96]. Consequently, non-invasive beat-to-beat 
measurement has become established in clinical practice for the assessment of 
syncope and in research for the investigation of BPV [98-101]. 
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Table 9: Accuracy (mean difference (SD)) of blood pressure measurements with the 
Finapres® and the Task Force Monitor® [95, 96]. The Finapres® has been compared to 
both invasive and non-invasive methods and weighted average values are presented. 
The Task Force Monitor® has only been compared against non-invasive devices. 
 Finapres® Task Force Monitor® 
SBP -1.3 ± 9.0 mmHg -1.8 ± 7.6 mmHg 
DBP -2.0 ± 5.1 mmHg -1.8 ± 6.4 mmHg 
 
SD denotes standard deviation; SBP, systolic blood pressure; DBP, diastolic blood 
pressure.
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2.4.3 Out-of-Office Measurement 
 
For out-of-office BP measurement UK guidelines recommend the use of ambulatory BP 
measurement (ABPM) as the first-line method [91]. ABPM involves the use of an 
automated BP monitor, usually over 24 hours, programmed to measure BP at set time 
intervals. The recommended measurement interval varies [54, 91, 92], but to ensure 
the minimum required 14 daytime and seven night-time readings the maximum 
frequency should probably be every 30 minutes [89]. A major advantage of ABPM is 
that night-time measurements are obtained. BP normally falls by around 10-20% at 
night. Those who do not display this pattern are labelled “non-dippers”, this status 
being associated with increased target organ damage and an increased risk of 
cardiovascular events, coronary heart disease, stroke, and death [102, 103]. Indeed, 
night-time BP values and patterns may relate more closely to the risk of cardiovascular 
events than daytime values [104], though not all studies support this [105]. The other 
major advantage of ABPM is that a more accurate ‘usual’ BP is obtained as 
measurements are taken during the patient’s normal activities away from the clinic 
environment, an increased number of measurements are obtained, and technical 
limitations like observer bias/terminal digit preference are eliminated. These factors 
reduce the influence of natural variation in BP measurements and improve the 
reproducibility of the data. Research has shown that this translates to improved 
prediction of cardiovascular risk and a better correlation with target organ damage 
than CBPM [105-107]. Unfortunately, ABPM is significantly more expensive due to the 
equipment cost and the need for supporting software to interpret the data. Its 
interpretation also requires some additional expertise. Perhaps most importantly 
though, not all patients are able to tolerate ABPM and this can limit its practical use.  
 
An alternative to ABPM is home BP measurement (HBPM) (also referred to as self-BP 
measurement), which has become a viable alternative method with the development 
of cheaper, more accurate semi-automated monitors [89]. HBPM is recommended 
alongside ABPM in guidelines for the diagnosis and monitoring of hypertension [54, 91, 
92]. With this technique the patient measures their own BP at home, commonly being 
instructed to take two measurements in the morning and two in the evening for at 
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least three, but preferably seven consecutive days [92]. The mean of all 
measurements, excluding those from day one to allow for acclimatisation, can then be 
used. Like ABPM, HBPM provides an increased number of measurements and can 
identify both WCH and MH. Although it does not provide night-time measurements 
and can be susceptible to some of the same observer bias as CBPM, HBPM is probably 
more tolerable than ABPM and therefore may be more practical for monitoring long-
term control. It is reported that HBPM correlates at least as well as ABPM with 
cardiovascular risk and target organ damage and also out-performs CBPM in this 
respect [106, 108, 109]. 
 
2.4.4 Comparisons of Office and Out-of-Office Measurements 
 
It is known that out-of-office BP levels are not identical to office levels when 
contemporaneous measurements are taken in the same subjects. At a CBPM of 
140/90mmHg the equivalent daytime ABPM value is on average 4/3mmHg lower, 
though this difference increases as BP rises [110]. The current diagnostic threshold for 
daytime ABPM from European guidelines is 135/85mmHg (Table 8) [91, 92]. The 
threshold for HBPM is considered equivalent to daytime ABPM, but it should be noted 
that this has not been as thoroughly investigated [93, 111]. In fact, available data 
regarding their comparison shows inconsistent differences between them (Table 10), 
some of which is attributable to methodological factors, such as the age of study 
participants [112-114]. In terms of diagnosing hypertension, agreement between the 
methods has been reported as between 59% and 82% [115, 116]. When ABPM is used 
as the reference standard, HBPM provides increased sensitivity but reduced specificity 
compared to CBPM (CBPM with threshold >140/90mmHg mean sensitivity 74.6% [95% 
CI 60.7% to 84.8%] and specificity 74.6% [95% CI 47.9% to 90.4%], HBPM with 
threshold >135/85mmHg mean sensitivity 85.7% [95% CI 78.0% to 91.0%] and 
specificity 62.4% [95% CI 48.0% to 75.0%]) [122]. It is possible that CBPM, HBPM and 
ABPM are not interchangeable methods of measuring BP and this will be discussed 
further in a later chapter of this thesis.  
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Table 10: Studies taking contemporaneous blood pressure values from clinic, 
ambulatory, and home measurements for comparison. Mean values for each method 
are presented. 
Study N 
Mean CBPM 
(mmHg) 
Mean ABPM 
(mmHg)† 
Mean HBPM 
(mmHg) 
Denolle 1995 [117] 16 156/91 131/89 128/87 
Juhanoja 2016 [118] 461 132.8/85.2 138.4/85.1 130.0/85.2 
Larkin 1998 [119] 65 127.8/82.7 132.8/81.9 131.4/80.0 
Mancia 1995 [120] 1438 127.4/82.3 123.0/78.7 119.2/74.7 
Nasothimiou 2012* 
[116] 
44 152/86 138/80 144/81 
Nunan 2015 [121] 203 145.0/92.0 133.6/82.6 141.1/87.0 
Sega 1997 [112] 248 147.7/82.9 127.6/77.0 138.2/78.0 
Stergiou 2000 [115] 133 143.2/93.0 139.3/91.1 138.7/89.3 
*patients with clinic resistant hypertension (defined as average CBPM ≥140/90mmHg 
from two visits while on stable treatment with ≥3 antihypertensive drugs for ≥4 weeks. 
†daytime ABPM values reported with the exception of Denolle et al. and Larkin et al. 
who reported 24 hour ABPM values. 
CBPM denotes clinic blood pressure measurement; ABPM, ambulatory blood pressure 
measurement; HBPM, home blood pressure measurement.
  
 
51 
2.5 Blood Pressure Variability 
 
2.5.1 Concept 
 
Hypertension diagnosis and monitoring has traditionally been based on CBPM with a 
manual sphygmomanometer [89]. It has already been noted that, for an individual, BP 
readings obtained using this method will not be exactly the same on separate 
occasions, with some of this difference attributable to natural variation. Factors that 
contribute to this over the short-term include the circadian rhythm (most people’s BP 
is 10-20% lower at night-time) [102, 103, 122], emotional state, behavioural stimuli 
(e.g. caffeine, exercise, smoking), homeostatic mechanisms (e.g. the renin-angiotensin 
system) and the autonomic nervous system [90, 122]. Longer-term fluctuations may be 
attributable to seasonal variation and may also relate to inadequacies in measurement 
technique, changes to antihypertensive treatment, or poor adherence to 
antihypertensive treatment regimens [90, 122]. However, patients may also 
experience ‘episodic hypertension’ whereby, similar to WCH or MH, recorded BP may 
sometimes be within the normal range and sometimes be raised. For example, in 150 
patients with a recent stroke who were not on antihypertensive treatment prior to 
their cerebrovascular event, 87% of patients had at least one recorded SBP >160mmHg 
and 69% had at least two recorded SBP’s <130mmHg in the 10 years preceding their 
stroke [26]. Hypertension guidelines recommend that multiple CBPM are taken over 
several visits to try and establish an individual’s ‘usual BP’ before diagnosing them with 
hypertension, and that CBPM should be corroborated using out-of-office 
measurements [54, 91, 92]. However, recent expert opinion has suggested that this 
variability may be more than just a barrier to establishing an individual’s ‘usual BP’. 
Rather, there is evidence that it is a reproducible measurement that provides 
information about cardiovascular risk [17, 123-125]. 
 
Much of the recent interest in BPV stems from a review article by Rothwell which 
highlighted several observations not fully explained by the currently accepted concept 
of ‘usual BP’ (particularly in relation to stroke) and which suggest that there may be 
additional important factors [126]. One of those factors may be BPV. For example, the 
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predictive value of mean SBP for stroke falls with increasing age despite the fact that 
stroke incidence increases with age and elderly patients benefit from antihypertensive 
treatment. Furthermore, the benefit seen with BP reduction may be greater than 
expected given the level of risk predicted by mean SBP. Secondly, conditions such as 
WCH, MH, and episodic hypertension, which imply that at least sometimes an 
individual’s BP is ‘normal’ yet is also subject to increased variability [127], are 
associated with an increased risk of stroke. Similarly, BP surges seen in the morning as 
part of the usual circadian BP rhythm, or associated with conditions like postural 
hypertension and hypotension, are predictive of stroke but are not associated with 
mean SBP. Finally, data from trials of antihypertensive medications indicates that, 
despite similar reductions in mean BP, not all classes of medications convey an equal 
reduction in stroke risk.  
 
2.5.2 Practical Aspects 
 
Variability can be derived from any of the BP recording methods previously described, 
provided multiple BP measurements are obtained. The main difference between BP 
measurement methods is that they allow the quantification of BPV over different 
timescales according to the gap between measurements. Very short-term variability 
(over seconds to minutes) can be obtained from beat-to-beat BP monitoring. Short-
term variability (over minutes to hours) can be obtained from ABPM or repeated CBPM 
within a single encounter. Medium-term variability (over days to weeks) is best 
assessed using HBPM, but could also be derived from repeated CBPM on consecutive 
days. Finally long-term variability (over months to years), also referred to as visit-to-
visit variability, is usually calculated from repeated CBPM over separate visits, but 
could also be obtained from repeated sets of ABPM or HBPM over time. 
 
Not only can BPV data come from different BP measurement methods over varying 
timescales, it can also be calculated in a number of different ways (Table 11). SD is a 
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Table 11: Statistical measures that can be applied to a set of blood pressure 
measurements to derive average values and variability data.  
Measure Abbreviation Description 
Mean  
The sum of all recorded values divided by the 
number of measurements. 
Standard deviation SD 
The square root of the mean of the squared 
difference of all values in the set from the overall 
mean value. 
Coefficient of variation CV 
The standard deviation of a set of recordings 
divided by the mean value and multiplied by 100. 
Variation independent 
of the mean 
VIM 
The standard deviation of a set of recordings 
divided by the mean raised to the power “x”. The 
value “x” is derived by fitting a curve (SD = meanx 
multiplied by a constant) to a plot of SD against 
mean values. 
Maximum-minimum 
difference 
MMD 
The maximum recorded blood pressure minus 
the minimum recorded blood pressure. 
Peak value  
The maximum recorded blood pressure minus 
the mean value of a set of recordings. 
Trough value  
The mean blood pressure from a set of 
recordings minus the minimum recorded value. 
Average successive 
variation 
ASV 
The mean value of the squared difference in 
blood pressure between successive 
measurements. 
Average real variability ARV 
The mean value of the absolute difference in 
blood pressure between successive 
measurements. 
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common statistical method of describing variance in a dataset and is the most 
frequently quoted method of presenting BPV [128]. However, its use for 
demonstrating BPV may be limited. For example, when applied to 24 hour ABPM 
recordings SD may just represent the natural variation between daytime and night-
time BP. This can be overcome by using weighted SD, which takes account of the 
greater number of readings acquired during waking hours [129], but a more intractable 
issue may be that because SD is statistically related to the mean value it may not 
provide useful information over and above mean BP [130, 131]. One approach to 
remove the influence of the mean value is to use the coefficient of variation (CV). A 
more statistically sophisticated method is variation independent of the mean (VIM), 
which employs curve fitting techniques to derive a population specific value which 
removes the influence of mean BP [131]. The maximum-minimum difference (MMD) is 
another simple measure of BP range, describing the maximal change within a 
recording. Peak and trough values can also be used to capture variation in terms of BP 
spikes. Finally, average successive variation (ASV) and average real variability (ARV) are 
methods of deriving variability that account for the time sequence of BP recordings 
within a set. Both may be particularly applicable to data from 24 hour ABPM as they 
avoid the difficulty in accounting for day-night differences that may be encountered 
with the other indices described [132]. 
 
2.5.3 The Prognostic Value of Blood Pressure Variability 
 
Rothwell’s group has published a body of work relating to BPV to complement his 
review article. Other contemporaneous publications include a study demonstrating 
that BPV is a reproducible phenomenon and two papers re-examining the data from 
several RCT [17, 131, 133]. The first of these re-examinations analysed data from the 
UK-TIA trial and three other cohorts designed to validate its findings (European Stroke 
Prevention Study (ESPS-1), Dutch TIA, and Anglo-Scandinavian Cardiac Outcomes Trial-
Blood Pressure Lowering Arm (ASCOT-BPLA)). This analysis demonstrated that visit-to-
visit variability of SBP (adjusted for mean BP) was a stronger predictor of future stroke 
than mean BP (Table 12) [131].  
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Table 12: Systolic blood pressure parameters and their predictive value for stroke (HR 
with 95% CI for the top vs. bottom decile of each parameter) in four cohorts of 
patients with TIA and minor stroke [131]. 
 UK-TIA ESPS-1 Dutch TIA ASCOT-BPLA 
    Atenolol arm Amlodipine arm 
N 1324 1247 3150 1012 999 
Mean  
3.63 (2.41 to 
5.48) 
1.89 (0.96 to 
3.71) 
2.34 (1.41 to 
3.89) 
1.81 (0.89 to 
3.67) 
0.94 (0.36 to 
2.42) 
SD* 
4.84 (3.03 to 
7.74) 
1.78 (1.12 to 
2.62) 
3.35 (1.63 to 
6.87) 
4.29 (1.78 to 
10.36) 
4.39 (1.68 to 
11.50) 
CV* 
3.82 (2.54 to 
5.73) 
2.22 (1.52 to 
3.22) 
3.41 (1.62 to 
7.19) 
3.51 (1.56 to 
7.93) 
3.25 (1.32 to 
8.00) 
VIM* 
3.27 (2.06 to 
5.21) 
1.86 (1.28 to 
2.69) 
1.83 (0.76 to 
4.39) 
3.96 (1.66 to 
9.43) 
3.57 (1.38 to 
9.19) 
*Adjusted for mean SBP 
HR denotes hazard ratio; 95% CI, 95% confidence interval; TIA, transient ischaemic 
attack; SD, standard deviation; CV, coefficient of variation; VIM, variation independent 
of the mean.
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Variability from ABPM was also predictive of future stroke independent of mean BP, 
but less so than visit-to-visit variability. The second analysed data from the ASCOT-
BPLA and Medical Research Council (MRC) trials to investigate the differential effects 
of antihypertensive medication classes on stroke risk, showing that the difference in 
stroke risk may be accounted for by differences in BPV [133]. In the wake of these 
publications other groups have sought to replicate and extend these findings. Studies 
relating to the prognostic value of BPV will be summarised here and the relationship 
between BPV and antihypertensive drug classes will be revisited. 
 
2.5.4 Markers of Organ Damage 
 
Various studies have reported positive associations between BPV and markers of 
damage to the kidneys, brain, and heart. Regarding renal damage, short-term BPV is 
positively associated with the presence of microalbuminuria and proteinuria in 
patients with hypertension [134-136]. Regarding the brain, short-term and long-term 
BPV are both associated with increased signs of cerebrovascular small vessel disease 
on neuroimaging [137, 138], with long-term variability also positively associated with 
the presence of cerebral micro-haemorrhages [138]. This may translate into an 
association with cognitive impairment and dementia as increased BPV has been linked 
to worse scores on cognitive screening in cross-sectional and longitudinal analyses 
[139-146]. Finally, in terms of cardiac organ damage the evidence is inconsistent with 
varying reports about the relationship between BPV and left ventricular mass [134, 
136, 147]. 
 
2.5.5 Cardiovascular Events and Mortality 
 
Several studies have questioned the finding of Rothwell’s group that BPV is an 
independent cardiovascular risk factor, with post-hoc review of at least three large 
datasets suggesting that increased BPV does not provide prognostic information over 
that of mean BP levels [148-150]. Analysis of a general population cohort 
demonstrated that baseline BPV, defined as the between-visit VIM from two visits with 
a 2-4 week interval, did not predict all-cause mortality, cardiovascular events, or stroke 
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events over a median follow-up of 12 years (HR 1.00 [95% CI 0.91-1.10], 1.05 [0.96-
1.15], 1.13 [0.88-1.46] respectively) [148]. In a second general cohort, variability 
derived as the root mean square error (an estimate of variation around a regression 
line for BP values recorded over time), from a minimum of six visits over two years, did 
not predict all-cause mortality over a median follow-up of 12.9 years (HR for the top 
quartile of variability 1.09 [95% CI 0.95-1.25]) [149]. Finally, in a post-hoc analysis of 
the Syst-Eur trial, increased VIM of systolic visit-to-visit variability, from visits every 
three months over two years, did not predict all-cause mortality, combined fatal and 
non-fatal cardiovascular events, or stroke events after adjustment for mean BP (HR per 
one SD increase in variability 0.95 [95 % CI 0.82-1.10], 0.92 [0.80-1.05], 1.03 [0.83-1.27] 
respectively) [150]. However, analysis of the US Veteran’s database, which represents 
the largest reported cohort (N=2,865,157), supports Rothwell et al. Over a median 
follow-up of eight years the HR for total mortality, coronary heart disease events, and 
stroke events were all incrementally higher with quartiles of SD of systolic visit-to-visit 
variability (e.g. HR for all-cause mortality in the top quartile 1.80 [95% CI 1.78-1.82]) 
[151]. Several meta-analyses also demonstrate that long-term BPV is an independent 
cardiovascular risk factor, predicting all-cause mortality, cardiovascular mortality, 
incident cardiovascular events, and stroke events (Figure 4) [14, 128, 152, 153]. 
Although there is less data regarding medium and short-term variability, both are 
probably also independent risk factors for all-cause mortality [128]. 
 
2.5.6 Potential Inconsistencies 
 
A criticism of studies reporting that increased BPV is an independent cardiovascular 
risk factor is that they have enrolled populations with a higher baseline cardiovascular 
risk and therefore the results may not be generally applicable. Whilst it is true that the 
negative studies described in the previous section are either based on general 
population cohorts or patients with hypertension but no additional cardiovascular 
disease, the impact of study population heterogeneity may not be significant. This is 
because when the predictive value of increased visit-to-visit variability was assessed in 
groups stratified by baseline cardiovascular risk according to European guidelines it  
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Figure 4: Forest plots showing the association of visit-to-visit systolic blood pressure 
variability (as standard deviation) with outcomes [14]. HR denotes hazard ratio; 95% 
CI, 95% confidence interval; CHD, coronary heart disease; CVD, cardiovascular disease. 
  
 
59 
was found that increased variability predicted cardiovascular events irrespective of 
baseline risk [154]. Other methodological issues may go further towards explaining 
some of the inconsistency in the evidence. Presently there is no consensus as to the 
optimum way to derive BPV [90, 155, 156], therefore, studies have used different 
approaches in terms of BP measurement protocols and have defined variability with a 
multitude of statistical methods. The latter may be less important because, although it 
can inhibit direct comparisons of data, for visit-to-visit variability from repeated clinic 
BP measurements BPV values from different indices are strongly correlated [157]. 
However, with reference to the former, BP measurement protocols have not only 
differed in terms of the BP measurement method used, but also with respect to the 
number and timing of measurements obtained. For example, HBPM has not always 
been undertaken for the same number of consecutive days and visit-to-visit variability 
may be taken from different numbers of visits spread over variable study durations. 
These aspects of BP measurement have been shown to influence BPV values when 
calculated as SD [130]. Although perhaps not relevant to short-term variability from 
ABPM, medium-term variability is influenced by the number of consecutive days on 
which BP is measured and the number of readings per day, with two sets of duplicate 
measurements for three consecutive days probably the minimum required to assess 
variability [158]. Similarly, the number of visits used influences visit-to-visit variability 
[159]. It is not clear if this also applies to other BPV indices, but the predictive value of 
BPV from several metrics increases with the number of BP measurements available 
[131], with one study suggesting that a minimum of four visits are necessary to 
calculate visit-to-visit variability with sufficient accuracy [123]. At least two of the 
previously described negative trials are likely to have been influenced by the BP 
measurements obtained. In the study by Schutte et al. between-visit variability was 
calculated from just two visits with 2-4 weeks between them [148]. Gao et al. 
retrospectively collected clinic BP data and so, whilst there was no standardised 
protocol, it is likely that only a single BP measurement was obtained at each visit [149]. 
 
In addition to the fact that measurement factors may influence BPV values and their 
prognostic relevance, there is evidence that variability values from different 
measurement methods are not strongly related. Correlations between 24 hour ABPM 
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variability and repeated CBPM variability in hypertensive patients (either untreated or 
on stable therapy) are either weak or non-significant [157, 160], as are correlations 
between beat-to-beat BPV and variability from 24 hour ABPM and HBPM [134]. 
Considering that natural BPV over different timescales has different influencing factors 
the same may be true for pathological BPV. Consequently, BPV as it is currently 
understood and discussed in the literature may not be a singular concept and the same 
pathological processes may not be elucidated by all measures of variability. 
 
Finally, in addition to these potential methodological issues, interpretation of the data 
is inhibited by the lack of established ‘normal’ values for BPV. Some studies have 
demonstrated increased variability in the study population compared to control 
subjects [13, 100, 161], but data to suggest how much of a difference is significant is 
limited. Two studies reporting long-term variability as CV found different levels of 
variability that may explain their inconsistent findings. Rothwell et al. reported average 
CV of SBP values of 9% and found a positive association between visit-to-visit 
variability and risk of recurrent stroke [131]. In contrast, Veloudi et al. found that 
increased visit-to-visit variability was not associated with target organ damage, but 
they reported average CV of SBP values of 7% [147]. This difference is in keeping with 
the findings from the only study that has attempted to establish BPV thresholds using 
outcome data [162]. In a general population cohort followed-up for approximately 10 
years, participants were separated into deciles of BPV, with variability calculated as CV 
from HBPM conducted over four consecutive days. The risk of cardiovascular events 
and mortality was increased for those participants with CV of SBP >11%, suggesting 
that this may be a threshold value. Clearly further research is needed to establish the 
limits of ‘natural’ variability in order to properly establish the relevance of pathological 
BPV. 
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2.6 Pathological Mechanisms Underlying Blood Pressure Variability 
 
2.6.1 Arterial Stiffness 
 
At present the pathophysiological mechanisms underlying BPV are undetermined. 
Several factors have been associated with BPV, but the majority of studies have been 
cross-sectional and so unable to prove a causal relationship. Perhaps most frequently 
discussed is the association between BPV and arterial stiffness. BP is not consistent 
throughout the arterial system. Although DBP and mean arterial pressure (MAP) 
remain relatively unchanged from the aorta to the peripheries, SBP increases with the 
distance from the heart. This is because peripheral arteries are less elastic than the 
aorta resulting in so-called “amplification” of BP [163]. Two theories are often cited to 
explain this. The pulse wave model hypothesises that the arterial pressure waveform is 
a composite of a forward travelling wave generated by left ventricular contraction and 
a reflected wave generated by tapering of arterial size and the associated reduction in 
arterial wall compliance [164]. The reflected wave augments systolic pressure with the 
effect diminishing as it travels further back towards the central vessels. The 
Windkessel model proposes that the elastic properties of the central arteries allows 
them to act as a reservoir that fills in systole and empties in diastole [165]. This 
elasticity buffers some of the pressure generated by left ventricular contraction and 
the buffering effect diminishes further down the arterial tree. Increased arterial 
stiffness can theoretically both reduce the capacity of central arteries to act as a buffer 
and increase the amplification of BP by enhancing the reflected wave, which in turn 
can increase BP and its variability. Several markers of arterial stiffness are measurable, 
with the gold standard considered to be carotid-femoral pulse wave velocity (c-fPWV) 
[166]. Studies show that increased short and long-term BPV are both positively 
correlated with reduced aortic distensibility in general adult populations [167, 168]. In 
hypertensive adults they are also positively correlated with c-fPWV [136, 169, 170]. 
Similarly, increased long-term BPV both predicts and is predicted by increased 
brachial-ankle pulse wave velocity [171, 172]. Whether change in BPV correlates with 
change in arterial stiffness is unclear with two studies reporting same directional 
change in BPV and arterial stiffness over time [173, 174], but another finding no 
association [147]. Furthermore, increased BPV may be associated with endothelial 
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dysfunction [175]. Therefore, whether increased arterial stiffness causes increased BPV 
or vice versa, or whether both influence each other in a vicious circle remains to be 
elucidated. 
 
2.6.2 Autonomic Dysfunction and Cardiac Baroreceptors 
 
Another potential mechanism underlying BPV is autonomic dysfunction. It is known 
that syndromes characterised by abnormal BP changes, such as postural hypotension, 
can be associated with conditions that can cause dysautonomia, such as Parkinson’s 
disease and Diabetes Mellitus. Short-term BPV from 24 hour ABPM is increased in 
diabetic hypertensive patients compared to non-diabetic hypertensives suggesting that 
this may be another clinical manifestation of diabetic autonomic neuropathy [176]. 
The BP volatility associated with autonomic dysfunction could be mediated by 
impairment of cardiac baroreceptors, which are a major determinant of short-term BP 
regulation [177-179]. Cardiac baroreceptors are stretch receptors, stimulated by 
changes in BP, located in the carotid sinus, aortic arch, and right atrium. Afferent 
signals to the central nervous system, via the glossopharyngeal and vagus nerves, are 
co-ordinated in the nucleus tractus solitaries, but multiple other central areas are 
involved in processing. Efferent sympathetic and parasympathetic outputs modulate 
heart rate, cardiac output, and peripheral vascular tone resulting in homeostatic 
alteration of BP. Baroreflex failure can result in a number of syndromes characterised 
by BP fluctuations, such as volatile hypertension and malignant vagotonia [178, 180]. 
Damage anywhere along the baroreceptor feedback pathway can potentially result in 
reduced baroreceptor function or baroreflex failure, including, for example, damage to 
central processing areas by stroke [181, 182]. Consequently, reduced baroreceptor 
sensitivity (BRS) may be particularly relevant to increased BPV post-stroke. 
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2.7 Blood Pressure Variability Post Stroke 
 
2.7.1 Short and Medium-term Variability 
 
The evidence suggests that in hypertensive individuals longer-term BPV, and to a lesser 
extent shorter-term, is predictive of cardiovascular events and mortality, with the 
strongest prognostic relationship possibly between increased BPV and stroke risk. This 
may also suggest a prognostic relationship with recurrent stroke. Additionally, given 
the theoretical link between central nervous system damage, BRS dysfunction, and 
BPV described in the previous section, increased BPV post-stroke may have an impact 
on outcomes. Furthermore, if we consider that cerebral autoregulation is disrupted in 
acute stroke [13, 183], resulting in CBF becoming dependent on systemic BP, then this 
question becomes more pertinent. In theory, if cerebral autoregulation is unable to 
maintain CBF within the normal limits (i.e. MAP 60-150mmHg [12]), then any increases 
in systemic BPV could result in cerebral hypo or hyper-perfusion. The consequences of 
the former could be tissue hypoxia, particularly in the under-perfused ischaemic 
penumbra, and infarct expansion. The consequences of the latter could be additional 
endothelial damage and blood-brain barrier disruption leading to secondary 
haemorrhage and/or cerebral oedema. Several studies have attempted to address 
these gaps in the knowledge base. 
 
Studies of the impact of BPV post-stroke have investigated variability in different 
phases following the cerebrovascular event. In these studies the hyper-acute phase 
has generally been defined as the first 24 hours after symptom onset, the acute phase 
as days 1-3 or 1-7 post-event, and the subacute phase as beyond one week. Studies 
show that increased systolic BPV measured over hours in both the hyper-acute and 
acute phases after ischaemic stroke is associated with an increased risk of 
haemorrhagic transformation in patients receiving thrombolysis [184-186]. Increased 
day-to-day systolic variability over the first three days post-event is also associated 
with an increased risk of haemorrhagic transformation in patients not receiving 
thrombolysis [187]. Furthermore, increased systolic BPV measured over hours during 
the same period after ischaemic stroke is associated with an increased risk of END 
[188, 189]. In terms of stroke recovery there is no evidence to show that increased 
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variability in the hyper-acute and acute phases is related to early functional outcome 
(defined as two weeks post event) [190]. However, with a few exceptions [98, 191, 
192], studies investigating the impact of increased systolic variability on functional 
outcome after three months show that increased variability is associated with an 
increased risk of poor outcome (Table 13). Meta-analysis of seven studies reinforces 
these positive findings, indicating that BPV within the first 72 hours after stroke onset 
affects outcomes (OR per 10mmHg increase in SD of SBP 1.2 [95% CI 1.1-1.3, 
p=0.0004]) [15]. There is also emerging evidence that increased variability from HBPM 
in the three months post-event is associated with an increased risk of stroke 
recurrence [16], and one study has also reported an increased risk of post-stroke 
cognitive impairment at 12 months [193]. 
 
2.7.2 Beat-to-Beat Variability 
 
The majority of studies have utilised multiple ward BP measurements to derive BPV, 
thereby investigating short or medium-term variability. Beat-to-beat variability has not 
been extensively studied, but there is evidence to show that in patients with ischaemic 
stroke SD of SBP is increased in the first 72 hours post-event compared to control 
subjects [100]. Whilst the SD of beat-to-beat SBP was not associated with long-term 
outcome or stroke subtype (according to the Oxford Community Stroke Project (OCSP) 
classification) in the study by Dawson et al., the SD of beat-to-beat DBP was related to 
the risk of poor functional outcome in this cohort (OR 1.33 [95% CI 1.1-1.7, p<0.03]) 
[98]. Furthermore, in a study from the OXVASC database both SD and CV of beat-to-
beat SBP recorded within six weeks of a cerebrovascular event (TIA, ischaemic stroke, 
or ICH) was predictive of recurrent stroke [200]. This suggests that, whilst the current 
evidence is limited, very short-term BPV post-stroke may be relevant to stroke 
recovery as well as long-term cardiovascular health. 
  
 
Table 13: Summary of studies investigating the impact of increased blood pressure variability on outcomes after stroke. 
Study N Patient Cohort BP measurement method 
BPV 
index* 
Outcome OR (95%CI)
†
 P value 
Yong 2008 
[184] 
793 
Ischaemic stroke within 6 hours of 
onset, thrombolysis vs. placebo 
(post-hoc analysis of ECASS-II) 
Ward BP as per protocol (x37 
over 24 hours) 
ASV SBP 
Functional independence at 3 
months (mRS 0-1) 
Thrombolysed: 
0.57 (0.35-0.92) 
 
Placebo: 0.41 
(0.22-0.76) 
Not 
reported 
Endo 2013 
[194] 
527 
Ischaemic stroke receiving 
thrombolysis (Samurai registry) 
Ward BP as per standard 
treatment (x7 over 24 hours) 
MMD 
SBP 
Functional independence at 3 
months (mRS 0-1) 
0.88 (0.77-0.99) <0.05 
Liu 2016 [185] 461 
Ischaemic stroke receiving 
thrombolysis 
Ward BP as per standard 
treatment (x1 per hour for 24 
hours) 
ASV SBP 
Functional independence at 3 
months (mRS 0-1) 
0.25 (0.14-0.45) <0.05 
Kellert 2017 
[186] 
16,434 
Ischaemic stroke receiving 
thrombolysis (SITS database) 
Ward BP as per standard 
treatment (minimum x3 over 24 
hours) 
ASV SBP 
Functional independence at 3 
months (mRS 0-2) 
0.94 (0.90-0.98) 0.002 
Bennett 2018 
[195] 
182 
Ischaemic stroke receiving 
thrombectomy 
Ward BP as per standard 
treatment (x38 over 24 hours) 
ASV SBP 
Ordinal shift in mRS after 3 
months 
2.63 (1.47-4.70) 0.001 
Chung 2018 
(hyper-acute 
phase) [196] 
386 
ICH within 2 hours of onset (post-
hoc analysis of FAST-MAG) 
Ward BP as per protocol (x6 0-6 
hours after onset) 
CV SBP 
Functional independence at 3 
months (mRS 0-2) 
Top quintile of 
BPV: 4.78 (2.00-
11.40) 
<0.001 
Chung 2018 
(acute phase) 
[196] 
386 
ICH within 2 hours of onset (post-
hoc analysis of FAST-MAG) 
Ward BP as per protocol (x11 0-
24 hours after onset) 
CV SBP 
Functional independence at 3 
months (mRS 0-2) 
Top quintile of 
BPV: 4.97 (1.93-
12.84) 
<0.001 
  
 
Zhang 2018 
[192] 
542 
Ischaemic stroke admitted within 
24 hours of onset 
24 hour ABPM (set to measure 
BP at 2 hourly intervals) 
CV SBP 
Poor functional outcome at 3 
months (mRS ≥3) 
CV ≥ median 
value: 1.07 (0.71-
1.59) 
Not 
reported 
De Havenon 
2016 [197] 
215 
Anterior circulation ischaemic 
stroke 
Ward BP as per standard 
treatment (median 34 measures 
over 120 hours) 
CV SBP 
Ordinal shift in mRS after 3 
months per 10mmHg 
increase 
3.16 (1.25-7.94) 0.02 
Wang 2017 
[198] 
873 
Ischaemic stroke admitted within 
24 hours of onset 
Ward BP as per standard 
treatment (x6 per day for 7 days) 
CV SBP 
Poor functional outcome at 3 
months (mRS ≥2) 
Top quintile of 
BPV: 2.02 (1.52-
2.53) 
0.001 
Fukuda 2015 
(acute phase) 
[199] 
2566 
First ischaemic stroke admitted 
within 24 hours of onset (Fukuoka 
stroke registry) 
Ward BP as per standard 
treatment (x3 days 1-3 post 
onset) 
CV SBP 
Poor functional outcome at 3 
months (mRS ≥3) 
Top quartile of 
BPV: 0.91 (0.66-
1.24) 
0.54 
Fukuda 2015 
(subacute 
phase) [199] 
2566 
First ischaemic stroke admitted 
within 24 hours of onset (Fukuoka 
stroke registry) 
Ward BP as per standard 
treatment (x1 days 4-10 post 
onset) 
CV SBP 
Poor functional outcome at 3 
months (mRS ≥3) 
Top quartile of 
BPV: 1.63 (1.20-
2.22) 
0.002 
Dawson 2000 
[98] 
92 
Ischaemic stroke within 10 days of 
onset 
Beat-to-beat BP for 10 minutes SD SBP 
Poor functional outcome at 3 
months (mRS ≥3) 
1.07 (0.9-1.2) 0.29 
*For studies reporting multiple BPV indices the largest effect is presented. 
†Adjusted for confounding variables, including baseline BP and NIHSS. 
BP denotes blood pressure; BPV, blood pressure variability; OR, odds ratio; 95% CI, 95% confidence interval; ASV, average successive variation; SBP, systolic blood 
pressure; mRS, modified Rankin score; MMD, maximum-minimum difference; ICH, intracerebral haemorrhage; CV, coefficient of variation; ABPM, ambulatory 
blood pressure measurement; SD, standard deviation.
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2.7.3 Limitations of the Evidence 
 
As with studies on the prognostic relevance of BPV to the risk of cardiovascular events 
discussed previously, some of the inconsistencies in the evidence for the impact of BPV 
post-stroke probably relate to methodological issues. For example, the method of BP 
measurement used, the number of measurements obtained, and the timescale 
encompassing and between measurements. In particular, the timing of measurements 
in relation to stroke onset may be important, with studies suggesting that increased 
variability may naturally decrease to a degree after the acute phase, similar to the 
pattern seen with mean BP described in section 3.1 [100, 189]. The degree of 
variability observed in different studies may also explain differences in reported 
outcomes. For example, in their negative study Tziomalos et al. observed a CV of SBP 
of 6% in the first 72 hours after admission, whereas Chung et al. found a CV of SBP of 
11% to be associated with END and Wang et al. found a CV of SBP >11% to be 
associated with poor three month outcome [188, 191, 198]. Again, this is in keeping 
with the limited data regarding BPV threshold values [162]. Of course, interpretation of 
the evidence should be done in the context of its strengths and weaknesses. With that 
in mind, it should be noted that the majority of these studies have been either post-
hoc analyses of trial data, or retrospective reviews of registry data or unselected 
secondary care cohorts. A major limitation of these designs is that BP measurements 
have not necessarily been standardised and, where they have, have not necessarily 
been designed to adequately capture variability. It could be argued that this is 
advantageous as it represents “real world” data, but further research based on 
specifically designed prospective trials would undoubtedly be beneficial to further 
investigate the impact of BPV post-stroke. Having said that, the available evidence 
(which includes a small but robust meta-analysis) is certainly intriguing and invites the 
question as to whether BPV might be a therapeutic target in addition to mean BP. 
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2.8 Differential effects of Antihypertensive Medication Classes on Blood Pressure 
Variability 
 
2.8.1 Studies on Long-term Variability 
 
As alluded to in section 2.5.3, evidence suggests that not all antihypertensive 
medications are equal with respect to their effect on stroke risk reduction, and these 
differential effects may be class effects. One potential explanation for this is that not 
all antihypertensive medications have an equal effect on BPV as suggested by Rothwell 
et al. in their post-hoc analysis of the ASCOT-BPLA and MRC trials (Table 14) [133]. In 
both of these trials there was an unexpected difference in stroke risk between the 
treatment arms (calcium channel blocker (CCB) vs. beta blocker in ASCOT-BPLA and 
thiazide diuretic vs. beta blocker in MRC), with both suggesting an increased stroke risk 
in the beta blocker arm. In ASCOT-BPLA visit-to-visit variability was greater in those 
treated with a beta blocker compared to a CCB. Moreover, this difference was able to 
account for the difference in stroke risk, whereas the between-group difference in 
mean BP was not. In MRC the findings were similar, with increased visit-to-visit 
variability in the beta blocker arm, but no effect on visit-to-visit variability seen in the 
thiazide diuretic arm.  
 
Rothwell et al. have also performed a systematic review, incorporating 398 
antihypertensive trials, to further explore the potential effects of different medication 
classes on BPV [201]. As individual BPV data was not routinely reported interindividual 
variance (the variance within the whole treatment group) was assessed as a surrogate. 
The review found that visit-to-visit variability of SBP was reduced by CCB, and to a 
lesser extent non-loop diuretics, but was increased by beta blockers and drugs 
inhibiting the renin-angiotensin system. The greatest increase in variability was seen in 
those treated with beta blockers. Furthermore, in keeping with their previous findings, 
increased BPV in this analysis was associated with an increased risk of stroke. 
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Table 14: Visit-to-visit variability of systolic blood pressure by treatment arm from the 
ASCOT-BPLA and MRC studies. Data presented are mean (SD) [133]. 
 ASCOT-BPLA MRC 
Atenolol arm 
Amlodipine 
arm 
Atenolol arm Diuretic arm 
Mean (mmHg) 141.8 (13.0) 139.1 (11.1) 156.6 (12.1) 151.2 (12.1) 
SD (mmHg) 13.42 (5.77) 10.99 (4.79) 14.38 (5.34) 11.64 (4.39) 
CV (%) 9.41 (3.78) 7.87 (3.23) 9.18 (3.33) 7.69 (2.77) 
VIM (units) 13.13 (5.21) 11.14 (4.52) 14.55 (5.31) 11.98 (4.38) 
ASV (mmHg) 13.79 (6.50) 11.28 (5.32) 14.71 (5.65) 12.40 (5.09) 
 
SD denotes standard deviation; CV, coefficient of variation; VIM, variation independent 
of the mean; ASV, average successive variation.
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Further work looking at visit-to-visit variability with individual patient data has been 
conducted in the wake of this systematic review. A post-hoc analysis of ALLHAT was 
able to compare angiotensin converting enzyme inhibitors (ACEI), CCB and thiazide-like 
diuretics. Systolic visit-to-visit variability (defined as SD, ARV, and SD independent of 
the mean (a statistically similar method to VIM)) was significantly increased with ACEI 
compared to both other medication classes [202]. Similarly, in a retrospective review 
of a large primary care database Smith et al. were able to assess the impact of all 
major antihypertensive classes on visit-to-visit variability, finding that variability was 
reduced with non-loop diuretics and CCB, but increased with beta blockers and ACEI or 
angiotensin receptor blockers (ARB) [203]. In contrast, in a substudy of the Losartan 
Intervention For Endpoint reduction in hypertension (LIFE) trial, which compared 
losartan with atenolol, it was reported that there was no significant difference in 
systolic visit-to-visit variability between the treatment arms [204]. However, the 
majority of participants in this study took other antihypertensive medications in 
addition to their investigational product, with most taking a CCB. Also, variability was 
only defined as SD. Both of these factors could have confounded the results. 
 
When considering long-term BPV, it would be reasonable to suggest that the degree of 
variability could be influenced by factors other than medication effects. One such 
factor could be medication adherence, which is known to be problematic in patients 
with hypertension [205, 206]. Two studies have investigated the impact of medication 
adherence on visit-to-visit variability. Although both are post-hoc analyses and data on 
adherence was self-reported, both found that whilst poor adherence was associated 
with increased visit-to-visit variability, it was not able to account for the link between 
increased BPV and increased cardiovascular risk [207, 208]. 
 
2.8.2 Studies on Short-term Variability 
 
A few studies have investigated the effect of different antihypertensive medication 
classes on short-term BPV, measured either with ABPM or HBPM. In a small study of 
valsartan vs. amlodipine daytime systolic BPV from ABPM (defined as SD and CV) was 
increased with the former compared to the latter [209]. Similarly, in a post-hoc 
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subgroup analysis of the Natrilix SR Versus Candesartan and Amlodipine in the 
Reduction of Systolic Blood Pressure in Hypertensive Patients (X-CELLENT) study, after 
three months treatment with candesartan, amlodipine, or indapamide, BP was 
reduced in all groups whereas BPV (defined as ARV) was only reduced in the 
amlodipine and indapamide groups [210]. Another study reported on the SD of 24 
hour ABPM in a larger cohort, observing that systolic variability was increased with 
beta blockers, decreased with both CCB and thiazide-like diuretics, but not affected by 
renin-angiotensin inhibitors [211]. Post-hoc analysis of the Hypertension Objective 
Treatment Based on Measurement by Electrical Devices of Blood Pressure 
(HOMED-BP) study measured the impact of CCB or renin-angiotensin inhibitors on the 
variability of HBPM two to four weeks after treatment initiation [212]. No difference 
was reported between the two groups, but the study was limited as only a small 
number of BP measurements were obtained (one in the morning and one in the 
evening for five days). Finally, in the only study to focus on a population with 
cerebrovascular disease, Webb et al. investigated the impact on variability of HBPM of 
antihypertensive medication changes (either dose increases or medication additions) 
in patients with a recent ischaemic stroke [213]. They reported that the addition or 
increase in dose of a CCB or diuretic reduced BPV compared to the same changes using 
an ACEI. 
 
2.8.3 Studies on Combination Therapy 
 
Given that many patients with hypertension will require multiple medications to 
achieve good BP control [214-216], whether these apparent class effects persist when 
antihypertensive therapies are combined could be of clinical relevance. Again, 
Rothwell and colleagues have examined this question, conducting a systematic review 
of 97 trials [217]. As with their previous systematic review interindividual BPV was 
used as a surrogate measure of individual BPV. The results were in keeping with the 
data regarding antihypertensive monotherapy, with systolic BPV being reduced by the 
addition of a CCB to the antihypertensive regimen, and less so by the addition of a 
diuretic, but increased by the addition of a beta blocker. In the same systematic review 
they also analysed trials comparing high and low doses of the same antihypertensive 
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class, finding that higher doses of CCB further reduced BPV, with the opposite for beta 
blockers, and no difference for other antihypertensive classes. 
 
2.8.4 Potential Explanations for Antihypertensive Class Effects on Blood Pressure 
Variability 
 
The various classes of BP lowering medications exert their antihypertensive effects via 
different mechanisms and consideration of these mechanisms may provide some 
theoretical explanation of their effects on BPV. Dihydropyridine CCB (e.g. amlodipine) 
cause smooth muscle relaxation, which leads to peripheral vascular dilatation and a 
reduction in peripheral vascular resistance [133, 211]. Thiazide-like diuretics reduce 
peripheral vascular resistance via increased excretion of sodium and water, but also 
have vasodilatory effects, with the latter more likely to be the mechanism for long-
term BP reduction [218, 219]. Both of these medication classes could consequently 
increase arterial compliance, which may reduce arterial stiffness and BPV. Notably, 
concurrent reductions in c-fPWV and BPV have been demonstrated with CCB therapy 
[220], though whether there is a causal link is unproven. Conversely, beta blockers 
primarily exert their antihypertensive effect through negative chronotropic activity, 
with less cardio-selective agents causing peripheral vasoconstriction, meaning they 
could be expected to have the opposite effect on arterial stiffness and, as a result, BPV 
[133, 211]. Finally, ACEI and ARB lower BP by inhibiting aldosterone release, altering 
sodium and water excretion, with relatively little effect on peripheral vascular tone. 
 
Caution must be taken in interpreting the available evidence as the majority has been 
generated from post-hoc analyses of trials of antihypertensive medications that were 
designed to assess the medication’s effects on overall BP, not BPV [221]. These trials 
are heterogeneous in terms of the particular medications studied, length of follow-up, 
and methods of BP measurement among other things, which could confound any 
further analysis. It should also be noted that interindividual BPV is a surrogate marker, 
although it is reported that within-individual BPV accounts for up to 40-60% of the 
variability within a group [131, 133]. Having said that, the weight of evidence is 
compelling and, as previously stated, warrants further investigation with dedicated 
primary trials. Findings to date suggest that available antihypertensive medications 
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may have an effect on BPV as well as overall BP and so theoretically these treatments 
could be used to target BPV therapeutically. Furthermore, given the apparent impact 
of BPV in acute ischaemic stroke this patient group could potentially benefit from such 
treatment. The final part of this thesis will be concerned with a feasibility RCT 
investigating the reduction of BPV in acute ischaemic stroke. 
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3 Methodology 
 
This chapter describes the general materials and methods in this thesis. Any chapter 
specific methodology, including methods for statistical analysis, are described in that 
chapter.  
 
3.1 Trials Contributing Data to this Thesis 
 
Data for this thesis have been generated from four clinical trials, each of which is 
summarised, including my involvement. All trials were registered (ISRCTN registry) and 
full details are freely available online. The protocols for SERVED Memory and CAARBS 
have been published, as have the main findings from TEST-BP [222-224]. 
 
3.1.1 Trial of the Effectiveness and cost effectiveness of Self-monitoring and Treatment of 
Blood Pressure in secondary prevention following stroke or TIA (TEST-BP) 
(http://www.isrctn.com/ISRCTN86192648) 
 
TEST-BP was an RCT investigating the benefit of HBPM, with and without guided self-
management of antihypertensive treatment, in patients with a recent stroke or TIA. I 
was directly involved in participant follow-up, data management, and data analysis for 
this trial. Participants were adults (>18 years old) who had experienced a TIA, 
ischaemic stroke or primary ICH of mild/moderate severity (defined as National 
Institutes of Health Stroke Scale (NIHSS) score <15), who needed antihypertensive 
therapy for secondary stroke prevention (at the discretion of their clinician but based 
on UK guidelines), and were willing to self-monitor their own BP and adjust their 
treatment with study team clinician guidance if necessary. Exclusion criteria were a 
history of atrial fibrillation (AF), life expectancy less than six months due to terminal 
illness or end-stage chronic disease, diagnosed dementia or cognitive impairment, and 
not currently receiving or expected to commence antihypertensive therapy. Enhanced 
CBPM was undertaken as part of the screening procedure. 
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Participants were recruited from the inpatient and outpatient stroke services at the 
Norfolk and Norwich University Hospital (NNUH) between 72 hours and 12 weeks after 
the qualifying cerebrovascular event. At enrolment they were randomised in a 1:1:1 
ratio to one of three study arms: treatment as usual (standard BP management by 
their General Practitioner (GP)), self-monitoring only (HBPM with treatment decisions 
managed by their GP), or self-monitoring and self-management (HBPM with 
telemonitoring of results to the trial team and self-managed treatment, guided by the 
trial clinician). Study measurements, including 24 hour ABPM and beat-to-beat BP 
measurements, were taken at baseline and after a follow-up period of six months. 
Participants in the HBPM intervention groups performed self-monitoring at six weeks, 
three months, and five months post-randomisation. 
 
The main aim of the trial was to determine whether HBPM with or without guided self-
management of BP treatment resulted in lower BP levels and better control than usual 
care in hypertensive patients with a recent stroke or TIA. The primary outcome 
measure was difference in ambulatory SBP at six months, with 48 participants per 
group required to detect a difference in mean daytime ambulatory SBP of 6mmHg, 
with a power of 0.8 at the 5% significance level, assuming SD of 10.3mmHg for daytime 
ABPM [225]. 
 
3.1.2 Feasibility study of Screening and Enhanced Risk management for Vascular Event 
related Decline in Memory (SERVED Memory) 
(http://www.isrctn.com/ISRCTN42688361) 
 
SERVED Memory was a feasibility RCT investigating the impact of enhanced monitoring 
and target driven treatment of vascular risk factors on post-stroke cognitive 
impairment. My roles in this trial included participant recruitment, data acquisition at 
baseline and follow-up, data management, and data analysis. Participants were adults 
(>18 years old) with a clinically or radiologically confirmed TIA or stroke (infarct or 
primary ICH), recruited within eight weeks of the qualifying cerebrovascular event. 
Patients were excluded if they had a formal diagnosis of dementia documented in their 
past medical history, a life expectancy less than one year, and if they did not wish, or 
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were unable to complete a cognitive screening test (Montreal Cognitive Assessment 
(MoCA)). 
 
Participants were recruited from the inpatient and outpatient stroke services at NNUH. 
At enrolment they were stratified according to their baseline MoCA score and placed 
into one of three study arms. Patients with normal cognition (defined as MoCA ≥26) 
were allocated to an observational group [226]. This group received standard care, did 
not undergo any enhanced monitoring of their vascular risk factors, and had repeat 
cognitive screening after 12 months with the aim of providing data about the natural 
history of the development of post-stroke cognitive impairment. Patients with a MoCA 
score consistent with mild cognitive impairment (defined as MoCA 20-25 [226, 227]) 
were randomised in a 1:1 ratio to a control group or intervention group. Both groups 
underwent enhanced vascular risk factor measurement at baseline and after 12 
months follow-up. Vascular risk factors targeted included BP (assessed with enhanced 
CBPM, 24 hour ABPM, and beat-to-beat BP measurement) and serum cholesterol in all 
individuals. Where applicable control of diabetes (assessed with serum HbA1C), and 
adequacy of anticoagulation (being prescribed a direct oral anticoagulant, or INR 2.5-
3.0 if on warfarin) and heart rate control (target 60-80 beats per minute) in 
participants with AF were also targeted. In the interim the control group received usual 
care with no intervention by the study team, whereas those in the intervention group 
saw the trial team at three monthly intervals for additional risk factor assessment, with 
results and recommendations for interventions if necessary from these visits being 
passed to their GP for action. Patients with a MoCA score <20 were excluded from the 
trial. 
 
The primary objective of the study was to determine the feasibility of recruiting 
patients with signs of early cognitive decline, but no dementia, into the trial and to 
assess adherence to the proposed intervention. The trial also aimed to provide data 
about the incidence of post-stroke cognitive impairment, the potential benefit of the 
intervention in terms of preventing cognitive decline, and help inform the necessary 
sample size for a future potentially definitive trial. 
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3.1.3 Blood Pressure Variability – definition, natural history, and prognosis following 
acute stroke (BPV observational study) (http://www.isrctn.com/ISRCTN86821598)  
 
The BPV observational study was a prospective cohort study to investigate BPV in 
patients with an acute stroke/TIA. In this trial I participated in patient recruitment, 
follow-up, and data management. The cohort comprised adult patients with an acute 
stroke/TIA recruited within 48 hours of symptom onset. Patients with pre-event mRS 
>3, life expectancy <3 months, AF, and those required to take a beta blocker were 
excluded.  
 
Participants were recruited from the inpatient and outpatient stroke services at NNUH 
and Leicester Royal Infirmary, and the outpatient stroke services at the John Radcliffe 
Hospital in Oxford. Alongside the collection of clinical data, baseline BP was measured 
using multiple methods (beat-to-beat BP, enhanced CBPM, 24 hour ABPM) to provide 
data on BPV over various timeframes. Participants were then followed-up at five points 
over 12 months, either by telephone (providing outcome data only), or in person (with 
BP measurements being repeated on these occasions). The main aims of the trial were 
to describe the natural history of BPV after stroke/TIA, determine the optimal 
measurement method for both patients and clinicians/researchers, and provide data 
relating to the prognostic relevance of BPV after stroke/TIA. 
 
3.1.4 A Calcium channel or Angiotensin converting enzyme inhibitor/Angiotensin receptor 
blocker Regime to reduce Blood pressure variability in acute ischaemic Stroke (CAARBS): a 
feasibility trial (http://www.isrctn.com/ISRCTN10853487) 
 
CAARBS was an open label, feasibility RCT investigating the effect of two classes of 
standard antihypertensive medications on BPV in patients with ischaemic stroke or 
TIA. I was involved in the design and setup of this trial, including writing the protocol 
and gaining regulatory approvals, and acted as trial co-ordinator. At the NNUH site I 
also undertook participant recruitment and data acquisition. Finally, I was responsible 
for data management and was involved in the data analysis for this trial. Participants 
were adults with a first episode TIA or mild/moderate ischaemic stroke (NIHSS <10) 
who also required antihypertensive therapy for secondary stroke prevention (in 
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accordance with current guidelines [18]). Full inclusion and exclusion criteria are 
detailed in Table 15. 
 
Participants were recruited from the inpatient and outpatient stroke services at NNUH 
and Leicester Royal Infirmary, and the outpatient stroke services at the John Radcliffe 
Hospital in Oxford. At enrolment, they were randomised using a computer generated 
protocol with block design in a 1:1 ratio, to treatment with a dihydropyridine CCB or an 
ACEI/ARB, with the choice of medication from within the randomly allocated class at 
the discretion of the treating clinician. Follow-up data were obtained at three weeks 
and three months post-randomisation. Titration of antihypertensive medication to try 
and achieve secondary prevention target BP was allowed during follow-up, including 
the use of additional antihypertensive medications provided they were not of the class 
from the opposite intervention arm. 
 
The primary objectives of the trial were the assessment of feasibility and safety. This 
included recruitment and retention rates, compliance with trial treatment and BP 
measurements, and differences in adverse event rates between the trial arms. The 
exploratory primary outcome measure was three month mRS, with pre-specified 
exploratory secondary outcome measures including early (three week) and late (three 
month) differences in mean BP and BPV, and late differences in cognition (assessed 
using a cognitive battery including MoCA, Albert’s line test, and the Motor Neuron 
Disease Behavioural Instrument (MiND-B)). 
 
3.2 Consent 
 
All participants chose to take part in the research trials of their own volition. Eligible 
patients were provided with a participant information sheet relevant to the trial for 
which they were being considered. After having the opportunity to read the 
information sheet and ask questions about the trial, those who were willing to take 
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Table 15: Inclusion and exclusion criteria for CAARBS. 
Inclusion criteria Exclusion criteria 
Age >18 years old 
Known contra-indication to proposed 
investigational medical products 
First-ever clinically definite TIA or 
ischaemic stroke (NIHSS<10) 
Definite indication for a specific 
antihypertensive 
BP >130/80mmHg Pre-event mRS >3 
Within 72 hours of symptom onset Life expectancy <3 months 
Able to comply with antihypertensive 
treatment and BP measurements 
Atrial fibrillation 
 Unable to take oral medication 
 
Participation in another investigational 
drug trial 
 
Currently, or planning to become 
pregnant 
 
TIA denotes transient ischaemic attack; NIHSS, National Institutes of Health Stroke 
Scale; BP, blood pressure; mRS, modified Rankin score.
  
 
80 
part provided written informed consent before any study specific procedures were 
conducted. Proxy consent was not used in any of the trials. 
 
3.3 Regulatory Approvals 
 
All of the trials received ethical approval prior to commencement: 
 TEST-BP was approved by the Research Ethics Committee East of England – 
Norfolk (REC No. 11/EE/0147); 
 SERVED Memory was approved by the East of England Cambridge Research 
Ethics Committee (REC No. 15/EE/0061); 
 BPV observational study was approved by the London – South East Research 
Ethics Committee (REC No. 13/LO/0979); 
 CAARBS was approved by the London – Central Research Ethics Committee 
(REC No. 17/LO/1427).  
CAARBS was also approved by the Medicines and Healthcare products Regulatory 
Agency (EudraCT number 2017-002560-41) prior to receiving full Health Research 
Authority approval. Local approval was provided by the relevant Research and 
Development Office at all sites involved in the trials prior to their commencement.  
 
3.4 Power Calculations 
 
For the purposes of this thesis the analyses of data from TEST-BP, SERVED Memory, 
and the BPV observational study are post-hoc exploratory analyses of outcomes not 
specified at the conception of the trials. Therefore, although TEST-BP was powered for 
its primary outcome as described in section 3.1.1, power calculations for the analyses 
in this thesis were not performed. For CAARBS the primary objectives were the 
assessment of feasibility, including rates of recruitment, measurement of changes in 
BPV over three months follow-up, compliance with trial interventions, and safety of 
trial interventions. However, the trial was designed with the potential to detect a 
difference between the treatment arms as a pre-specified secondary outcome. If a 
sample of 150 patients (64 per group allowing for a 15% drop-out rate) was achieved 
this would have an 80% power at the 5% significance level of detecting an 8mmHg 
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difference in systolic BPV, assuming a mean systolic BPV SD of 14.97mmHg in the CCB 
arm and 16.95mmHg in the ACEI/ARB arm [201]. 
 
3.5 Data Collection 
 
3.5.1 Clinical Information 
 
Clinical data were collected through direct questioning to the participant and from 
review of their medical notes. Data collected included demographic information (age, 
gender, height and weight, smoking and alcohol history), past medical history, drug 
history, and relevant family history, details of the qualifying cerebrovascular event (the 
diagnosis and results of neuroimaging), and the results of routine investigations 
(including blood tests, electrocardiogram (ECG), carotid ultrasound, and further 
neuroimaging where applicable). For participants in the BPV observational study and 
CAARBS all routine ward or clinic BP measurements were recorded at baseline. 
 
3.5.2 Enhanced Clinic Blood Pressure 
 
Enhanced CBPM was undertaken in all of the studies, as part of eligibility screening in 
TEST-BP, and at baseline and follow-up visits in the other trials. I define enhanced 
CBPM as a set of three clinic/ward-based BP measures taken on the same occasion 
using a semi-automated oscillometric BP monitor (Omron 705IT, Omron Healthcare UK 
Ltd., Milton Keynes, UK) that can be used to provide an average BP reading and within-
visit BPV data. The Omron 705IT monitor is approved by the British Hypertension 
Society (BHS) and has been validated against BHS and AAMI criteria [228]. Monitors 
were regularly checked for accuracy using a greenlight reference monitor. 
Measurements were taken using an appropriately sized cuff with the patient seated, 
after a period of five minutes rest, with at least a one minute gap between readings in 
accordance with guideline recommendations [91, 229]. In the BPV observational study 
and CAARBS, two sets of enhanced CBPM measurements were recorded at each visit, 
with a gap of at least 10 minutes between sets.  
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3.5.3 Ambulatory Blood Pressure Monitoring 
 
Ambulatory monitoring in these studies was undertaken using a Spacelabs 90207 
monitor (Spacelabs Healthcare Ltd. (UK), Hertford, UK) which has been validated 
against BHS and AAMI criteria [230]. Monitoring was done over 24 hours in all studies 
except CAARBS, where only daytime ABPM was performed. Daytime was defined as 
between 0700-2200 hours with night-time conversely defined as 2200-0700 hours. 
Arm circumference was measured prior to device fitting to ensure the use of an 
appropriately sized cuff. In keeping with guideline recommendations [91], monitors 
were programmed to measure BP at 20 minute intervals during the daytime and 
hourly overnight in order to provide a minimum number of 14 daytime measurements 
and seven night-time measurements. 
 
3.5.4 Home Blood Pressure Measurement 
 
In studies collecting HBPM data (TEST-BP) participants received face-to-face, written, 
and audiovisual instruction on how to measure their own BP from a member of the 
research team. The protocol for self-monitoring was in concordance with guideline 
recommendations [91], with participants being instructed to take two measurements, 
with a gap of two minutes between them, in the morning and the evening for seven 
consecutive days. The target was for 75% of readings (i.e. ≥21 readings) to be 
completed for a set of HBPM to be considered valid. Participants were instructed to 
take measurements in the non-dominant arm, in a seated position, after a period of 
five minutes rest. They were also instructed to take measurements prior to 
antihypertensive medications or meals. In TEST-BP participants randomised to self-
monitoring only used an Omron 705IT monitor, whereas participants randomised to 
self-monitoring with self-management were provided with a different monitor (A&D 
UA-767PBT, A&D Instruments Ltd., Abingdon, UK) with the facility to telemonitor 
readings directly to the trial team. The UA-767PBT monitor is also BHS approved and 
has been validated against BHS and AAMI criteria [231]. Readings from the first day of 
recording were discarded prior to analysis. 
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3.5.5 Beat-to-beat Blood Pressure Measurement 
 
Non-invasive beat-to-beat BP recordings of 10 minutes duration were taken using the 
middle finger of the unaffected hand and an appropriately sized cuff in accordance 
with manufacturer guidance. The recording length was chosen to try to ensure that a 
minimum of five minutes valid data was available after inspection and the removal of 
artefacts. Participants were positioned supine with their arm supported at the level of 
the heart for the duration of the recording, with ECG leads attached to quantify heart 
rate by monitoring the R-R interval. A Task Force® Monitor (APC Cardiovascular Ltd, 
Southport, UK) was used in TEST-BP and SERVED Memory to obtain a single 10 minute 
recording. These participants also had a brachial oscillometric BP cuff of appropriate 
size fitted to the opposite arm to provide systemic BP calibration readings throughout 
the recording. In the BPV observational study and CAARBS recordings were made using 
the Finapres® MIDI device (Finapres Medical Systems, Enschede, The Netherlands), 
with two recordings per visit obtained in the former study and three in the latter. The 
servo adjust mechanism of the Finapres® MIDI was disabled during the recording 
period to prevent artefacts in the data, but was re-applied prior to each 10 minute 
recording for calibration. Recordings from the Finapres® MIDI were manually 
calibrated to systemic BP at the point of data inspection using a CBPM taken 
immediately prior to the recording. As previously described in section 2.4.2, both of 
these devices have been validated for the measurement of very short-term changes in 
BP and the assessment of BPV [95-97]. 
 
Both devices measure arterial BP in the finger using the “volume-clamp” method 
described by Penaz [232]. The finger cuff is inflated until the built-in plethysmograph 
detects maximal finger arterial pulsation. Finger volume is then calculated and changes 
in the cuff pressure on a beat-to-beat basis monitored (which equate to changes in 
arterial pressure). The analogue output from the devices was recorded onto a 
dedicated computer with an analogue-to-digital signal converter and appropriate 
software. Task Force® Monitor outputs were recorded using the standard bespoke 
software. Finapres® MIDI outputs were recorded using specially designed software 
(Professor Ronney Panerai, Medical Physics, University of Leicester) which was also 
used for the initial data processing as described in section 3.6. 
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3.5.6 Tools for Stroke Subtype and Severity 
 
Data on stroke severity were collected using two common scales. The NIHSS is a 
graded neurological examination designed for use in clinical trials as a rapid method 
for assessing the extent of stroke impairment. The examination tests a range of 
potential deficits due to stroke including, but not limited to, motor weakness, visual 
field defects, language, and ataxia. The scale has since been simplified and the 
modified version has been widely adopted in clinical practice as a reproducible tool 
that correlates with functional outcomes [233]. The mRS is probably the most 
frequently used scale for judging outcomes in stroke research. It is a simple validated 
scale that assesses whether the patient is functionally independent with activities of 
daily living or requires some level of assistance due to residual stroke symptoms, with 
reference to their pre-stroke functional ability [234]. 
 
As already described in section 2.1.3 and Table 1, another commonly used 
classification of stroke subtypes is by the pathophysiological TOAST classification [32]. 
This tool was used in the BPV observational study and CAARBS at baseline data 
collection. However, a limitation of the TOAST classification is that it cannot be applied 
until thorough investigations have been completed. An alternative is the OCSP 
classification (Table 16), which was employed in all of the trials described. The OCSP is 
a clinical classification which divides patients according to the vascular territory 
involved in the stroke (anterior or posterior circulation) and, for anterior circulation 
strokes, the extent of the territory involved, based on the pattern of clinical findings 
[235]. The different OCSP categories correlate with outcomes in terms of the risk of 
short and long-term mortality and the likelihood of functional recovery. 
 
3.6 Data processing 
 
I processed data from TEST-BP, SERVED Memory, and CAARBS, whereas the research 
fellow in Leicester (Karen Appiah) processed data from the BPV observational study. 
Raw BP data from clinic, ABPM, HBPM, and beat-to-beat BP measurements using the 
Task Force® Monitor were exported directly to Excel where the data were inspected 
for completeness, outlying values, and artefacts. Raw beat-to-beat BP data recorded 
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Table 16: The Oxford Community Stroke Project (OCSP) Classification [235]. 
Subtype Criteria 
Total anterior 
circulation stroke 
(TACS) 
All of: 
 Motor and/or sensory deficit of at least two of the 
face/arm/leg 
 Homonymous visual field defect 
 Higher cerebral dysfunction (e.g. aphasia, 
dyscalculia, visuospatial disorder) 
Partial anterior 
circulation stroke 
(PACS) 
One of: 
 Two out of three components of the TACS subtype 
 Higher cerebral dysfunction alone 
 Motor-sensory deficit that is more restricted than 
the LACS subtype (e.g. confined to one limb) 
Lacunar stroke (LACS) 
One of the following lacunar syndromes which correlate 
with occlusion of a single deep penetrating artery at 
strategic locations: 
 Pure motor stroke 
 Pure sensory stroke 
 Motor-sensory stroke 
 Ataxic hemiparesis 
 Dysarthria with clumsy hand 
Posterior circulation 
stroke (POCS) 
Any of: 
 Ipsilateral cranial nerve palsy and contralateral 
motor and/or sensory deficit 
 Bilateral motor and/or sensory deficit 
 Disorder of conjugate eye movement 
 Cerebellar dysfunction with ipsilateral long tract sign 
 Isolated hemianopia or cortical blindness 
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using the Finapres® MIDI were initially processed using specially designed software 
(Professor Ronney Panerai, Medical Physics, University of Leicester). This software 
allowed for the visualisation of the arterial waveform and heart trace, and was used to 
assess the quality of the recording and remove artefacts before the data was exported 
to Excel for further processing using the same method as for Task Force® Monitor 
recordings.   
 
The average values and variability of SBP and DBP for each valid recording were 
calculated using formulae embedded in the Excel worksheet. For the SBP and DBP of 
each recording the mean, SD, CV, ARV, maximum BP, minimum BP, and MMD were 
calculated as described in section 2.5.2 and Table 11, though for enhanced CBPM this 
was limited to the mean, SD, and CV due to the small number of measurements. For 
clinic BP data, variability was derived from all available readings from each visit. For 
ABPM data, BPV was derived for the whole 24 hour recording and also separately for 
daytime and night-time periods of the recording where available. For HBPM data, BPV 
was derived from all readings from days 2-7. For beat-to-beat recordings, the BPV 
formulae were applied to full recordings and also separately to each 10 minute interval 
where multiple recordings were made. 
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4 Blood Pressure Differences Between Home Monitoring and Daytime Ambulatory Values 
and their Reproducibility in Hypertensive Stroke and TIA Patients 
 
 
4.1 Declaration 
 
The study presented in this chapter has been published elsewhere as a jointly 
authored paper [236]. I devised the study and jointly designed the statistical analysis 
plan along with Dr Allan Clark, carrying out all statistical analyses myself. I authored 
the paper and the co-authors reviewed it prior to submission for publication. The co-
authors were Professor Myint and Professor Potter (co-investigators for TEST-BP which 
provided the data for the study), and Dr Allan Clark (statistician for TEST-BP). Although 
the paper has been amended for this thesis some parts, particularly the results section, 
remain substantively similar to the published version. 
 
4.2 Introduction 
 
In terms of both primary and secondary stroke prevention hypertension is one of, if 
not the most important modifiable risk factor [8, 43]. However, rates of achieving 
target BP post-stroke are suboptimal [237]. The diagnosis of high BP and monitoring 
response to antihypertensive treatment relies on having access to reliable methods 
that provide accurate and reproducible BP measurements. The traditional 
standardised method has been CBPM using a manual sphygmomanometer, yet this 
method may be undermined by factors such as poor technique, unconscious observer 
bias, terminal digit preference, and BPV [89, 90]. Whilst taking multiple CBPM values at 
successive visits may counter some of these limitations, CBPM alone is unlikely to 
provide an accurate BP in all patients (e.g. those with WCH or MH) [93]. Therefore, the 
use of out-of-office BP monitoring, using either ABPM or HBPM, is recommended to 
improve the accuracy of hypertension diagnosis and support management [54, 91, 92, 
238]. ABPM is held to be the “gold standard” technique by some [91, 156], but use of 
HBPM has become more widespread following the emergence of evidence that its use 
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can improve BP control [239]. However, uncertainties remain about the effectiveness 
of HBPM in patients with cerebrovascular disease [240]. 
 
Using the same diagnostic and monitoring threshold values for CBPM and out-of-office 
BP measurements is considered inappropriate. The guideline threshold for the upper 
limit of normal BP from daytime ABPM is <135/85mmHg [91, 92], based on 
comparisons demonstrating that for a CBPM of 140/90mmHg the equivalent daytime 
ABPM readings are on average 4/3mmHg lower [110]. HBPM is ascribed the same 
threshold value as daytime ABPM, but some studies suggest this is incorrect [241, 
242]. It is acknowledged that there is less evidence comparing HBPM with CBPM than 
is the case for ABPM [156], but also there are limited direct comparisons of HBPM with 
ABPM as the reference standard. Studies that have tried to address this gap have 
reported inconsistent findings, have not assessed the consistency of any differences 
between ABPM and HBPM, and have not enrolled high-risk patients (e.g. those with 
cerebrovascular disease) [106, 113-116, 121, 243]. Given the rising interest in BPV, 
particularly in relation to higher risk cardiovascular patient groups, there is a need to 
better establish the equivalence of BP measurement techniques as this could help with 
the standardisation of assessments for variability. 
 
4.3 Hypothesis 
 
This study aimed to investigate, using trial participants with a recent cerebrovascular 
event, whether differences exist between BP values obtained with daytime ABPM and 
HBPM. The hypothesis being tested was that the two measurement methods would 
not be equivalent in this patient group. If differences between daytime ABPM and 
HBPM were found, then the study also aimed to assess the reproducibility of these 
differences and explore related factors. 
 
4.4 Methods 
 
Data for this analysis comes from the TEST-BP trial, the methodology for which has 
been published elsewhere and is described in section 3.1.1 [223]. The methodology 
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specific to this analysis is summarised here. Participants in TEST-BP were adults with a 
recent stroke or TIA who also required antihypertensive treatment as part of their 
stroke secondary prevention management. Those randomised to one of the two home 
monitoring intervention groups who provided complete BP data (defined as baseline 
enhanced CBPM taken as the mean of three readings, ≥14 daytime ABPM readings at 
both baseline and six month follow-up, and ≥21 readings from HBPM performed at six 
weeks and five months post-randomisation) were considered eligible for this 
secondary analysis. HBPM data from the second recording period (three months after 
randomisation) were not used in this analysis. BP data was collected as described in 
sections 3.5.2 to 3.5.4. Participants had their medication history checked by the study 
nurse at each visit along with assessment of treatment compliance using a self-report 
questionnaire (Hill-Bone compliance scale). Anyone whose antihypertensive 
medications were altered between BP recordings that were planned for comparison in 
this analysis were excluded. Participants with ICH were also excluded. 
 
Outcomes for this analysis were the comparison of mean SBP and DBP from the 
baseline daytime ABPM readings with the first (six week) HBPM readings, the follow-
up ABPM readings with the last (five month) HBPM readings, and the CBPM readings 
with both the baseline daytime ABPM and first HBPM readings. 
 
4.5 Statistical Analysis 
 
SPSS version 23.0 was used for data analysis. Excluded participants were compared to 
those included using either a two-sample Student’s t-test for normally distributed 
continuous variables, a Mann-Whitney U test for non-normally distributed continuous 
variables, or a chi-squared test for categorical variables. For each measurement 
method mean SBP and DBP were calculated along with SD. Comparison of the mean 
difference in SBP and DBP between measurement methods as described above was 
based on paired Student’s t-tests. As the two intervention groups used different home 
monitors (as described in section 3.5.4), BP differences for each group were initially 
analysed separately, and subsequently pooled once it was apparent that the results of 
individually tested outcomes were comparable. Sensitivity and specificity of the 
diagnostic accuracy of HBPM was assessed against daytime ABPM as the reference 
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standard using the kappa statistic. A diagnostic threshold for hypertension of 
≥135/85mmHg was taken for both methods [54, 91, 92]. The limits of agreement in 
measuring SBP and DBP, according to Bland and Altman’s method, were derived for 
contemporaneous ABPM and HBPM recordings as defined previously [244]. To 
investigate variables that might predict individual variance in SBP or DBP difference 
from ABPM and HBPM exploratory univariate analyses were undertaken. These were 
initially descriptive, using scatter plots for continuous variables and box and whisker 
plots for categorical variables. Where descriptive analyses suggested possible 
relationships they were further explored with formal testing, using Pearson’s 
correlation for continuous variables and independent samples t tests for categorical 
variables. The potential predictor variables tested were age, gender, body mass index 
(BMI), baseline clinic BP, being on antihypertensive treatment, history of diabetes, 
diagnosis (TIA or stroke), baseline mRS, baseline cognition (assessed using MoCA 
score), and the number of measurements from daytime ABPM and HBPM. 
 
4.6 Results 
 
Ninety-nine participants were randomised to one of the two trial intervention arms 
and were therefore eligible for inclusion in this analysis. Nineteen of them were 
excluded, 11 because their antihypertensive therapy was altered in between BP 
monitoring periods that were compared, and eight because they returned an 
insufficient number of HBPM measurements from one or both of the recordings. This 
left 80 participants for analysis. Demographics of those included and are presented in 
Table 17. There were no significant differences between the groups. 
 
Mean CBPM SBP and DBP values were the highest, followed by HBPM values and then 
daytime ABPM values (Table 18). The difference in mean BP values from HBPM and 
daytime ABPM were consistent across both comparisons (Figure 5), were similar for 
both trial groups, and were unrelated to the HBPM device that was used (Table 19). 
Medication adherence judged by self-assessment was good at baseline and follow-up 
(median Hill-Bone score 9.0 [IQR 1.0] for both periods). 
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Table 17: Demographic data. Data presented are mean (SD) or frequency (%). Alcohol 
use and mRS are presented as median (IQR).  
  Included Excluded 
N  80 19 
Age (years)  74.1 (10.3) 75.4 (8.8) 
Gender Male 53 (66.3%) 12 (63.2%) 
BMI (kg/m2)  28.6 (5.3) 26.8 (2.1) 
Smoking status 
Never 36 (45.0%) 6 (31.6%) 
Ex-smoker 40 (50.0%) 13 (68.4%) 
Current smoker 4 (5.0%) 0 (0.0%) 
Alcohol (units/week)  4.0 (14.0) 4.0 (12.0) 
Diagnosis Stroke 27 (33.8%) 5 (26.3%) 
OCSP classification 
LACS 9 (33.3%) 4 (80.0%) 
PACS 9 (33.3%) 1 (20.0%) 
TACS 1 (3.7%) 0 (0.0%) 
POCS 8 (29.6%) 0 (0.0%) 
Baseline mRS (stroke only)  1.0 (1.0) 1.0 (1.0) 
Past medical history 
TIA 51 (63.7%) 15 (78.9%) 
Stroke 33 (41.3%) 7 (36.8%) 
IHD 20 (25.0%) 4 (21.1%) 
Diabetes 17 (21.3%) 5 (26.3%) 
Hypertension 58 (72.5%) 14 (73.7%) 
On antihypertensive therapy  75 (93.8%) 17 (89.5%) 
Antihypertensive use by class 
ACEI 52 (65.0%) 10 (52.6%) 
ARB 11 (13.8%) 4 (21.1%) 
Beta blockers 15 (18.8%) 6 (31.6%) 
CCB 33 (41.3%) 9 (47.4%) 
Thiazide-like 
diuretics 
14 (17.5%) 4 (21.1%) 
SD denotes standard deviation; mRS, modified Rankin score; IQR, interquartile range; BMI, 
body mass index; OCSP, Oxford Community Stroke Project; LACS, lacunar stroke; PACS, partial 
anterior circulation stroke; TACS, total anterior circulation stroke; POCS, posterior circulation 
stroke; TIA, transient ischaemic attack; IHD, ischaemic heart disease; ACEI, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. 
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Table 18: Mean (SD) group systolic and diastolic blood pressure from each 
measurement method. 
Measurement 
method 
Number of 
measurements 
Mean SBP (mmHg) Mean DBP (mmHg) 
Baseline CBPM 3 (0) 150.8 (20.2) 85.1 (11.8) 
Baseline daytime 
ABPM 
38.1 (9.1) 133.5 (13.7) 76.4 (8.5) 
HBPM at six weeks 27.3 (1.4) 140.1 (15.8) 78.5 (8.7) 
HBPM at five 
months 
26.8 (3.1) 134.7 (13.7) 76.2 (9.7) 
Daytime ABPM at 
six months 
37.2 (8.4) 127.6 (12.2) 74.2 (9.2) 
SD denotes standard deviation; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; CBPM, clinic blood pressure measurement; ABPM, ambulatory blood 
pressure measurement; HBPM, home blood pressure measurement. 
 
 
Figure 5: Mean differences in blood pressure for head-to-head comparisons of out-of-office 
measurement methods. Error bars are 95% confidence intervals. P values represent paired 
Student’s t-tests comparing the difference between measurement methods. ABPM denotes 
ambulatory blood pressure measurement; HBPM, home blood pressure measurement; SBP, 
systolic blood pressure; DBP, diastolic blood pressure. 
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1st ABPM vs HBPM SBP 
1st ABPM vs HBPM DBP 
2nd ABPM vs HBPM SBP 
2nd ABPM vs HBPM DBP 
p<0.0001 p<0.000
p=0.03 p=0.02 
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Table 19: Mean differences in systolic and diastolic blood pressure between home and 
daytime ambulatory blood pressure measurements at different time-points according 
to intervention group and type of home monitor used. Data presented are mean (SD) 
or mean (95% CI). P values represent independent samples t-tests to investigate the 
mean difference in blood pressure between the two groups. 
 
Home 
monitoring 
only 
(N=42) 
Home 
monitoring 
with guided 
self-
management 
(N=38) 
Mean 
difference 
between 
groups 
P value 
Baseline daytime 
ABPM vs. first HBPM 
SBP (mmHg) 
-7.6 (14.4) -5.5 (12.6) 
-2.1 
(-8.1 to 4.0) 
0.49 
Baseline daytime 
ABPM vs. first HBPM 
DBP (mmHg) 
-1.5 (8.9) -2.8 (8.1) 
1.3 
(-2.5 to 5.1) 
0.50 
Follow-up daytime 
ABPM vs. last HBPM 
SBP (mmHg) 
-8.1 (11.2) -5.9 (10.9) 
-2.2 
(-7.1 to 2.7) 
0.38 
Follow-up daytime 
ABPM vs. last HBPM 
DBP (mmHg) 
-1.1 (7.0) -2.9 (7.4) 
1.8 
(-1.4 to 5.0) 
0.27 
SD denotes standard deviation; 95% CI, 95% confidence interval; ABPM, ambulatory 
blood pressure measurement; HBPM, home blood pressure measurement; SBP, 
systolic blood pressure; DBP, diastolic blood pressure.
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The limits of agreement for ABPM vs. HBPM for the first comparison of SBP were -33.0 
to 19.9mmHg and for the second comparison were -28.7 to 14.5mmHg (Figure 6). For 
DBP the limits of agreement were -18.8 to 14.5mmHg and -16.1 to 12.2mmHg 
respectively. For the whole cohort the differences in mean SBP and DBP were 
consistent across both comparisons, however, this was not the case for individual 
participants. For the difference in SBP between daytime ABPM and HBPM the mean 
change over time was 11.0 ± 8.3mmHg (range 0.65 to 43.3mmHg), and the mean 
change for DBP was 6.5 ± 5.1mmHg (range 0.21 to 19.8mmHg) (Figure 7). Exploratory 
analyses for variables that might predict the differences between daytime ABPM and 
HBPM values did not reveal any clear significant relationships. Descriptive testing 
suggested possible relationships with being on antihypertensive treatment and 
baseline clinic SBP (Figures 8-9), but further testing of the latter showed only a weak 
correlation (r=-0.25, p=0.02) that was not consistent across both comparisons. Further 
testing of the former was not possible due to the small number of participants (N=5) 
who were not taking antihypertensive medications.  
 
Taking a diagnostic threshold value for hypertension of ≥135/85mmHg for both 
methods and using daytime ABPM as the reference standard, HBPM had a diagnostic 
sensitivity of 76.1% and specificity of 55.9% (k=0.36, p=0.004) when comparing the 
first set of readings. Using the second set of readings provided consistent data, with 
HBPM having a diagnostic sensitivity of 70.8% and specificity of 55.4% (k=0.22, 
p=0.03). At baseline, 46/80 (57.5%, 95% CI 46.3-67.9%) participants were classified as 
having uncontrolled hypertension according to daytime ABPM readings and at follow-
up the rate was 24/80 (30.0%, 95% CI 20.0-40.3%). Using HBPM readings, 50/80 
(62.5%, 95% CI 52.5-72.7%) were classified as uncontrolled hypertension on the first 
recording and 42/80 (52.5%, 95% CI 41.7-63.6%) on the second recording. 
Classification of hypertension status was the same according to both methods in 54/80 
(67.5%, 95% CI 57.8-77.8%) participants at the first recording period (35 uncontrolled 
hypertension and 19 controlled hypertension) and 48/80 (60.0%, 95% CI 49.4-71.6%) 
at the second recording period (17 uncontrolled hypertension and 31 controlled 
hypertension).  
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Figure 6: Bland-Altman plots to show the limits of agreement for within-individual 
blood pressure recorded by ambulatory blood pressure measurement (ABPM) and 
home blood pressure measurement (HBPM). Thick lines show the mean difference, 
dotted lines the 95% confidence interval for the mean difference, and dashed lines the 
limits of agreement (± 2 SD). A shows systolic blood pressure (SBP) comparing baseline 
ABPM and the first HBPM. B shows SBP comparing outcome ABPM and the last HBPM. 
C shows diastolic blood pressure (DBP) comparing baseline ABPM and the first HBPM. 
D shows DBP comparing outcome ABPM and the last HBPM. SD denotes standard 
deviation. 
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Figure 7: Histograms to show the change in the blood pressure difference recorded by 
daytime ambulatory and home blood pressure measurement from the first to the 
second comparison for individuals. A shows the change in systolic blood pressure 
(SBP). B shows the change in diastolic blood pressure (DBP). 
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Figure 8: Box and whisker plots showing the difference in blood pressure between baseline 
daytime ambulatory blood pressure measurement and the first home blood pressure 
measurement according to whether individuals were taking antihypertensive treatment. A is 
the difference in systolic blood pressure (SBP). B is the difference in diastolic blood pressure 
(DBP).
A 
B 
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Figure 9: Scatter plots showing mean clinic systolic blood pressure (SBP) at baseline plotted 
against the difference in SBP from daytime ambulatory blood pressure measurement (ABPM) 
and home blood pressure measurement (HBPM). Fit lines and r values represent Pearson’s 
correlation between the two values. A is the SBP difference from the first comparison. B is the 
SBP difference from the second comparison.
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4.7 Discussion  
 
These data show that in a population with a recent cerebrovascular event there are 
significant differences in BP measurements obtained from daytime ABPM compared to 
HBPM, with the former approximately 7/2mmHg lower than the latter on average. This 
difference was consistent across two recording periods several months apart. Although 
the average difference between the measurement methods was reproducible, the 
limits of agreement were wide and for individuals the difference between the methods 
was not consistent over time. This suggests that BP values obtained using daytime 
ABPM cannot be used to infer values from HBPM, and vice versa, meaning that the 
methods may not be interchangeable. Additionally, the difference recorded was large 
enough that it could be clinically important, considering a reduction in SBP in the order 
of 10mmHg might reduce the risk of stroke by as much as 30% [9, 43]. The difference 
might also influence patient management, potentially causing discordant treatment 
decisions depending on which method is used to confirm diagnosis or monitor 
treatment response. In this group, using the same threshold value for both methods 
(≥135/85mmHg) resulted in a mismatch in classification of hypertension status in 
26/80 (32.5%) participants at baseline and 32/80 (40.0%) at follow-up, which is not an 
insignificant proportion. Unfortunately, in the exploratory analysis no predictive 
factors for the observed measurement differences were demonstrated, with the 
possible relationship with clinic SBP likely to be a chance finding. 
 
CBPM has been used as the reference standard to assess both ABPM and HBPM [110, 
245], but fewer studies have directly compared both out-of-office methods. Of those 
that have, not all have used an HBPM protocol consistent with current guidelines. 
Several studies have reported findings consistent with this analysis. A randomised 
controlled trial investigating the benefit of HBPM in hypertensive adults recruited from 
primary care reported a difference of -3.1/+0.7mmHg between daytime ABPM and 
HBPM at follow-up, though this was not formally investigated [246]. Similarly, 
differences between daytime ABPM and HBPM ranging from -5 to -7mmHg for SBP and 
-1 to -4mmHg for DBP have been reported in three cross-sectional studies that 
recruited either treated or untreated hypertensive adults [106, 116, 121]. Comparable 
limits of agreement have also been reported elsewhere [247]. Conversely, equivalence 
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between daytime ABPM and HBPM has been reported in one study on untreated 
hypertensive adults [115]. Importantly, none of these studies performed repeated BP 
measures to investigate the reproducibility of any differences.  
 
The age of included participants could at least in part account for differences in the 
literature, and may partly explain the results of this analysis, as there is evidence that 
the difference between the two methods may alter across age groups [113, 114]. It is 
reported that daytime ABPM values are higher than HBPM values in children, but with 
increasing age the two values converge and may cross over at around 60 years. That 
age was not a predictive factor for the difference between the two methods in this 
cohort might be due to the narrow age range of included participants. Nevertheless, as 
many people experience their first cerebrovascular event at older ages the difference 
remains relevant. Alternatively, being on antihypertensive treatment (which is more 
likely with increasing age) may relate to the difference between the two methods [106, 
248]. This could be because morning HBPM measurements are routinely taken prior to 
medications, thereby capturing BP at the trough of antihypertensive activity. These 
‘trough values’ might be less influential to mean values from daytime ABPM than 
HBPM due to the increased number of measurements acquired per day. Similarly, 
increased BPV in an individual might also account for differences between 
measurement methods with varying numbers of readings. Greater BPV could 
potentially increase mean values from HBPM relative to daytime ABPM due to there 
being fewer measurements to contribute to the average, resulting in the differences 
seen here. Importantly, the recent cerebrovascular event is unlikely to have 
confounded BP readings from participants in this study as it has been demonstrated 
that patients with previous stroke are able to accurately measure their own BP [249]. 
 
In terms of diagnostic accuracy at a threshold value of ≥135/85mmHg, a sensitivity of 
86% and specificity 62% has been reported for HBPM assessed against daytime ABPM 
as reference, which is in keeping with the findings of this analysis [243]. Whether these 
values are sufficiently high is at least in part a matter of judgement. However, one 
other study has suggested, as suggested here, that the difference may have important 
clinical consequences at an individual patient level by showing that despite both 
daytime ABPM and HBPM diagnosing the same proportion of a cohort with MH, it was 
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not the same people that were diagnosed by both methods. In fact, almost half of 
those diagnosed with MH by daytime ABPM were not according to HBPM [250]. The 
question of the equivalence and diagnostic accuracy of out-of-office BP measurement 
methods may also be relevant when considering the measurement of BPV. Firstly, 
there is evidence that BPV increases linearly with mean BP [130, 251]. Therefore, if 
different methods are not interchangeable with respect to measuring BP it may also be 
the case that they differ in their measurement of BPV, perhaps simply because 
recorded mean BP may be higher, or perhaps because different aspects of an 
individual’s BP profile are captured. Secondly, although threshold values for variability 
are yet to be established, if threshold values for absolute BP differ between 
measurement methods it might also be expected that BPV thresholds will not be 
equivalent. It will therefore be important to assess whether BPV values from different 
measurement methods are in agreement, and, if not, what level of BPV is of relevance 
for each method. 
 
These data, and the wider literature, support the assertion that daytime ABPM and 
HBPM are not interchangeable methods of BP measurement, despite the 
recommendation in hypertension guidelines that the same threshold values should be 
used for both methods [91, 229]. It therefore follows that, in an individual, the 
diagnosis of raised BP and the follow-up of response to antihypertensive treatment 
should not be based on a mix of out-of-office measurements using these different 
methods. Choosing which method to utilise may come down to questions of cost, ease 
of use and interpretation, and patient preference, all of which may favour HBPM over 
ABPM. However, if accuracy of measurement is the primary concern then it is likely 
that ABPM will be the method of choice. Firstly, the threshold values for raised BP as 
they apply to ABPM have been more clearly established than for HBPM. Secondly, 
ABPM is less prone to measurement and reporting bias because the patient takes no 
role in acquiring readings. Thirdly, a greater number of BP readings are obtained when 
using ABPM, with the further addition of nighttime readings when recording is 
performed over 24 hours. For these reasons, and also because it is likely that improved 
accuracy will be important for the measurement of BPV, it is my opinion that at 
present ABPM should be favoured over HBPM where both modalities are available. 
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A strength of this study is that it was possible to compare values from daytime ABPM 
and HBPM at two different times in the same population, thereby providing data about 
the consistency of the difference between the two methods and allowing 
consideration of the reproducibility of this difference. It was also the first study, to the 
best of my knowledge, to compare and assess the limits of agreement between 
daytime ABPM and HBPM in a population with cerebrovascular disease. However, the 
study is not without its limitations. Firstly, whilst I argue that selecting a high-risk 
population is a strength of the study, it does also limit the generalisability of the 
findings. Secondly, this is a post-hoc analysis with a relatively small sample size and so 
should be interpreted with caution, as it was not powered to assess the stated 
outcomes. Thirdly, the findings could be influenced by methodological factors, such as 
the short time lag between measurements that were compared, the use of two 
different home BP monitors, or patients being on antihypertensive treatment. With 
regard to the former this is not a unique feature of this study, with other studies 
comparing measurements taken up to 4-6 weeks apart [114, 116, 121], and I have tried 
to mitigate the impact of the latter two potential issues through the statistical analysis 
approach and participant selection. 
 
4.8 Summary 
 
 Significant differences exist between BP values from daytime ABPM and HBPM, 
despite guidelines recommending the same threshold values for both methods. 
 Differences were not consistent between individuals suggesting that daytime 
ABPM and HBPM are not interchangeable. 
 The difference might be clinically important given its magnitude and the 
potential to result in over or under-treatment of patients depending on which 
measurement method is used. 
 The difference also has implications for the measurement of BPV as, if different 
measurement methods are not equivalent in their assessment of absolute BP, it 
might reasonably be expected that they will also be at variance in their 
assessment of BPV. 
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 It is my opinion that ABPM should be favoured over HBPM as this method is 
likely to provide the most accurate estimation of a patient’s BP and its 
variability. 
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5 A Comparison of Beat-to-beat Blood Pressure Variability with Variability Derived from 
other Blood Pressure Measurement Methods in Patients with Cerebrovascular Disease 
 
 
5.1 Introduction 
 
BPV, as opposed to mean BP level, has been proposed as a potential explanatory factor 
for gaps in the established theory of BP as a cardiovascular risk factor [126]. Evidence 
is accumulating to suggest that BPV is a cardiovascular risk factor independent of mean 
BP [128, 152, 153]. Increased BPV may also be associated with adverse outcomes after 
acute ischaemic stroke [98], its relevance being related to the reliance of CBF on 
systemic BP in the face of disordered cerebral autoregulation post stroke [13]. In the 
previous chapter it was demonstrated that there are discrepancies between commonly 
used out-of-office BP measurement methods in quantifying mean BP in patients with a 
recent ischaemic cerebrovascular event. This may have implications for the 
measurement of BPV, as variability from different measurement methods may also be 
discordant in this patient group. At present there is a lack of consistency in how BPV is 
defined in the literature, with no consensus on the optimal approach to measurement 
and calculation, and a lack of evidence as to whether treatment that reduces BPV is of 
value [90, 155, 156].  
 
One factor in this lack of consistency is that BPV can be measured over different 
timescales depending on the BP measurement method used. Potential timescales 
range from the very short-term (over seconds to minutes) using beat-to-beat BP 
monitoring, through the short-term (minutes to hours) and medium-term (hours to 
days) using ABPM and HBPM respectively, up to the long-term (months to years) 
usually derived from repeated CBPM over time. All timescales of BPV have been shown 
to predict cardiovascular risk [128, 131, 200, 252-254], but studies suggest that their 
prognostic relevance may not be equal [90, 131, 155]. Furthermore, the few studies 
that have made direct comparisons of different timescales of variability indicate that 
they are not closely correlated. Comparisons reported to date include within-visit or 
visit-to-visit clinic BPV over eight weeks with 24 hour or daytime ABPM and HBPM 
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[160], daytime ABPM with HBPM and visit-to-visit clinic BPV over four weeks [118], 
and beat-to-beat BPV with 24 hour ABPM and HBPM [134].  
 
Beat-to-beat BPV is increased in acute ischaemic stroke [100]. Furthermore, the 
evidence that BPV is associated with stroke outcome relates to short-term BPV 
measured over minutes or hours [15]. Beat-to-beat BPV may therefore be of particular 
importance in this patient group. However, beat-to-beat BP measurement is not 
routinely used in clinical practice, with guideline recommended methods, such as 
CBPM, ABPM and HBPM, being more commonplace [91, 92]. Consequently, only one 
study comparing timescales of BPV has included beat-to-beat measurements [134]. 
This study enrolled untreated hypertensive adults without any cerebrovascular disease 
and did not assess whether beat-to-beat BPV has any relationship with other shorter-
term BPV measurements (i.e. within-visit clinic BPV, or within-hour BPV calculated 
from ABPM measurements). Investigation of this would be useful to determine if these 
alternative measurements could be used as a surrogate for beat-to-beat BPV 
measurement.  
 
5.2 Hypothesis 
 
Using data from the TEST-BP trial, the aim of this analysis was to compare beat-to-beat 
BPV with variability from other measurement methods with the intention of assessing 
comparisons not previously reported, and making these comparisons in a cohort of 
patients with cerebrovascular disease. The hypothesis being tested is that BPV values 
calculated over different timescales will not have significant inter-relationships and will 
not provide interchangeable data. 
 
5.3 Methods 
 
Data for this analysis comes from the TEST-BP trial, which was a trial of BP self-
monitoring and guided self-management in patients with a recent stroke or TIA. The 
general methodology for TEST-BP is described in section 3.1.1 and has been published 
elsewhere [223]. The methodology specific to this secondary analysis is described here. 
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Eligible participants were subjects from TEST-BP who had a complete set of baseline BP 
data, including enhanced CBPM with three readings, daytime ABPM with ≥14 readings, 
and beat-to-beat measurement with a recording duration of ≥ 5minutes after data 
cleaning, all of which were recorded at the same visit. An additional subgroup of 
participants who undertook HBPM six weeks after the baseline visit was also included. 
Participants with BP data that was incomplete according to these criteria or who were 
diagnosed with ICH were excluded. Participants were excluded from the subgroup if 
they provided <21 HBPM readings or if their antihypertensive medications were 
altered between the baseline visit and the HBPM recording period at six weeks. 
 
BP measurements from the baseline visit have been used in this analysis, along with 
the first set of HBPM measurements taken at six weeks for the subgroup. BP 
measurements for each method were taken as described in sections 3.5.2 to 3.5.5. 
Mean and variability values for SBP and DBP from each BP measurement method were 
calculated as described in section 3.6. In addition to variability over the whole daytime 
period, within-hour BPV was calculated from ABPM recordings. For each hourly period 
with at least two valid measurements the mean, SD, CV, ARV and MMD of these 
measurements were calculated, with the arithmetic means of these calculated values 
representing within-hour mean and BPV values. 
 
Outcomes for this analysis were the comparison of beat-to-beat BPV indices with the 
same index from other contemporaneous measurement methods, including CBPM, 
daytime ABPM, and HBPM, and the assessment of their limits of agreement. 
 
5.4 Statistical Analysis 
 
Data were analysed using SPSS version 25.0. Scatter plots were constructed to visually 
assess the relationship between each BPV index from beat-to-beat measurements with 
the same BPV index from other measurement methods. BPV data were not normally 
distributed; therefore formal testing of correlations between BPV indices from 
different measurement sets was undertaken using Spearman’s rho. Conversely, mean 
BP measurements were normally distributed and so were formally compared using 
Pearson’s correlations.  Correlations were considered weak if r or rs=0.10-0.29, 
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moderate if r or rs=0.30-0.49, and strong if r or rs=>0.50 [255]. Further exploration of 
the relationships between beat-to-beat BPV and variability from other measurement 
methods was conducted where there was a suggestion of a positive relationship. This 
was done using Bland and Altman’s method for assessing the limits of agreement 
between tests [244]. The mean value for both methods was plotted against the 
difference between them, with reference lines added to the plot to show the mean 
difference and two standard deviations either side of the mean. Outliers were 
excluded to ensure that the differences between methods were normally distributed 
(p>0.05 using the Kolmogorov-Smirnov test correlated against a histogram of the data 
with distribution curve). Due to weak or moderate correlations between the mean 
values and the differences, the latter were plotted as ratio data rather than absolute 
values. As this was an exploratory analysis no adjustments for multiple testing were 
made, with p<0.05 considered statistically significant. 
 
5.5 Results 
 
One hundred and thirty three participants from the trial had complete baseline BP 
data, with a subgroup of 82 providing valid HBPM data in addition to the baseline 
measurements. Demographic data for the full cohort and the HBPM subgroup is 
presented in Table 20.  
 
Mean SBP and DBP, and median values for BPV indices from each measurement 
method for the whole cohort and the HBPM subgroup are displayed in Tables 21-22. 
BPV values from within-hour ABPM appeared to be more closely matched to beat-to-
beat BPV than other methods. The exception to this was ARV, where values from 
within-hour ABPM were more closely matched to daytime ABPM, with ARV from beat-
to-beat measurements different to all other methods.  
 
Mean SBP and DBP from each method was moderately or strongly correlated with the 
corresponding mean value from beat-to-beat BP (r=0.33-0.62, p<0.01 for all 
correlations). However, correlations between BPV indices were either weak or non-
significant, with the exception of ARV of DBP from daytime ABPM and HBPM with 
beat-to-beat measurement which showed moderate correlations (rs=0.32 and 0.34  
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Table 20: Demographic data. Data presented are mean (SD) for normally distributed 
continuous variables, median (IQR)* for non-normally distributed continuous variables, 
and frequency (%) for categorical variables. 
  All HBPM subgroup 
N  133 82 
Age (years)  73.7 (9.9) 74.9 (9.6) 
Gender Male 86 (64.7%) 55 (67.1%) 
BMI (kg/m2)  28.7 (5.0) 28.5 (4.8) 
Smoking status 
Never smoked 53 (39.8%) 33 (40.2%) 
Ex smoker 74 (55.6%) 46 (56.1%) 
Current 
smoker 
6 (4.5%) 3 (3.7%) 
Alcohol 
(units/wk)* 
 4.0 (16.0) 5.0 (16.0) 
Diagnosis Stroke 41 (30.8%) 26 (24.4%) 
NIHSS (stroke 
patients only)* 
 3.0 (2.5) 2.0 (2.0) 
OCSP 
classification 
LACS 17 (41.5%) 11 (42.3%) 
PACS 16 (39.0%) 8 (30.8%) 
TACS 1 (2.4%) 1 (3.8%) 
POCS 7 (17.1%) 6 (23.1%) 
Past medical 
history 
TIA 93 (69.9%) 56 (68.3%) 
Stroke 52 (39.1%) 33 (40.2%) 
IHD 28 (21.1%) 20 (24.4%) 
Diabetes 35 (26.3%) 20 (24.4%) 
Hypertension 98 (73.7%) 63 (76.8%) 
On 
antihypertensive 
therapy 
 124 (93.2%) 76 (92.7%) 
No. of 
antihypertensives 
 1.7 (0.9) 1.7 (1.0) 
Antihypertensive ACEI 78 (58.6%) 50 (61.0%) 
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use by class ARB 22 (16.5%) 14 (17.1%) 
Beta blockers 34 (25.6%) 18 (22.0%) 
CCB 54 (40.6%) 31 (37.8%) 
Thiazide-like 
diuretics 
23 (17.6%) 15 (18.3%) 
 
SD denotes standard deviation; IQR, interquartile range; HBPM, home blood pressure 
measurement; BMI, body mass index; NIHSS, National Institutes of Health Stroke Scale; 
OCSP, Oxford Community Stroke Project; LACS, lacunar stroke; PACS, partial anterior 
circulation stroke; TACS, total anterior circulation stroke; POCS, posterior circulation 
stroke; TIA, transient ischaemic attack; IHD, ischaemic heart disease; ACEI, angiotensin 
converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel 
blocker. 
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Table 21: Average baseline blood pressure and blood pressure variability parameters 
from each measurement method in the full cohort. Mean systolic and diastolic blood 
pressure are presented as mean (SD). Systolic and diastolic variability values are 
presented as median (IQR). 
 Enhanced 
CBPM 
Beat-to-beat BP Daytime ABPM 
Within-hour 
ABPM 
Mean SBP 
(mmHg) 
152.1 (19.3) 131.9 (16.3) 135.1 (14.0) 134.9 (14.0) 
Mean DBP 
(mmHg) 
83.7 (12.0) 81.0 (12.7) 76.1 (8.9) 76.0 (9.0) 
SD SBP  
(mmHg) 
5.4 (3.7) 5.4 (2.9) 13.2 (5.1) 6.3 (2.2) 
SD DBP  
(mmHg) 
2.9 (3.3) 4.2 (2.3) 8.9 (3.1) 4.4 (1.4) 
CV SBP  
(%) 
3.7 (2.4) 4.1 (2.1) 9.7 (3.5) 4.6 (1.4) 
CV DBP  
(%) 
3.5 (3.4) 5.2 (2.6) 11.6 (4.7) 5.8 (2.1) 
ARV SBP 
(mmHg) 
- 1.5 (1.0) 9.4 (3.0) 10.1 (3.1) 
ARV DBP 
(mmHg) 
- 1.1 (0.8) 7.1 (2.3) 7.0 (2.6) 
MMD SBP 
(mmHg) 
- 32.5 (21.6) 58.0 (24.0) 33.8 (20.3) 
MMD DBP 
(mmHg) 
- 26.8 (16.9) 46.0 (13.5) 23.8 (12.7) 
 
CBPM denotes clinic blood pressure measurement; BP, blood pressure; ABPM, 
ambulatory blood pressure measurement; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; SD, standard deviation; CV, coefficient of variation; ARV, average real 
variability; MMD, maximum-minimum difference.
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Table 22: Average baseline blood pressure and blood pressure variability parameters 
from each measurement method in the home blood pressure measurement subgroup. 
Mean systolic and diastolic blood pressure are presented as mean (SD). Systolic and 
diastolic variability values are presented as median (IQR). 
 
Enhanced 
CBPM 
Beat-to-beat 
BP 
Daytime 
ABPM 
Within-hour 
ABPM 
HBPM 
Mean SBP 
(mmHg) 
151.2 (19.6) 132.9 (17.0) 135.0 (13.6) 134.9 (13.3) 141.7 (16.6) 
Mean DBP 
(mmHg) 
84.4 (11.6) 81.6 (12.5) 76.4 (8.3) 76.3 (8.4) 77.8 (8.4) 
SD SBP 
(mmHg) 
5.4 (4.1) 5.4 (2.7) 13.2 (5.4) 6.3 (2.3) 11.2 (4.4) 
SD DBP 
(mmHg) 
3.1 (3.3) 4.0 (2.4) 9.1 (3.1) 4.3 (1.3) 6.2 (2.8) 
CV SBP  
(%) 
3.8 (2.4) 4.2 (2.2) 9.6 (3.3) 4.7 (1.5) 8.0 (3.0) 
CV DBP  
(%) 
3.8 (3.2) 5.0 (2.9) 11.5 (4.5) 5.7 (1.8) 8.3 (3.0) 
ARV SBP 
(mmHg) 
- 1.5 (1.0) 9.2 (3.2) 9.9 (3.6) 11.2 (5.2) 
ARV DBP 
(mmHg) 
- 1.0 (0.9) 7.1 (2.3) 7.0 (2.5) 6.0 (3.1) 
MMD SBP 
(mmHg) 
- 33.0 (23.3) 58.5 (23.8) 32.7 (21.8) 47.0 (19.3) 
MMD DBP 
(mmHg) 
- 26.5 (19.1) 44.5 (14.3) 23.9 (12.1) 25.0 (12.0) 
 
CBPM denotes clinic blood pressure measurement; BP, blood pressure; ABPM, 
ambulatory blood pressure measurement; HBPM, home blood pressure measurement; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation; CV, 
coefficient of variation; ARV, average real variability; MMD, maximum-minimum 
difference.
  
 
112 
respectively, p<0.01 for both correlations) (Tables 23-24). Correlations between beat-
to-beat BPV and within-hour ABPM variability parameters were not stronger than 
correlations with variability from other methods. The Bland-Altman analyses of the 
relationship between beat-to-beat and within-hour ABPM systolic BPV (Figure 10) 
showed a large bias for ARV of SBP (mean difference -142.82% (95% confidence 
interval -146.53% to -139.11%), but not for SD (mean difference -11.60% (95% 
confidence interval -19.04% to -4.16%), CV (mean difference -9.08% (95% confidence 
interval -16.29% to -1.87%), or MMD (mean difference -0.73% (95% confidence 
interval -9.67% to 8.20%). However, the limits of agreement were wide ranging for all 
measures of systolic BPV (SD = -96.61% to 73.41%, CV = -91.50% to 73.34%, ARV = -
184.39% to -101.25%, MMD = -102.83% to 101.37%). The analyses comparing beat-to-
beat with daytime ABPM systolic BPV (Figure 11) and beat-to-beat with HBPM systolic 
BPV (Figure 12) showed a moderate to large bias and wide ranging limits of agreement 
for all BPV indices. Findings for DBP were similar to those for SBP (Figures 13-15). 
Further comparison of beat-to-beat BPV and within-visit clinic BPV was deemed not 
appropriate. 
 
5.6 Discussion 
 
These data show that there is no evidence of significant relationships between BPV 
from beat-to-beat BP measurements and within-visit variability from enhanced CBPM. 
They also show that, despite apparent similarities between the average values 
obtained with beat-to-beat and within-hour ABPM BPV measurements, which are not 
present between beat-to-beat and other methods of assessing BPV, these two 
methods of measuring BPV are not closely correlated. Furthermore, the limits of 
agreement between the two methods are wide ranging, suggesting that they are not 
interchangeable methods of measuring BPV. When assessing beat-to-beat with 
daytime ABPM and beat-to-beat with HBPM the correlations were also weakly 
significant at best, with even more wide ranging limits of agreement and marked bias 
in the mean differences between these methods.  
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Table 23: Correlations for systolic blood pressure and variability between beat-to-beat 
and other blood pressure measurement methods. Correlations are based on the full 
cohort, except those with home blood pressure measurements which are based on the 
subgroup only. Correlations are Pearson’s r for mean values and Spearman’s rho for 
BPV values. *p<0.05 **p<0.01. 
Comparator Mean SD CV ARV MMD 
Enhanced 
CBPM 
0.50** 0.04 -0.01 - - 
Daytime ABPM 0.35** 0.26** 0.23** 0.23** 0.17 
Within-hour 
ABPM 
0.33** 0.20* 0.20* 0.25** 0.11 
HBPM 0.50** 0.20 0.17 0.27* 0.20 
SD denotes standard deviation; CV, coefficient of variation; ARV, average real variability; 
MMD, maximum-minimum difference; CBPM, clinic blood pressure measurement; ABPM, 
ambulatory blood pressure measurement; HBPM, home blood pressure measurement. 
 
 
Table 24: Correlations for diastolic blood pressure and variability between beat-to-
beat and other blood pressure measurement methods. Correlations are based on the 
full cohort, except those with home blood pressure measurements which are based on 
the subgroup only. Correlations are Pearson’s r for mean values and Spearman’s rho 
for BPV values. *p<0.05 **p<0.01. 
Comparator Mean SD CV ARV MMD 
Enhanced 
CBPM 
0.62** 0.06 0.02 - - 
Daytime ABPM 0.57** 0.27** 0.28** 0.32** 0.18* 
Within-hour 
ABPM 
0.55** 0.17 0.21* 0.29** 0.13 
HBPM 0.55** 0.28* 0.28* 0.34** 0.29** 
SD denotes standard deviation; CV, coefficient of variation; ARV, average real variability; 
MMD, maximum-minimum difference; CBPM, clinic blood pressure measurement; ABPM, 
ambulatory blood pressure measurement; HBPM, home blood pressure measurement. 
  
 
 
  
  
Figure 10: Bland-Altman plots to show the limits of agreement for short-term within-individual systolic blood pressure variability (BPV) from beat-to-beat blood pressure 
measurement and within-hour ambulatory blood pressure measurement. Thick lines show the mean difference, dotted lines the 95% confidence interval for the mean 
difference, and dashed lines the limits of agreement (± 2 SD). A shows BPV assessed as standard deviation (SD). B shows BPV assessed as coefficient of variation (CV). C 
shows BPV assessed as average real variability (ARV). D shows BPV assessed as maximum-minimum difference (MMD). 
  
 
  
  
Figure 11: Bland-Altman plots to show the limits of agreement for short-term within-individual systolic blood pressure variability (BPV) from beat-to-beat blood pressure 
measurement and daytime ambulatory blood pressure measurement. Thick lines show the mean difference, dotted lines the 95% confidence interval for the mean 
difference, and dashed lines the limits of agreement (± 2 SD). A shows BPV assessed as standard deviation (SD). B shows BPV assessed as coefficient of variation (CV). C 
shows BPV assessed as average real variability (ARV). D shows BPV assessed as maximum-minimum difference (MMD). 
  
 
  
  
Figure 12: Bland-Altman plots to show the limits of agreement for short-term within-individual systolic blood pressure variability (BPV) from beat-to-beat blood pressure 
measurement and home blood pressure measurement. Thick lines show the mean difference, dotted lines the 95% confidence interval for the mean difference, and 
dashed lines the limits of agreement (± 2 SD). A shows BPV assessed as standard deviation (SD). B shows BPV assessed as coefficient of variation (CV). C shows BPV 
assessed as average real variability (ARV). D shows BPV assessed as maximum-minimum difference (MMD). 
  
 
 
 
Figure 13: Bland-Altman plots to show the limits of agreement for short-term within-individual diastolic blood pressure variability (BPV) from beat-to-beat blood 
pressure measurement and within-hour ambulatory blood pressure measurement. Thick lines show the mean difference, dotted lines the 95% confidence interval for 
the mean difference, and dashed lines the limits of agreement (± 2 SD). A shows BPV assessed as standard deviation (SD). B shows BPV assessed as coefficient of 
variation (CV). C shows BPV assessed as average real variability (ARV). D shows BPV assessed as maximum-minimum difference (MMD). 
  
 
 
  
Figure 14: Bland-Altman plots to show the limits of agreement for short-term within-individual diastolic blood pressure variability (BPV) from beat-to-beat blood 
pressure measurement and daytime ambulatory blood pressure measurement. Thick lines show the mean difference, dotted lines the 95% confidence interval for the 
mean difference, and dashed lines the limits of agreement (± 2 SD). A shows BPV assessed as standard deviation (SD). B shows BPV assessed as coefficient of variation 
(CV). C shows BPV assessed as average real variability (ARV). D shows BPV assessed as maximum-minimum difference (MMD). 
  
 
  
  
Figure 15: Bland-Altman plots to show the limits of agreement for short-term within-individual diastolic blood pressure variability (BPV) from beat-to-beat blood 
pressure measurement and home blood pressure measurement. Thick lines show the mean difference, dotted lines the 95% confidence interval for the mean difference, 
and dashed lines the limits of agreement (± 2 SD). A shows BPV assessed as standard deviation (SD). B shows BPV assessed as coefficient of variation (CV). C shows BPV 
assessed as average real variability (ARV). D shows BPV assessed as maximum-minimum difference (MMD). 
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No previous studies have investigated the relationships between beat-to-beat BPV and 
very short-term or short-term BPV derived from within-visit enhanced CBPM or a 
within-hour analysis of daytime ABPM. However, a few other studies have presented 
detailed comparisons of variability from other BP measurement methods, with findings 
that are in keeping with this analysis. In a cohort of adults with stable hypertension 
(N=108, 15% with established coronary heart disease or cerebrovascular disease) clinic 
BP from eight weekly visits, 24 hour ABPM, and HBPM over three days were carried 
out, with BPV calculated as SD, CV, and ARV from each set of measurements [160]. 
From the HBPM data variability was assessed over the whole measurement period and 
over a series of shorter periods (daily variability and variability within each day’s 
morning and evening measurements only). Correlations between all measures of BPV 
were found to be either weak or non-significant. Similarly, in a larger cohort 
incorporating healthy adults and adults with stable hypertension but no established 
cardiovascular or cerebrovascular disease (N=461) BPV calculated as SD, CV, ARV, 
MMD, and VIM from clinic BP over four weekly visits, daytime ABPM, and HBPM over 
four days were all either weakly correlated or not correlated [118]. Two additional 
studies have presented correlations with beat-to-beat BPV. In a cohort of untreated 
hypertensive adults without established cardiovascular or cerebrovascular disease 
(N=256) Wei et al. demonstrated weak or non-significant correlations in ARV, MMD, 
and VIM from beat-to-beat BP, 24 hour ABPM, and HBPM over seven days [134]. 
Similarly, in a cohort of adults with a recent stroke or TIA (N=472) Webb et al. showed 
only weak correlations in CV from beat-to-beat BP, daytime ABPM, and HBPM [200].  
 
As suggested by the results of the previous chapter these results may be related to 
discrepancies in BP values obtained from the different measurement methods. 
However, it may also be the case that different timescales of BPV have different 
underlying physiological or pathophysiological mechanisms. Whilst the underlying 
mechanisms of BPV have not been fully established, there is evidence that very short-
term BPV is associated with reduced cardiac BRS in both the acute and chronic phases 
after ischaemic stroke [13, 67, 68, 256]. Furthermore, previous work using this cohort 
has demonstrated that reduced BRS and heart rate variability (HRV) were predictors 
for increased beat-to-beat BPV following a cerebrovascular event [257]. Conversely, 
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medium and long-term BPV are associated with markers of arterial stiffness [167, 170, 
174], yet beat-to-beat variability has an uncertain relationship with these factors [134, 
258]. Whilst the parameter chosen to calculate BPV may not matter (different 
parameters derived from the same set of measurements are strongly correlated 
regardless of the BP measurement method used [118, 157, 259]), it seems the 
timescale over which it is measured may be important. This is reflected by the 
inequalities in prognostic relevance to cardiovascular events that the different 
timescales of BPV provide [128, 131, 200, 252-254]. Ultimately, BPV may not be a 
singular concept and work to establish which measures are most relevant to different 
patient groups is required. 
 
Strengths of this study include that it provides a comprehensive comparison of beat-
to-beat BPV with variability from other BP measurement methods, using a variety of 
commonly reported BPV indices, some of which have not previously been reported. 
Furthermore, to the best of my knowledge, it is the first study to compare beat-to-beat 
BPV with an analysis of very short-term variability from ABPM (i.e. within-hour 
variability). In using the Bland-Altman method to compare different timescales of BPV, 
I have been able to provide a level of insight into their relationships that has not been 
present in previous studies. However, several important limitations to the study 
deserve mention. Firstly, as TEST-BP was an interventional trial with the aim of 
improving BP control after stroke the gap between the first HBPM used in this analysis 
and the other baseline BP measurements may limit comparisons with that 
measurement method as BP levels could have altered in the interim, thereby affecting 
variability. However, by excluding participants whose antihypertensive treatment was 
altered between the two measurement periods the design of the analysis should have 
mitigated the impact of this limitation. Secondly, with the majority of participants 
being on antihypertensive therapy, but being prescribed agents from diverse classes it 
is possible that the results were influenced by treatment. However, as the Bland-
Altman analyses compared within-individual BPV measurements, and change in BPV 
over time was not an outcome measure, I would argue that antihypertensive 
treatment is unlikely to have had an impact. Furthermore, in the study by Abellan-
Huerta et al. participants were also on antihypertensive therapy [160]. Thirdly, the 
findings may not be generalizable to patients without cerebrovascular disease. 
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However, they are consistent with other studies that have included both patients with 
and without previous stroke, and if beat-to-beat BPV is particularly relevant to patients 
with cerebrovascular disease as previously suggested then this may actually be a 
positive aspect of the study. 
 
5.7 Summary 
 
 There appears to be little relationship between BPV derived from beat-to-beat 
BP recordings and any other BP measurement method. 
 The initial data suggested that there might be a relationship between beat-to-
beat variability and within-hour variability, but further analysis using Bland and 
Altman’s technique demonstrated very wide limits of agreement, indicating any 
relationship was insufficient for the latter to be a surrogate for the former. 
 It seems plausible that shorter and longer-term BPV are not a singular 
phenomenon. 
 The inclusion of beat-to-beat assessment of BPV in future research is 
recommended, along with further work to clarify which timescales of BPV are 
most relevant to cardiovascular risk and outcomes after stroke.
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6 Associations Between Blood Pressure Variability and Stroke Severity or Subtype in 
Patients with a Recent Ischaemic Stroke 
 
 6.1 Declaration 
 
I would like to acknowledge the contribution of Karen Appiah, research fellow in 
Leicester, to this chapter. Her work in processing the data from the BPV observational 
study helped to make this work possible. 
 
6.2 Introduction 
 
In the preceding experimental chapters the focus of this thesis has been on the 
measurement of BPV following an ischaemic cerebrovascular event. I will now turn my 
attention to investigating the potential of BPV as a therapeutic target in this patient 
group. In acute ischaemic stroke, the area of under-perfused penumbral tissue 
surrounding the core infarct is vulnerable to changes in CBF, with reduced blood flow 
potentially leading to infarct expansion and increased blood flow resulting in 
haemorrhagic change or cerebral oedema [35]. Due to disruption of cerebral 
autoregulatory mechanisms post stroke, CBF becomes more dependent upon systemic 
BP [13, 183]. Consequently, variability in systemic BP could influence CBF and overall 
infarct volume. BPV is increased in acute ischaemic stroke [100], and similar patterns 
may be seen in chronic stroke patients [256]. Furthermore, evidence is accumulating 
that increased BPV is associated with early clinical deterioration [188, 189], secondary 
haemorrhagic transformation [187], and poor long-term functional outcomes in 
ischaemic stroke patients [197-199]. Consequently, interest has arisen in whether BPV 
may be a therapeutic target in patients with stroke and, if so, which patients might 
benefit from these treatments.  
 
In addition to abnormal BPV, autonomic dysfunction has been demonstrated in acute 
ischaemic stroke. HRV and cardiac BRS are two measureable indicators of autonomic 
function, both of which are reduced post-stroke [179, 181, 182]. As with BPV, these 
changes may persist into the chronic phase [256]. Although it remains a topic of 
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debate, there is some evidence that autonomic functions may be lateralised within the 
central nervous system, with sympathetic activity being focused in the right cerebral 
hemisphere and parasympathetic activity focused in the left [63, 179]. Therefore, the 
degree of HRV and cardiac BRS reduction may differ depending on which cerebral 
hemisphere is involved. Given the role of cardiac baroreceptors in the regulation of 
systemic BP, the cerebral hemisphere affected by stroke may also influence the degree 
of BPV, though this is yet to be established. 
 
Should BPV prove to be a viable therapeutic target it would be useful to know whether 
all patients with ischaemic stroke would benefit equally from such treatment, or 
whether it would be prudent to focus on treating certain groups of patients? To that 
end, it would be of relevance to know if there are differences in BPV amongst 
subgroups of ischaemic stroke patients, but presently this has not been investigated. It 
could be expected that patients with more severe ischaemic stroke might also exhibit 
greater BPV due to the larger extent of damage to cerebral tissue, and the potential for 
a larger penumbra that might necessitate greater adjustments in systemic BP to 
maintain adequate CBF. Furthermore, we might anticipate that there will be 
differences in the degree of BPV between patients with left hemisphere and right 
hemisphere lesions due to associated imbalances in autonomic BP regulation.  
 
6.3 Hypothesis 
 
The aim of this study was to investigate potential relationships between BPV and 
stroke severity (according to commonly applied clinical tools) and affected cerebral 
hemisphere. Data from three cohorts including subjects with a recent ischaemic stroke 
have been pooled to test two hypotheses. Firstly, that differences will exist in BPV 
values across participants with a range of stroke severity, with the expectation that 
BPV values will be greater in those with a higher NIHSS score or more disabling stroke 
according to the OCSP classification. Secondly, that BPV values will not be the same in 
participants with unilateral left hemisphere or right hemisphere infarcts. 
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6.4 Methods 
 
Combined data from participants recruited to TEST-BP, SERVED Memory, and the BPV 
observational trial was used to generate the database for this study. The general 
methodologies for these trials are described in sections 3.1.1 to 3.1.3, with TEST-BP 
and SERVED Memory having also been published elsewhere [222, 223]. The 
methodology specific to this analysis is described here. Eligible subjects were 
participants in any of the above trials with a diagnosis of ischaemic stroke who had 
complete baseline BP data, incorporating enhanced CBPM with three measurements 
and daytime ABPM with ≥14 readings. A subgroup of these participants who also had 
baseline beat-to-beat BP measurement with a recording duration of ≥5 minutes after 
data cleaning was also included in the analysis. Participants with BP data that was 
incomplete according to these criteria or who were diagnosed with TIA or ICH were 
excluded. 
 
All baseline BP measurements were recorded as outlined in the general methodology 
chapter; enhanced CBPM as described in section 3.5.2, daytime ABPM as described in 
section 3.5.3, and beat-to-beat BP as described in section 3.5.5. For each set of BP 
measurements average and variability values for SBP and DBP were calculated as 
described in section 3.6. Stroke severity was assessed using the NIHSS score at baseline 
and the OCSP classification, both of which are described in section 3.5.6. The involved 
cerebral hemisphere was inferred from any lateralising clinical features of the stroke 
and any positive findings on cerebral imaging investigations where applicable and was 
classified as “left” or “right”. If there were no lateralising features or positive findings 
on neuroimaging then the participant was not categorised as having a unilaterally 
involved hemisphere and was excluded from the testing of the second hypothesis. 
 
Outcomes for this analysis were the separate assessment of relationships between 
BPV derived from each of the three measurement methods described above with (i) 
stroke severity according to baseline NIHSS score, (ii) stroke severity according to OCSP 
classification, and (iii) stroke subtype according to the affected cerebral hemisphere. 
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6.5 Statistical Analysis 
 
Data were analysed using SPSS version 25.0. Assessment of median NIHSS score by 
OCSP classification was based on a Kruskal-Wallis test. All BP and BPV variables were 
visually assessed for normality by constructing histograms with overlaid distribution 
curves and formally tested using the Kolmogorov-Smirnov test (p>0.05 deemed 
consistent with normal distribution). Mean SBP and DBP values were normally 
distributed, but BPV data from all measurement methods were not. Therefore, a 
logarithmic transformation was applied to these variables prior to any statistical 
testing. This transformation resulted in normalisation of the variables. The results of 
any testing on transformed variables have been back-transformed for presentation. 
Initial exploratory univariate analyses were undertaken to assess the relationship 
between BPV variables and each measure of stroke severity or subtype. The 
relationship between BPV and NIHSS was assessed using Pearson’s correlations. 
Correlations were considered weak if r=0.10-0.29, moderate if r=0.30-0.49, and strong 
if r=>0.50 [255]. The relationship between BPV and OCSP classification was assessed 
using one-way ANOVA with the BPV parameter as the dependent variable and OCSP 
classification as the grouping variable. Post-hoc testing was carried out where any 
between-group differences were identified in the model as a whole. The relationship 
between BPV and affected hemisphere was assessed using independent samples t 
tests, with ‘affected hemisphere’ as the bivariate grouping variable and the BPV 
parameter as the dependent variable. Where univariate analyses suggested significant 
relationships further multivariate analyses were conducted using a regression model, 
with the BPV parameter as the dependent variable, adjusted for differences between 
the trial cohorts and factors known to influence BPV [130, 251, 260]. Independent 
variables used in the model in addition to those tested with univariate analysis 
included time from stroke onset to baseline measurement, age, gender, mean BP 
(from the relevant BP measurement method), past medical history of hypertension, 
and past medical history of diabetes. 
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Table 25: Demographic data. Data presented are mean (SD) for normally distributed 
continuous variables, median (IQR)* for non-normally distributed continuous variables, 
and frequency (%) for categorical variables. 
  All 
Beat-to-beat 
subgroup 
N  181 67 
Age (years)  70.6 (11.0) 71.0 (10.3) 
Gender Male 134 (74.0%) 49 (73.1%) 
BMI (kg/m2)  28.5 (5.5) 29.5 (6.1) 
Smoking 
Never 71 (39.2%) 31 (46.3%) 
Ex smoker 90 (49.7%) 34 (50.7%) 
Current smoker 19 (10.5%) 2 (3.0%) 
Alcohol (units/wk)*  4.0 (12.0) 4.0 (16.0) 
NIHSS*  3.0 (4.0) 3.0 (2.0) 
OCSP classification 
LACS 60 (33.7%) 24 (35.8%) 
PACS 78 (43.8%) 29 (43.3%) 
TACS 6 (3.4%) 1 (1.5%) 
POCS 34 (19.1%) 13 (19.4%) 
Affected hemisphere Left 80 (55.2%) 44 (66.7%) 
Past medical history 
TIA 19 (10.7%) 13 (19.4%) 
Stroke 78 (43.6%) 53 (79.1%) 
IHD 23 (12.8%) 9 (13.4%) 
Diabetes 34 (19.0%) 19 (28.4%) 
Hypertension 105 (58.7%) 44 (65.7%) 
No. on 
antihypertensive 
treatment 
 118 (65.2%) 55 (82.1%) 
No. of 
antihypertensives* 
 1.0 (2.0) 1.0 (1.0) 
Antihypertensive use 
by class 
ACEI 60 (33.1%) 33 (49.3%) 
ARB 25 (13.8%) 11 (16.4%) 
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Beta blockers 24 (13.3%) 14 (20.9%0 
CCB 57 (31.5%) 29 (43.3%) 
Thiazide-like 
diuretics 
15 (8.3%) 9 (13.4%) 
SD denotes standard deviation; IQR, interquartile range; BMI, body mass index; NIHSS, 
National Institutes of Health Stroke Scale; OCSP, Oxford Community Stroke Project; 
LACS, lacunar stroke; PACS, partial anterior circulation stroke; TACS, total anterior 
circulation stroke; POCS, posterior circulation stroke; TIA, transient ischaemic attack; 
IHD, ischaemic heart disease; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; CCB, calcium channel blocker. 
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Table 26: Average baseline blood pressure and variability parameters. Clinic and 
ambulatory blood pressure data are for the full cohort. Beat-to-beat data are for the 
subgroup only. Mean systolic and diastolic blood pressure are presented as mean (SD). 
Systolic and diastolic variability values are presented as median (IQR). 
 
Enhanced CBPM Daytime ABPM 
Beat-to-beat 
BP 
Mean SBP (mmHg) 151.4 (21.6) 138.1 (16.8) 135.1 (18.8) 
Mean DBP (mmHg) 83.7 (12.6) 78.9 (10.8) 81.7 (15.0) 
SD SBP (mmHg) 5.8 (4.1) 12.4 (5.6) 6.5 (4.5) 
SD DBP (mmHg) 3.4 (3.0) 8.7 (3.3) 4.7 (3.2) 
CV SBP (%) 4.0 (2.5) 9.1 (3.8) 5.1 (3.4) 
CV DBP (%) 4.2 (3.8) 11.2 (5.0) 6.0 (4.5) 
ARV SBP (mmHg) - 8.9 (2.8) 2.1 (2.1) 
ARV DBP (mmHg) - 6.8 (2.8) 1.5 (1.3) 
CBPM denotes clinic blood pressure measurement; ABPM, ambulatory blood pressure 
measurement; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; SD, standard deviation; CV, coefficient of variation; ARV, average real 
variability.
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Figure 16: Box and whisker plot showing distribution of National Institutes of Health 
Stroke Scale (NIHSS) scores across different Oxford Community Stroke Project 
classification groups. LACS denotes lacunar stroke; PACS, partial anterior circulation 
stroke; TACS, total anterior circulation stroke; POCS, posterior circulation stroke. 
 
 
Table 27: Correlations between baseline National Institutes of Health Stroke Scale 
score and mean blood pressure and variability indices from clinic, daytime ambulatory, 
and beat-to-beat measurements. Values presented are Pearson’s r. *p<0.01. 
 Enhanced CBPM Daytime ABPM Beat-to-beat BP 
Mean SBP -0.02 0.10 0.02 
SD SBP 0.10 -0.24* 0.06 
CV SBP 0.11 -0.28* 0.05 
ARV SBP - 0.09 0.15 
Mean DBP -0.08 0.05 -0.04 
SD DBP 0.12 -0.20* 0.01 
CV DBP 0.14 -0.21* 0.02 
ARV DBP - 0.06 0.03 
CBPM denotes clinic blood pressure measurement; ABPM, ambulatory blood pressure 
measurement; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
SD, standard deviation; CV, coefficient of variation; ARV, average real variability.
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Table 28: Summary of results from multivariate testing for the relationship between 
National Institutes of Health Stroke Scale (NIHSS) score and blood pressure variability 
from daytime ambulatory blood pressure measurement. Independent variables 
entered in the model were time from symptom onset to measurement, age, gender, 
mean blood pressure, past medical history of hypertension, past medical history of 
diabetes, and NIHSS. 
Dependent 
variable 
R2 F (df) P value Standardised beta 
coefficient for 
NIHSS 
P value 
SD SBP 0.135 
3.27  
(8, 168) 
0.002 -0.26 0.001 
CV SBP 0.139 
3.39 
 (8, 168) 
0.001 -0.26 <0.0001 
SD DBP 0.058 
1.30  
(8, 168) 
0.25 - - 
CV DBP 0.117 
2.77  
(8, 168) 
0.007 -0.19 0.01 
 
SD denotes standard deviation; SBP, systolic blood pressure; CV, coefficient of 
variation; DBP, diastolic blood pressure.
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6.6 Results 
 
Demographic data for the full cohort and the subgroup is presented in Table 25. 
Average BP and BPV values for each measurement method are displayed in Table 26. 
Mean BP values from CBPM were greater than both daytime ABPM and beat-to-beat 
measurements, with BPV values also differing depending between measurement 
methods. Median NIHSS score was not the same across OCSP classification groups 
(p<0.0001), with LACS<PACS<TACS and POCS similar to LACS (Figure 16). There were 
no significant correlations between baseline NIHSS score and mean SBP or DBP from 
any BP measurement method. Correlations between baseline NIHSS score and BPV 
parameters were all non-significant apart from weak negative correlations with SD and 
CV of SBP and DBP from daytime ABPM (Table 27). In linear regression models with 
these BPV parameters from daytime ABPM as the dependent variables, NIHSS 
remained a significant independent variable in all models except for SD of DBP (Table 
28). None of the other independent variables in the model were statistically significant. 
 
There were no significant between-group differences for mean SBP or DBP on one-way 
ANOVA testing with OCSP classification as the grouping variable for any of the BP 
measurement methods. Mean BPV parameters by OCSP grouping for each BP 
measurement method are presented in Figures 17-19. For clinic and beat-to-beat BPV 
there were no significant between-group differences. For daytime ABPM the one-way 
ANOVA testing suggested significant between-group differences for SD and CV of SBP 
(p=0.002 and p=0.001 respectively), and SD and CV of DBP (p=0.01 and p=0.03 
respectively). However, following post-hoc testing only significant between-group 
differences for SD and CV of SBP remained, with variability higher in patients with LACS 
compared to PACS and TACS, and lower variability in patients with TACS than POCS 
(Table 29). These significant between-group differences remained on multivariate 
testing, with the exception of difference in SD of SBP between participants with LACS 
or TACS (Table 30). There were no significant differences in mean BP or any BPV 
parameter between participants with left hemisphere stroke compared to right 
hemisphere stroke, with the exception of mean SBP from beat-to-beat BP 
measurements (Tables 31-33).
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Figure 17: Histograms showing mean blood pressure variability from enhanced clinic blood 
pressure measurement by Oxford Community Stroke Project classification of ischaemic 
stroke. Error bars are 95% confidence intervals. P values are from a one-way ANOVA to 
assess for between-group differences across the whole group. A shows standard deviation 
(SD) of systolic blood pressure (SBP). B shows SD of diastolic blood pressure (DBP). C shows 
coefficient of variation (CV) of SBP. D shows CV of DBP. LACS denotes lacunar stroke; PACS, 
partial anterior circulation stroke; TACS, total anterior circulation stroke; POCS, posterior 
circulation stroke. 
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Figure 18: Histograms showing mean blood pressure variability from daytime ambulatory 
blood pressure measurements by Oxford Community Stroke Project classification of 
ischaemic stroke. Error bars are 95% confidence intervals. P values are from a one-way 
ANOVA to assess for between-group differences across the whole group. A shows standard 
deviation (SD) of systolic blood pressure (SBP). B shows SD of diastolic blood pressure (DBP). 
C shows coefficient of variation (CV) of SBP. D shows CV of DBP. E shows average real 
variability (ARV) of SBP. F shows ARV of DBP. LACS denotes lacunar stroke; PACS, partial 
anterior circulation stroke; TACS, total anterior circulation stroke; POCS, posterior circulation 
stroke.
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Figure 19: Histograms showing mean blood pressure variability from beat-to-beat blood 
pressure measurements by Oxford Community Stroke Project classification of ischaemic 
stroke. Error bars are 95% confidence intervals. P values are from a one-way ANOVA to 
assess for between-group differences across the whole group. A shows standard deviation 
(SD) of systolic blood pressure (SBP). B shows SD of diastolic blood pressure (DBP). C shows 
coefficient of variation (CV) of SBP. D shows CV of DBP. E shows average real variability 
(ARV) of SBP. F shows ARV of DBP. LACS denotes lacunar stroke; PACS, partial anterior 
circulation stroke; POCS, posterior circulation stroke.
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Table 29: Post-hoc testing from the one-way ANOVA for between-group differences in 
systolic blood pressure variability from daytime ambulatory blood pressure 
measurements according to Oxford Community Stroke Project grouping. Differences 
are expressed as ratios (95% CI).  
 Difference in SD 
SBP 
P value Difference in CV 
SBP 
P value 
LACS vs. PACS 1.15 (1.01 to 1.32) 0.04 1.17 (1.03 to 1.34) 0.01 
LACS vs. TACS 1.44 (1.03 to 2.01) 0.03 1.53 (1.10 to 2.13) 0.01 
LACS vs. POCS 0.99 (0.85 to 1.18) 1.00 1.04 (0.88 to 1.22) 0.95 
PACS vs. TACS 1.25 (0.90 to 1.74) 0.31 1.30 (0.94 to 1.81) 0.16 
PACS vs. POCS 0.87 (0.74 to 1.02) 0.10 0.88 (0.75 to 1.04) 0.19 
TACS vs. POCS 0.69 (0.49 to 0.98) 0.04 0.68 (0.48 to 0.96) 0.02 
 
95% CI denotes 95% confidence interval; SD, standard deviation; SBP, systolic blood 
pressure; CV, coefficient of variation; LACS, lacunar stroke; PACS, partial anterior 
circulation stroke; TACS, total anterior circulation stroke; POCS, posterior circulation 
stroke.
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Table 30: Summary of results from multivariate testing for the relationship between 
Oxford Community Stroke Project (OCSP) classification and blood pressure variability 
from daytime ambulatory blood pressure measurements. Independent variables 
entered in the model were time from symptom onset to measurement, age, gender, 
mean blood pressure, past medical history of hypertension, past medical history of 
diabetes, and OCSP classification. 
Dependent 
variable 
Independent 
variable 
R2 F (df) P value Standardised 
beta 
coefficient 
for OCSP 
classification 
P value 
SD SBP 
LACS vs. 
PACS 
0.17 
3.19 
(8, 
128) 
0.003 0.25 0.003 
LACS vs. 
TACS 
0.18 
1.56 
(8, 56) 
0.16 - - 
TACS vs. 
POCS 
0.39 
2.33 
(8, 29) 
0.05 -0.40 0.01 
CV SBP 
LACS vs. 
PACS 
0.12 
2.19 
(8, 
128) 
0.03 0.26 0.002 
LACS vs. 
TACS 
0.24 
2.25 
(8, 56) 
0.04 0.38 0.003 
TACS vs. 
POCS 
0.50 
3.62 
(8, 29) 
0.01 -0.36 0.01 
*standardised beta coefficient 
SD denotes standard deviation; SBP, systolic blood pressure; LACS, lacunar stroke; 
PACS, partial anterior circulation stroke; TACS, total anterior circulation stroke; POCS, 
posterior circulation stroke; CV, coefficient of variation. 
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Table 31: Mean blood pressure and variability from enhanced clinic blood pressure 
measurement and differences between participants with left or right hemisphere 
infarct. Average values for each hemisphere are mean (SD). Differences for mean 
blood pressure are absolute differences. Differences for mean variability are ratios 
(95% CI). 
 Left Right Difference with 95% 
CI (left vs. right) 
P value 
Mean SBP 150.7 (21.6) 150.9 (22.2) -0.25 (-7.5 to 7.0) 0.95 
SD SBP 5.0 (2.1) 5.3 (2.0) 0.94 (0.76 to 1.19) 0.61 
CV SBP 3.4 (2.0) 3.6 (2.0) 0.95 (0.76 to 1.18) 0.61 
Mean DBP 82.8 (13.4) 84.7 (11.9) -1.90 (-6.1 to 2.3) 0.37 
SD DBP 2.9 (2.2) 3.4 (2.0) 0.87 (0.68 to 1.12) 0.27 
CV DBP 3.6 (2.2) 4.0 (2.0) 0.90 (0.71 to 1.14) 0.37 
SD denotes standard deviation; 95% CI, 95% confidence interval; SBP, systolic blood pressure; 
CV, coefficient of variation; DBP, diastolic blood pressure. 
 
Table 32: Mean blood pressure and variability from daytime ambulatory blood 
pressure measurement and differences between participants with left or right 
hemisphere infarct. Average values for each hemisphere are mean (SD). Differences 
for mean blood pressure are absolute differences. Differences for mean variability are 
ratios (95% CI). 
 Left Right Difference with 95% 
CI (left vs. right) 
P value 
Mean SBP 137.1 (17.3) 136.8 (16.2) 0.36 (-5.2 to 5.9) 0.89 
SD SBP 12.3 (1.3) 12.3 (1.4) 1.00 (0.91 to 1.10) 0.98 
CV SBP 9.1 (1.3) 9.1 (1.4) 0.99 (0.91 to 1.10) 0.98 
ARV SBP 9.1 (1.3) 9.2 (1.3) 0.99 (0.91 to 1.09) 0.87 
Mean DBP 78.3 (12.5) 78.3 (9.2) -0.06 (-3.6 to 3.5) 0.98 
SD DBP 8.4 (1.3) 8.7 (1.3) 0.97 (0.89 to 1.05) 0.42 
CV DBP 10.9 (1.3) 11.2 (1.3) 0.97 (0.89 to 1.07) 0.53 
ARV DBP 6.8 (1.3) 6.7 (1.3) 1.02 (0.92 to 1.13) 0.69 
SD denotes standard deviation; 95% CI, 95% confidence interval; SBP, systolic blood pressure; 
CV, coefficient of variation; ARV, average real variability; DBP, diastolic blood pressure. 
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Table 33: Mean blood pressure and variability from beat-to-beat blood pressure 
measurement and differences between participants with left or right hemisphere 
infarct. Average values for each hemisphere are mean (SD). Differences for mean 
blood pressure are absolute differences. Differences for mean variability are ratios 
(95% CI). 
 Left Right Difference with 95% 
CI (left vs. right) 
P value 
Mean SBP 131.6 (18.7) 141.7 (16.7) -10.16 (-19.6 to -0.7) 0.04 
SD SBP 6.4 (1.7) 7.7 (1.7) 0.83 (0.64 to 1.09) 0.18 
CV SBP 5.0 (1.7) 5.5 (1.6) 0.90 (0.69 to 1.18) 0.45 
ARV SBP 2.2 (1.8) 2.9 (2.3) 0.77 (0.52 to 1.16) 0.21 
Mean DBP 78.9 (15.4) 85.9 (13.0) -6.94 (-14.6 to 0.7) 0.08 
SD DBP 4.6 (1.6) 5.1 (1.7) 0.91 (0.70 to 1.16) 0.45 
CV DBP 5.9 (1.7) 6.0 (1.7) 1.00 (0.75 to 1.33) 0.98 
ARV DBP 1.6 (2.0) 1.6 (2.1) 0.89 (0.62 to 1.28) 0.54 
SD denotes standard deviation; 95% CI, 95% confidence interval; SBP, systolic blood 
pressure; CV, coefficient of variation; ARV, average real variability; DBP, diastolic blood 
pressure. 
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6.7 Discussion 
 
These data show that there are significant associations between short-term BPV 
derived from daytime ABPM and stroke severity defined by NIHSS and OCSP 
classification. Furthermore, the associations are independent of mean BP. Although 
the correlations between short-term BPV and NIHSS were relatively weak, the 
relationship indicated that BPV was increased in participants with lower NIHSS scores. 
Similarly, BPV was greater in participants with lacunar stroke compared to those with 
PACS or TACS, which is consistent with the relationship with NIHSS as the data also 
indicated that these participants had lower NIHSS scores. This would be expected as in 
an individual with LACS fewer of the domains tested by the NIHSS are clinically 
affected, as has been reported in other ischaemic stroke cohorts [261]. The findings 
also suggested that BPV might be increased in POCS compared to partial or total 
anterior circulation stroke, although a significant difference was only demonstrated 
with TACS. This could also be consistent with the inverse correlation between BPV and 
NIHSS as, similar to those with LACS, patients with POCS tend to have lower NIHSS 
scores as the scale does not capture POCS symptoms as well as those of partial or total 
anterior circulation stroke [262]. The findings are somewhat surprising as they are at 
odds with the hypotheses that were tested and the wider literature, which suggests 
that increased BPV is predictive of poor outcomes following stroke whereas patients 
with LACS tend to have a good prognosis. Potential explanations for this discrepancy 
are discussed in the following paragraph, yet it remains that the findings are 
potentially of relevance. This is because if BPV is proven to be a valid therapeutic 
target after stroke to improve outcomes and/or prevent recurrent stroke, they suggest 
that any such treatments may be most beneficial in patients with apparently less 
severe forms of ischaemic stroke. The data showed no significant associations between 
short-term or very short-term BPV and the cerebral hemisphere affected by ischaemic 
stroke, however this grouping may have been overly simplistic. It may be necessary to 
analyse relationships with ischaemic stroke affecting specific cerebral areas (e.g. the 
insular cortex) within each hemisphere, but this was not possible in this analysis. 
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That the findings of this analysis were not in keeping with the proposed hypotheses 
regarding the relationship between BPV and stroke severity could be related to the 
population studied. Firstly, this group consisted of mostly of patients with mild to 
moderate stroke symptoms (median NIHSS 3.0 [IQR 4.0]) and contained a limited 
number of patients with TACS classification (N=6). Furthermore, those patients with 
TACS were at the milder end of the spectrum for this classification as none of the trials 
that provided data for this analysis allowed inclusion of participants via proxy consent. 
Consequently, the study population may not be fully representative of the general 
stroke population in terms of stroke severity and stroke type, and may not have 
provided an accurate assessment of the degree of BPV in those with more severe 
ischaemic stroke. Secondly, the classification of severity was based on clinical 
presentation as opposed to radiological findings. Although an experienced stroke 
physician confirmed the clinical diagnoses, it is possible that some patients categorised 
as LACS may have had larger infarcts if it had been possible to confirm all diagnoses 
with MRI or other cerebral imaging. Thirdly, the proportion of participants who were 
recruited after a recurrent cerebrovascular event was higher than might be expected 
in the general stroke population (43.6% with a previous stroke, rising to above 50% if 
previous TIA is also included). If raised BPV can persist into the chronic phase post-
stroke [256], then this could have influenced the findings. Finally, although the findings 
did reach statistical significance there remains the possibility that they are due to 
chance. This potential explanation should be considered given that there are very 
limited reports in the literature for comparison. Having said that, the only other study 
to report on BPV in relation to OCSP classification is consistent with the findings of this 
analysis. In a small study of cerebral autoregulation in patients with acute ischaemic 
stroke (N=56, recruited within 72 hours of onset) Eames et al. showed that SD of SBP 
derived from beat-to-beat BP monitoring was greater in patients with LACS as opposed 
to PACS, TACS, and POCS [13]. To the best of my knowledge there have been no 
studies of BPV differences by OCSP classification using variability derived from BP 
measurement methods other than beat-to-beat measurement. However, one study 
has reported that increases in short-term BPV from repeated CBPM were greatest in 
patients with ischaemic stroke due to small vessel occlusion according to the TOAST 
classification [189]. Conversely, there is conflicting data regarding the relationship 
between BPV and NIHSS. A review of 2566 subjects with a first-episode ischaemic 
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stroke, recruited within 24 hours of onset, found that diastolic BPV from days 1-3 post-
event increased by quartile of baseline NIHSS, yet there was a non-significant trend for 
systolic BPV to reduce by quartile in the same cohort [199]. Other studies of BPV in the 
acute phase of ischaemic stroke have reported no significant relationship between BPV 
and baseline NIHSS [186, 198, 263]. However, none of these studies has used ABPM to 
derive BPV, which could account for the different findings of this analysis. 
 
Another slightly surprising aspect of the data from this analysis that may necessitate 
further caution in the interpretation of the findings relates to the mean BP and 
variability levels as measured by the different methods (Table 26). Firstly, that mean 
BP as recorded by CBPM was higher than that from daytime ABPM is not surprising. 
Nonetheless, the difference found was greater than is suggested by the literature 
[110]. This may be partly explained by the presence of some degree of white coat 
effect within the study population; however as other members of the research team 
collected some measurements I cannot guarantee that there was not some variation in 
practice (e.g. leaving insufficient time between clinic readings, or using a cuff of 
incorrect size) that may have introduced measurement bias. Secondly, as opposed to 
the findings in this study, it might be expected that beat-to-beat BP measured at the 
finger would be higher than CBPM measured at the brachial artery due to increasing 
arterial stiffness with distance from the aorta. However, the age of the study 
population may partly explain this finding as arterial stiffness alters with ageing and so 
the effect of BP amplification due to arterial stiffness throughout the arterial tree will 
also alter. Alternatively, the influence on peripherally measured BP of the reflected 
pressure wave may not be so great when the BP is measured at the most distal point 
(i.e. the finger), leading to a lower reading at this point than in the brachial artery. A 
final consideration is also the accuracy of beat-to-beat BP measurement devices. 
Although they have been shown to be accurate for tracking changes in BP, they may 
not be sufficiently accurate to measure mean BP due to the SD of measurements [95]. 
Indeed, limits of agreement up to ±17mmHg for SBP have been reported in direct 
comparison of the Finapres® with brachial CBPM [264]. Thirdly, any differences in BPV 
values between the different methods are likely due to a combination of the number 
of readings obtained and the time between measurements (particularly where BPV is 
derived using ARV). 
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No other studies have previously looked at the relationship between BPV and the 
cerebral hemisphere affected by ischaemic stroke. However, autonomic dysfunction 
post-stroke has been investigated. Evidence for the lateralisation of functions is mixed, 
with some studies demonstrating altered HRV and BRS in right-sided lesions, but 
others the opposite [179, 181, 182]. As suggested above, differentiating left vs. right 
alone may be an oversimplification. Damage to the insular cortex in particular has 
been implicated in post-stroke autonomic dysfunction [265], therefore it may be the 
affected region(s) within the hemisphere rather than the hemisphere itself which is of 
importance. This level of detail was not available for this cohort and so it was not 
possible to classify participants beyond the level of the involved hemisphere. Had it 
been possible to do so, it may have resulted in larger between-group differences in 
BPV. Despite this, it is worth highlighting that the differences in beat-to-beat BPV 
between left and right hemisphere lesions, although not reaching statistical 
significance, were larger than differences in BPV derived from other measurement 
methods. This may add weight to the idea that there is a stronger relationship 
between very short-term BPV and autonomic function/dysfunction than variability 
over longer timescales, and might further suggest that beat-to-beat BP measurement 
is the most appropriate method for investigating BPV in relation to autonomic function 
post-stroke.  
 
If, as suggested by this study, there is a genuine relationship between increased BPV 
and LACS, then no inference regarding causality can be made on the basis of the cross-
sectional analysis conducted here. However, there may be plausible reasons to suggest 
that increased BPV is more likely to cause LACS than other stroke subtypes, or vice 
versa. It is a subject of debate as to whether lacunar stroke is distinct from other 
stroke subtypes as a pathophysiological entity [266]. Comparison of risk factor profiles 
in ischaemic stroke subtypes indicates that LACS are less likely to be associated with 
previous IHD, a determined cardio-embolic source, or carotid stenosis [267]. It has also 
been proposed that atherothrombotic or embolic vessel occlusion may not be the only 
mechanism to cause LACS, rather endothelial damage and breakdown of the blood-
brain barrier may be a distinct causal mechanism [268]. Alternatively, cerebral tissue 
supplied by chronically damaged small vessels may be vulnerable to injury due to 
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vessel spasm and subsequent reductions in CBF in the context of disordered cerebral 
autoregulation [266]. Increased BPV could theoretically play a part in these alternative 
pathological processes, either causing small vessel endothelial damage by generating 
pulsatile haemodynamic stresses [269, 270], or by reducing CBF below critical levels 
sufficient to cause ischaemia in the context of this chronic small vessel damage. 
Conversely, it may be hypothesised that LACS could cause increased BPV by virtue of 
the involvement of subcortical structures. For example, damage to the thalamus has 
been implicated, with one study demonstrating autonomic dysfunction manifesting as 
reduced HRV following stroke affecting this region [271]. This analysis may not support 
this latter idea however, as if autonomic function is more involved in the regulation of 
very short-term BPV it might be expected that subjects with LACS would demonstrate 
increased beat-to-beat, as opposed to ambulatory BPV. 
 
The major positive aspect of this study is its novelty, it being the first, to my 
knowledge, to assess the relationship between OCSP classification of ischaemic stroke 
and BPV assessed as within-visit BPV from enhanced CBPM and BPV from daytime 
ABPM. It is also the first assessment of the association between BPV and affected 
stroke cerebral hemisphere. In addition, the study has also shed further light on the 
relationship between beat-to-beat BPV and stroke classification, which has previously 
only been sparsely reported. Several important limitations to the study also deserve 
mention, some of which have been discussed in detail above. Firstly, as a post-hoc 
exploratory analysis of trial data it was not powered to investigate the stated 
outcomes. Secondly, as a cross-sectional analysis no conclusions can be drawn about 
any potential causal relationship between increased BPV and stroke severity. Thirdly, 
there were some unexpected differences in BP values obtained using the different 
measurement methods and measurement bias cannot be excluded as a potential 
cause for these differences. Fourthly, there were some differences between the three 
trial cohorts that were pooled for this analysis, most notably the time from the 
qualifying stroke to the baseline assessment. In particular, although it was adjusted for 
in the multivariate analyses and not shown to be a significant predictive factor, this 
aspect could have confounded the relationship between BPV and NIHSS score, possibly 
reducing the effect seen as some participants (in TEST-BP and SERVED Memory) were 
recruited several weeks after their qualifying event. Fifthly, approximately two thirds 
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of participants were on antihypertensive treatment, including some who were on beta 
blockers. If there are class effects of antihypertensive medications on BPV as discussed 
in section 2.8, then this may have influenced the findings. However, those on different 
treatment regimens were evenly distributed across groups that were compared (e.g. 
different OCSP classification), and the study did not assess change in BPV over time, 
thereby minimising the potential impact of medications. Finally, it was only possible to 
analyse beat-to-beat BPV in a subgroup of patients, as this data was unavailable for 
participants in the BPV observational study. This limited the sample size and could 
increase the possibility of type two error in relation to the analysis of very short-term 
variability in this study. 
 
6.8 Summary 
 
 BPV is associated with severity of ischaemic stroke, with greater increases in 
variability associated with lacunar stroke as opposed to partial or total anterior 
circulation stroke. 
 This suggests that any interventions designed to reduce BPV following 
ischaemic stroke may be most beneficial for patients with lacunar stroke. 
 Furthermore, this relationship may support the concept that lacunar stroke, as 
a pathophysiological entity, is not identical to other stroke subtypes. 
 Although this study did not demonstrate a relationship between BPV and the 
affected cerebral hemisphere, this may be due to methodological limitations of 
the analysis. 
 These findings were at odds with the hypotheses being tested and so further 
work to corroborate them and investigate differences in BPV relating to 
subtypes of stroke, would be valuable, particularly as and when a consensus on 
measuring BPV in patients with stroke is achieved. This could help inform 
research into treatments aimed at reducing BPV post stroke. 
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7 The Influence of Antihypertensive Medication Class on Baseline Blood Pressure 
Variability in Patients with a Recent Stroke or TIA 
 
 7.1 Declaration 
 
I would like to acknowledge the contribution of Karen Appiah, research fellow in 
Leicester, to this chapter. Her work in processing the data from the BPV observational 
study helped to make this work possible. 
 
7.2 Introduction 
 
BPV is increased in patients with acute ischaemic stroke [100], and this increase may 
persist into the chronic phase post stroke [256]. Furthermore, raised BPV may not be 
benign, being associated with adverse outcomes following ischaemic stroke [197-199], 
risk of recurrent stroke [200], and cardiovascular risk in general [128]. These 
assertions, coupled with the findings of the previous chapter which suggested BPV may 
be related to stroke severity, have raised interest in identifying treatments that have 
the potential to reduce BPV in addition to mean BP levels. Whether all established 
antihypertensive treatment classes might fulfill both goals to the same extent has been 
questioned, as a retrospective review of antihypertensive drug trials suggests this may 
not be the case [133]. In particular, beta blockers appear to be less effective at 
reducing the risk of stroke events compared to other antihypertensive classes. One 
potential explanation for this observation is that different antihypertensive drug 
classes do not all equally alter BPV, an explanation that is supported by data 
demonstrating that beta blockers may actually increase BPV [201, 203, 211]. 
Conversely, CCB and, to a lesser extent, thiazide-like diuretics seem to reduce BPV, 
with ACEI and ARB possibly neutral or increasing BPV. These potentially different class 
effects on BPV, if proven, might relate to differing class effects on vascular smooth 
muscle, with the classes that exert vasodilatory effects being those that also reduce 
BPV. 
 
 147 
 
Hypertension guidelines recommend using an ACEI or ARB as the first-line treatment 
for patients under 55 years of age, and using a CCB or thiazide-like diuretic in patients 
over 55 years of age or of Afro-Caribbean ethnicity for primary prevention [91]. 
Recommendations for secondary prevention are the same in UK stroke guidelines [18], 
but American stroke guidelines suggest that thiazide-like diuretics (alone or in 
combination with ACEI) may be the most appropriate first-line therapy regardless of 
patient age [57]. In patients at high-risk of, or with established cardiovascular disease 
ACEI and ARB have become established treatments due to their inhibitory effects on 
atherosclerotic processes, and data suggest they may also have protective effects 
against stroke in addition to BP reduction [59]. However, data from major stroke 
secondary prevention trials question their value, suggesting that thiazide-like diuretics 
may be more effective [51, 52]. Limited evidence from systematic reviews and meta-
analyses supports this, indicating that treatment with thiazide-like diuretics as 
opposed to other antihypertensive classes may convey the lowest risk of recurrent 
stroke [8, 272]. The mechanism for this is unclear, but may be related to vasodilation 
rather than natriuretic activity, as that is the likely mechanism for long-term BP 
reduction with this medication class [219, 273].  
 
Whether any particular antihypertensive medication class should be preferred for 
secondary prevention post stroke, or whether it is simply BP lowering per se which is 
the important factor remains a subject of debate. The growing evidence relating to 
antihypertensive class effects on BPV is likely to fuel that debate. Furthermore, it 
seems to cast further doubt on whether drugs that inhibit the renin-angiotensin 
system are the most appropriate choice in this patient group. Crucially, with respect to 
the relevance of BPV to this debate there have been no dedicated prospective trials 
investigating the impact of antihypertensive medication class on BPV, and most 
retrospective analyses have focused on long-term visit-to-visit BPV rather than shorter 
timeframes of variability.  
 
7.3 Hypothesis 
 
This study aimed to add to the evidence base by exploring potential class effects of 
antihypertensive medications on shorter-term BPV in patients with established 
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cerebrovascular disease. Using data pooled from three trials that recruited patients 
with a recent ischaemic stroke or TIA, including some from a dedicated cohort study 
designed to investigate BPV post-stroke, it investigated if there are differences in 
short-term and very short-term baseline BPV in patients taking an ACEI or ARB based 
antihypertensive regimen as opposed to a CCB based regimen (either alone or in 
combination) with both groups compared separately to a control group. The 
hypothesis being tested is that BPV will be greater compared to control in those taking 
an ACEI or ARB than in those taking a CCB, irrespective of the BP measurement 
method used to derive BPV. 
 
7.4 Methods 
 
Combined data from participants recruited to TEST-BP, SERVED Memory, and the BPV 
observational trials were used to generate the database for this study. The general 
methodologies for these trials are described in sections 3.1.1-3.1.3, with TEST-BP and 
SERVED Memory having also been published elsewhere [222, 223]. The methodology 
specific to this analysis is described here. Eligible patients were participants in any of 
the above trials with a diagnosis of ischaemic stroke or TIA who were on at least one 
medication for hypertension at the time of baseline assessment. Participants also 
needed to have complete enhanced CBPM and daytime ABPM with ≥14 readings from 
the baseline assessment. A subgroup of these participants who also had baseline beat-
to-beat BP measurement with a recording duration of ≥5 minutes after data cleaning 
was also included in the analysis. Participants who were not on antihypertensive 
treatment, who were diagnosed with ICH, or whose BP data were incomplete were 
excluded. 
 
All baseline BP measurements were recorded as outlined in the general methodology 
chapter; enhanced CBPM as described in section 3.5.2, daytime ABPM as described in 
section 3.5.3, and beat-to-beat BP as described in section 3.5.5. For each set of BP 
measurements average and variability values for SBP and DBP were calculated as 
described in section 3.6. Medication history, including drug name (but not dose) was 
assessed by the study nurses at the baseline visit and corroborated using the medical 
notes. Participants taking an ACEI, an ACEI or ARB, or a dihydropyridine CCB were 
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grouped for comparison with a control group (consisting of participants taking any 
antihypertensive medication from classes other than the class being tested) as they are 
the most commonly prescribed classes of antihypertensive in UK clinical practice. 
These groups were also selected for consistency with the methodology of the 
feasibility trial presented in the subsequent experimental chapter. Participants taking 
an ARB were grouped with those taking an ACEI due to the similarities in mechanism of 
action and because the number of participants taking that medication class was too 
small to test independently. Treatment compliance at baseline was assessed in TEST-
BP using the Hill-Bone compliance questionnaire and in SERVED Memory using the 
eight-item Morisky Medication Adherence Scale, but was not assessed in the BPV 
observational trial. 
 
Outcomes for this analysis were the assessment of differences in systolic and diastolic 
BPV from enhanced CBPM, daytime ABPM, and beat-to-beat measurements in 
participants taking antihypertensive monotherapy or combination therapy. Groups 
tested were (i) ACEI vs. control; (ii) ACEI or ARB vs. control; (iii) CCB vs. control. 
 
7.5 Statistical Analysis 
 
Data were analysed using SPSS version 25.0. All BP and BPV variables were visually 
assessed for normality by constructing histograms with overlaid distribution curves 
and formally tested using the Kolmogorov-Smirnov test (p>0.05 deemed consistent 
with normal distribution). Mean SBP and DBP values were normally distributed, but 
BPV data from all measurement methods were not. Therefore a logarithmic 
transformation was applied to these variables prior to any statistical testing. This 
transformation resulted in normalisation of the variables. The results of any testing on 
transformed variables have been back-transformed for presentation. Initial exploratory 
univariate analyses were undertaken to assess any differences in BPV between those 
participants taking the medication of interest compared to a control group as 
described above. Testing was first restricted to participants taking antihypertensive 
monotherapy and then expanded to participants on combination therapy. Univariate 
testing was based on independent samples t tests, using whether the participant was 
taking the medication class of interest as a bivariate grouping variable and the BPV 
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parameter as the dependent variable. Where univariate testing suggested significant 
between-group differences (p<0.05 taken as the level for statistical significance) then 
further multivariate testing using a regression model was carried out, with the BPV 
parameter as the dependent variable, adjusted for differences between the trial 
cohorts and factors known to influence BPV [130, 251, 260]. Independent variables 
used in the model in addition to those tested with univariate analysis included time 
from stroke onset to baseline measurement, age, gender, mean BP, past medical 
history of hypertension, and past medical history of diabetes. 
 
7.6 Results 
 
Data from 238 participants were pooled for this analysis, with 142 participants making 
up the subgroup with valid beat-to-beat BP measurements as this data was not 
available for participants in the BPV observational trial. Demographic data for the full 
cohort and the subgroup is presented in Table 34. The majority of patients were taking 
an ACEI either alone or in combination, followed by CCB as the second most commonly 
prescribed antihypertensive medication class (Table 35). Fewer participants were 
taking an ARB than an ACEI, but this proportion was still greater than the proportion of 
participants taking a beta blocker or thiazide-like diuretic. Alpha blockers were the 
least commonly prescribed antihypertensive medication class. 
 
Results including participants taking a combination of antihypertensive medications 
were the same as results for testing restricted to those on antihypertensive 
monotherapy. The former are presented as this approach incorporated a larger sample 
size. There were no differences in mean SBP or mean DBP values between any of the 
designated testing groups compared to control, regardless of the method used to 
measure BP (Table 36). 
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Table 34: Demographic data. Data presented are mean (SD) for normally distributed 
continuous variables, median (IQR)* for non-normally distributed continuous variables, 
and frequency (%) for categorical variables. 
  All 
Beat-to-beat 
subgroup 
N  238 142 
Age (years)  73.3 (9.7) 73.6 (9.8) 
Gender Male 159 (66.8%) 97 (68.3%) 
BMI (kg/m2)  28.5 (5.1) 28.9 (5.1) 
Smoking 
Never smoked 99 (41.6%) 60 (42.3%) 
Ex smoker 118 (49.6%) 76 (53.5%) 
Current smoker 21 (8.8%) 6 (4.2%) 
Alcohol (units/wk)*  4.0 (14.0) 4.0 (16.0) 
Diagnosis 
TIA 123 (51.7%) 88 (62.0%) 
Stroke 115 (48.3%) 54 (38.0%) 
OCSP classification 
(stroke only) 
LACS 36 (31.9%) 20 (37.0%) 
PACS 51 (45.1%) 24 (44.4%) 
TACS 4 (3.5%) 1 (1.9%) 
POCS 22 (19.5%) 9 (16.7%) 
NIHSS (stroke only)*  3.0 (3.0) 2.5 (3.0) 
Past medical history 
TIA 103 (43.6%) 87 (61.3%) 
Stroke 85 (35.7%) 60 (42.3%) 
IHD 47 (19.7%) 31 (21.8%) 
Diabetes 52 (21.8%) 36 (25.4%) 
Hypertension 185 (77.7%) 112 (78.9%) 
No. of 
antihypertensives* 
 1.0 (1.0) 2.0 (1.0) 
 
SD denotes standard deviation; IQR, interquartile range; BMI, body mass index; OCSP, 
Oxford Community Stroke Project; LACS, lacunar stroke; PACS, partial anterior 
circulation stroke; TACS, total anterior circulation stroke; POCS, posterior circulation 
stroke; TIA, transient ischaemic attack; IHD, ischaemic heart disease.
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Table 35: Proportions of participants taking each class of antihypertensive medication 
(as monotherapy or in combination). 
 All Subgroup 
Monotherapy Combination Monotherapy Combination 
ACEI 60 (47.6%) 130 (54.6%) 34 (53.1%) 85 (59.9%) 
ARB 17 (13.5%) 46 (19.3%) 7 (10.9%) 25 (17.6%) 
Alpha blocker 3 (2.4%) 20 (8.4%) 0 (0.0%) 10 (7.0%) 
Beta blocker 12 (9.5%) 54 (22.7%) 8 (12.5%) 42 (29.6%) 
CCB 31 (24.6%) 101 (42.4%) 15 (23.4%) 62 (43.7%) 
Thiazide-like 
diuretic 
3 (2.4%) 35 (14.7%) 0 (0.0%) 24 (16.9%) 
 
ACEI denotes angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; CCB, calcium channel blocker.
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Table 36: Differences in mean enhanced clinic, daytime ambulatory, and beat-to-beat 
systolic and diastolic blood pressure between the defined testing groups and control. 
Data presented are mean (SD) or difference (95% CI). P>0.05 for all differences. 
 Antihypertensive medication regimen grouping 
ACEI Control ACEI or 
ARB 
Control CCB Control 
Enhanced 
CBPM SBP 
(mmHg) 
151.0 
(20.5) 
152.6 
(21.2) 
152.0 
(21.7) 
151.1 
(18.5) 
151.8 
(18.7) 
151.7 
(22.3) 
Difference 1.6 (-3.8 to 6.9) -0.9 (-7.0 to 5.2) -0.2 (-5.6 to 5.2) 
Enhanced 
CBPM DBP 
(mmHg) 
83.9 (12.3) 83.5 (12.0) 83.4 (12.3) 84.5 (11.7) 82.9 (11.4) 84.2 (12.6) 
Difference -0.4 (-3.5 to 2.7) 1.1 (-2.5 to 4.6) 1.3 (-1.9 to 4.4) 
Daytime 
ABPM SBP 
(mmHg) 
135.1 
(15.6) 
136.1 
(16.6) 
135.4 
(15.6) 
135.9 
(17.1) 
136.8 
(14.8) 
134.7 
(16.8) 
Difference 1.0 (-3.1 to 5.1) 0.5 (-4.2 to 5.2) -2.1 (-6.3 to 2.0) 
Daytime 
ABPM DBP 
(mmHg) 
77.3 (9.7) 77.0 (10.4) 76.8 (10.0) 78.1 (10.1) 76.3 (8.4) 77.8 (11.0) 
Difference -0.4 (-2.9 to 2.2) 1.3 (-1.6 to 4.2) 1.5 (-1.0 to 4.0) 
Beat-to-beat 
SBP  
(mmHg) 
134.0 
(18.3) 
131.0 
(16.0) 
133.6 
(17.7) 
130.2 
(16.5) 
130.7 
(17.1) 
134.5 
(17.6) 
Difference -3.0 (-8.9 to 2.9) -3.4 (-10.4 to 3.5) 3.8 (-2.0 to 9.7) 
Beat-to-beat 
DBP  
(mmHg) 
82.1 (13.2) 79.8 (13.7) 81.4 (13.7) 80.3 (12.5) 80.0 (13.2) 82.1 (13.5) 
Difference -2.4 (-6.9 to 2.2) -1.2 (-6.5 to 4.2) 2.1 (-2.4 to 6.6) 
SD denotes standard deviation; 95% CI, 95% confidence interval; ACEI, angiotensin converting 
enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CBPM, 
clinic blood pressure measurement; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; ABPM, ambulatory blood pressure measurement.
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Figure 20: Histograms showing mean blood pressure variability from enhanced clinic 
blood pressure measurement in participants on medications from different 
antihypertensive classes compared to control. Error bars are standard deviation (SD). P 
values are based on independent samples t tests for the difference between each active 
group and control. A shows SD of systolic blood pressure (SBP). B shows SD of diastolic 
blood pressure (DBP). C shows coefficient of variation (CV) of SBP. D shows CV of DBP. 
ACEI denotes angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; CCB, calcium channel blocker.
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Figure 21: Histograms showing mean blood pressure variability from daytime 
ambulatory blood pressure measurement in participants on medications from 
different antihypertensive classes compared to control. Error bars are standard 
deviation (SD). P values are based on independent samples t tests for the difference 
between each active group and control. A shows SD of systolic blood pressure (SBP). B 
shows SD of diastolic blood pressure (DBP). C shows coefficient of variation (CV) of 
SBP. D shows CV of DBP. E shows average real variability (ARV) of SBP. F shows ARV of 
DBP. ACEI denotes angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; CCB, calcium channel blocker.
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Figure 22: Histograms showing mean blood pressure variability from beat-to-beat 
blood pressure in participants on medications from different antihypertensive classes 
compared to control. Error bars are standard deviation (SD). P values are based on 
independent samples t tests for the difference between each active group and control. 
A shows SD of systolic blood pressure (SBP). B shows SD of diastolic blood pressure 
(DBP). C shows coefficient of variation (CV) of SBP. D shows CV of DBP. E shows 
average real variability (ARV) of SBP. F shows ARV of DBP. ACEI denotes angiotensin 
converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel 
blocker.
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With regard to BPV measures, there were no significant differences between any of 
the designated testing groups and control, with the exception of daytime ABPM ARV of 
DBP for CCB vs. control (mean difference ratio 1.12 [95% CI 1.03 to 1.21], p=0.01), with 
this difference not remaining after multivariate testing (Figures 20-22). Although not 
statistically significant, the findings for daytime ABPM variability indicated a pattern of 
increased BPV compared to control for ACEI and ACEI or ARB, and decreased BPV for 
CCB compared to control.  
 
7.7 Discussion 
 
This cross-sectional analysis did not demonstrate significant differences in mean BP or 
BPV in patients with a recent ischaemic cerebrovascular event who were taking 
antihypertensive medication regimens based on different drug classes, regardless of 
the method used to measure BP. However, there was a possible opposing trend in 
systolic BPV from daytime ABPM for renin-angiotensin inhibitors and CCB compared to 
control, with variability possibly increased in the former and decreased in the latter. 
Whilst this may be a chance finding, it might also be that it is a genuine difference and 
that the study is hindered by an insufficient sample size. Post hoc power calculations 
indicate that the required sample size to detect a difference in SD of SBP with 80% 
power at the 5% significance level would be N=522, assuming a SD of 10.5 ± 4.9mmHg 
for CCB and 12.2 ± 5.8mmHg for ACEI [202]. Assuming the same effect size, the power 
of this sample to detect a genuine difference was between 0.57 and 0.68 depending on 
the comparison. The negative findings may also relate to another aspect of the study 
methodology. Rather than with cross-sectional analysis, differences in BPV attributable 
to antihypertensive medications might be better investigated with changes in 
variability over time. Thirdly, it is possible that medication dose as well as class is 
relevant to levels of BPV, with one study showing that change in variability from 24 
hour ABPM was reduced in patients taking high doses of ACEI or CCB, but not low 
doses (high dose defined as 20mg of enalapril or lercanidipine, low dose defined as 
10mg) [274]. Due to the available data it was not possible to account for dose in this 
study. The results also suggested that the trends in BPV in different groups, if genuine, 
might not be the same for variability from CBPM and daytime ABPM. This difference 
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may be explained by differences in mean BP seen from CBPM and daytime ABPM 
measurements. Mean values in the latter were consistent with controlled 
hypertension, whereas they were raised in the former. This suggests a possible white 
coat effect in this cohort, which could have confounded the results. 
 
No other study results of the effect of antihypertensive medication class on BPV are 
directly comparable with those presented here. Either they have derived BPV over a 
different timeframe, or they have not included patients with cerebrovascular disease. 
However, although the trends in BPV from daytime ABPM seen in this study were not 
statistically significant, they are in keeping with those reported elsewhere. In a larger 
cross-sectional analysis of short-term BPV in patients with treated hypertension 
(N=2780, 10% with previous stroke), the SD of SBP from daytime ABPM was lower in 
participants taking a CCB (mean difference -0.22 ± 0.12mmHg) and higher in those 
taking an ACEI (mean difference 0.20 ± 0.15mmHg) or ARB (mean difference 0.40 ± 
0.18mmHg) compared to control (defined the same as in this study) [211]. SD of DBP 
was also reduced in the CCB group, but was unchanged in the ACEI and ARB groups. In 
the only other study to recruit patients with a recent cerebrovascular event (N=288), 
Webb et al. demonstrated a 4% reduction in systolic residual CV from HBPM 1-2 weeks 
after starting or increasing the dose of a CCB, but only a 1% reduction with a new or 
increased dose of ACEI/ARB [213]. Similarly, post hoc analysis of the X-CELLENT trial 
(N=496 with hypertension but no previous cerebrovascular or coronary heart disease) 
showed that the SD of SBP from daytime ABPM was significantly reduced after three 
months of treatment with CCB compared to placebo (-1.1mmHg [95% CI -1.9 to -0.3]), 
but not with ARB (-0.6mmHg [95%CI -1.4 to 0.3]) [210]. Finally, similar results are 
reported for long-term BPV, with a post hoc analysis of the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack (ALLHAT) trial indicating that systolic SD 
of visit-to-visit variability over 28 months of follow-up was lower in those treated with 
amlodipine compared to lisinopril (10.5mmHg [95% CI 10.3 to 10.7] vs. 12.2mmHg 
[95% CI 12.0 to 12.4]) [202]. Conversely, Asayama et al. reported no difference in the 
change in systolic VIM from HBPM between antihypertensive medication regimens 
after 2-4 weeks of monotherapy (N=2484 with no previous cardiovascular disease) 
[212]. However, the HBPM protocol used in the trial was not consistent with guideline 
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recommendations, requesting only a single BP measurement in the morning and 
evening for five consecutive days, which could have influenced the variability data. 
 
The mechanisms through which CCB (and thiazide-like diuretics) might reduce BPV 
have not been proven, but it is suggested that the effect may be mediated by vascular 
smooth muscle relaxation and vasodilation; ACEI and ARB having relatively little effect 
on vascular tone compared to CCB and thiazide-like diuretics [133, 211, 218, 219, 273]. 
In an RCT comparing treatment with a CCB or thiazide-like diuretic in addition to an 
ARB (N=207), Matsui et al. showed a greater reduction in the SD of SBP from HBPM 
after six weeks treatment in the CCB group [220]. Furthermore, they demonstrated 
that the reduction in BPV in the CCB group was independently associated with a 
concurrent reduction in c-fPWV. An alternative mechanism for the reduction in BPV 
may be modulation of the autonomic nervous system, specifically via increased cardiac 
BRS. A small study of the effect of lacidipine on 24 hour BPV in adults with 
hypertension and diabetes (N=10) found that BPV was reduced with four weeks of 
treatment compared to placebo, and was also associated with improved BRS [275]. 
This finding was replicated in the larger X-CELLENT trial, where the reduction in BPV 
observed in the CCB group was at least partly related to a reduction in HRV, indirectly 
suggesting a concomitantly increased BRS [210]. Interestingly, beta blockers have also 
been shown to increase cardiac BRS [276], yet they do not seem to effect BPV in the 
same way as CCB. Perhaps the effect on BRS seen with CCB, but not beta blockers, is 
due to increased activity of stretch receptors located in the aortic arch as a result of 
reduced arterial stiffness, and this combination of reduced arterial stiffness and 
increased BRS is important for the reduction of BPV. 
 
Strengths of this study include that it assessed BPV from a variety of BP measurement 
methods and is the only study, to the best of my knowledge, to investigate any 
differential effects of antihypertensive medication classes on beat-to-beat BPV. 
However, it also has limitations that require mention. As already discussed, the sample 
size may have been insufficient to detect statistically significant differences and it was 
not possible to stratify the analysis according to medication dose in addition to class. 
As it was only possible to investigate beat-to-beat variability in a subgroup these 
results in particular may be undermined by the small sample size. Furthermore, 
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although compliance was assessed in two of the trials providing data, it was not 
assessed in the BPV observational study. Similarly, it cannot be excluded that 
participants may have recently commenced antihypertensive therapy or had a recent 
dose adjustment prior to enrolment in any of the trials. Consequently, any effect on 
baseline BPV may be underestimated. Finally, participants on combinations of 
antihypertensive therapy were included in both the investigative and control groups; 
therefore any effect on BPV may not be entirely attributable to the medication class in 
question. However, other studies have shown that any medication class effects on BPV 
persist when the relevant medications are used in combination and so this approach is 
justifiable [217, 220, 277]. 
 
7.8 Summary 
 
 This study did not show significant differences in baseline BPV compared to 
control for participants taking an ACEI/ARB or CCB based antihypertensive 
medication regimen. 
 However, the study probably lacked sufficient statistical power to demonstrate 
a difference and may have been limited by the use of a cross-sectional analysis. 
 The trends seen for variability from daytime ABPM were comparable with 
those reported elsewhere. 
 Prospective, randomised trials to assess the impact of different 
antihypertensive medications on BPV post stroke would be valuable. 
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8 A Calcium channel or Angiotensin converting enzyme inhibitor/Angiotensin receptor 
blocker Regime to reduced Blood pressure variability in acute ischaemic Stroke (CAARBS): 
A Feasibility Trial 
 
8.1 Introduction 
 
In the preceding chapter, although the analysis did not demonstrate any significant 
differences in baseline BPV between patients taking an ACEI/ARB or a CCB compared 
to control, the argument remains that there is a need for prospective trials 
investigating the possibility of treating BPV post stroke. Following an acute ischaemic 
stroke BP levels are frequently above the accepted threshold value for hypertension of 
140/90mmHg [91, 92], even when there is no prior history of hypertension [10, 11]. 
The causes of this, often transient, increase are probably multifactorial, but one 
possibility is that it is a protective physiological response to maintain CBF to the 
ischaemic penumbra in the face of dysfunctional cerebral autoregulatory mechanisms 
[13, 63]. This explanation is supported by data demonstrating a spontaneous BP 
decrease in many patients, usually between 4-14 days after stroke onset [11, 63]. 
However, data from major stroke trials also indicates that raised BP in the acute period 
is associated with a poor prognosis [69]. In fact, the relationship between BP in the 
acute phase and both short and long-term mortality and morbidity from ischaemic 
stroke from observational studies is probably ‘U’ shaped, with the optimal BP level in 
the region of 150mmHg systolic [70]. Despite this, trials investigating the treatment of 
raised BP in acute ischaemic stroke have not shown any benefit to BP reduction [11], 
even if treatment is administered within 1-2 hours of symptom onset [278], with one 
trial reporting that it is possibly harmful [77]. Consequently, the management of raised 
BP in acute stroke remains uncertain, with guidelines suggesting that it is unlikely to be 
beneficial to start or continue treatment in the first few days after symptom onset 
unless there are adverse features related to accelerated hypertension or the patient 
has had thrombolytic therapy [18, 19, 57]. 
 
That trials of BP lowering in acute ischaemic stroke have shown no benefit may be 
because it is BPV rather than absolute BP level which is the important factor [126]. BP 
fluctuations may damage the vulnerable ischaemic penumbra, with drops in BP causing 
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hypoperfusion and infarct expansion, and spikes in BP causing increased oedema and 
haemorrhagic transformation. This may at least partly explain why the relationship 
between BP and stroke outcome appears to be ‘U’ shaped, and a growing body of 
evidence that BPV is a cardiovascular risk factor independent of mean BP also supports 
the theory [14, 128, 152, 153]. Furthermore, research has demonstrated that BPV is 
also increased in acute ischaemic stroke [100], is associated with adverse outcomes 
[98, 197-199], and is associated with the risk of recurrent stroke [200]. Whether BPV is 
a potential target for therapeutic intervention has not yet been tested. There are 
reports that some classes of routinely used antihypertensive medications can reduce 
BPV in addition to mean BP [133, 202, 209], but the evidence presented is either from 
observational cohorts or retrospective post-hoc analyses of trial data, and so cannot 
be said to be conclusive. Interestingly, some of these reports also indicate that not all 
commonly used antihypertensive medication classes effect BPV equally, despite 
lowering mean BP to a similar degree. CCB and thiazide-like diuretics are consistently 
reported to lower BPV, whereas beta blockers increase it, with renin-angiotensin 
inhibitors variably reported to be neutral or also increase BPV [201, 203, 211]. There is 
a need for prospective randomised trials to further investigate these reported effects. 
Furthermore, if lowering BPV is possible and it is the case that certain medication 
classes are more effective than others, it needs to be established whether lowering 
BPV following the acute period conveys any benefit in terms of morbidity and 
mortality after stroke.  
 
8.2 Hypothesis 
 
This study aimed to test the hypothesis that conducting a trial assessing the effect of 
two commonly used classes of antihypertensive medication on BPV in patients with a 
recent ischaemic cerebrovascular event in the subacute period was feasible. 
Specifically, the ability to recruit and retain trial subjects, the feasibility of measuring a 
change in BPV from baseline to three months post-event, compliance with the trial 
procedures, and the safety/side-effect profile of the intervention. Exploratory 
secondary aims were the assessment of functional and cognitive outcomes at three 
months to estimate potential differences between the intervention arms, which may 
help with the planning of a future definitive trial.  
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8.3 Trial Setup and Management 
 
I authored the protocol for the trial in conjunction with the investigators, Professor 
Tom Robinson, Professor John Potter, and Professor Peter Rothwell between 
November 2016 and May 2017. Following sponsor review by the University of 
Leicester, I applied for ethical approval on 25th July 2017 (IRAS ID 216241) and this was 
granted by the London – Central Research Ethics Committee on 25th September 2017 
(REC No. 17/LO/1427) after interview. As this was a clinical trial with investigational 
medicinal products I also applied for approval from the Medicines and Healthcare 
products Regulatory Agency, which was granted on 21st September 2017 (EudraCT 
number 2017-002560-41). Local Research and Development Department approval was 
provided for each trial site prior to sponsor green light approval to commence the trial. 
Recruitment for the trial opened on 3rd January 2018 in Leicester, 19th February 2018 in 
Norwich, and 26th March 2018 in Oxford. 
 
During the recruitment phase several amendments were made to the trial. A 
substantial amendment to the eligibility criteria was implemented on 11th September 
2018 in order to try and improve recruitment. This amendment increased the window 
of eligibility from <72 hours from symptom onset, to <7 days. Two non-substantial 
amendments were also made. The first was required to produce specific 
correspondence letters to the GP for use at the Oxford site to reflect that they were 
only recruiting participants from the outpatient clinic. This amendment was 
implemented on 20th March 2018. The second was required in order to extend the trial 
beyond the original end date and was implemented on 20th November 2018. This was 
done so that the trial could complete the originally planned duration of 15 months (12 
months recruitment with a further 3 months for follow-up) despite unexpected delays 
in the setup process. 
 
Oversight of the trial was conducted by the Trial Management Group, consisting of 
myself and Professor’s Tom Robinson, John Potter, and Peter Rothwell, meeting at 
minimum three monthly intervals. A separate Independent Trial Steering Committee 
was convened consisting of the trial management group, the trial statistician, 
independent clinicians (Professor Marcus Flather, Professor David Werring, and Dr 
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Kneale Metcalf), and a representative of the funding body (Kate Holmes). The Trial 
Steering Committee met at six monthly intervals following the commencement of the 
trial and provided independent advice to the Trial Management Group. In addition, a 
Data Safety Monitoring Committee consisting of further independent clinicians and an 
independent statistician also met at six monthly intervals to advise the Trial 
Management Group and Trial Steering Committee regarding any arising ethical or 
safety issues that might require adjustment to, or early termination of, the trial.  
 
8.4 Methods 
 
CAARBS was a multi-centre, open-label, randomised parallel group controlled 
feasibility trial. The methodology of the trial is described in detail in section 3.1.4 and 
has also been published in full elsewhere [224]. In brief, eligible patients were aged 
≥18 years with a first-episode TIA or mild/moderate ischaemic stroke (NIHSS <10), 
presenting within 72 hours of symptom onset (subsequently amended to within seven 
days of symptom onset), and requiring antihypertensive therapy for secondary stroke 
prevention (defined as repeated CBPM >130/80mmHg). Patients were excluded from 
the trial if they had a known contraindication to the proposed investigational medicinal 
products, clinically required treatment with a specific class of antihypertensive, had a 
pre-event mRS >3, life expectancy <3 months, or AF. Patients presenting to both the 
inpatient and outpatient stroke services at participating sites (outpatient services only 
in Oxford) were screened for eligibility by the trial nurse or Clinical Research Fellow. In 
accordance with local protocols, patient’s pre-existing antihypertensive therapy was 
stopped or suspended by the clinical team at admission and new antihypertensive 
therapy was not commenced (as part of the trial or otherwise) until at least 48 hours 
after symptom onset unless clinically indicated. All diagnoses were reviewed by two 
experienced stroke physicians to confirm eligibility. Eligible patients willing to 
participate in the trial provided written informed consent prior to being randomised in 
a 1:1 ratio using a computer generated protocol in blocks of four, to treatment with 
either a dihydropyridine CCB or an ACEI/ARB. Each trial site had a unique 
randomisation table and managed the randomisation process locally to simplify the 
process. Intervention groups were defined according to antihypertensive class, with 
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the choice of medication from within the randomly allocated class at the discretion of 
the treating clinician.  
 
At the baseline consultation clinical information was collected as described in section 
3.5.1. BP data were collected using enhanced CBPM as described in section 3.5.2, 
daytime ABPM as described in section 3.5.3, and beat-to-beat BP as described in 
section 3.5.5. In addition, stroke severity was recorded using the tools described in 
section 3.5.6 and participants completed a cognitive battery based on the MoCA as a 
screening test enhanced with the Albert’s line test for inattention and the MiND-B for 
frontal lobe cognitive symptoms. Participants also completed the Geriatric Depression 
Scale to exclude depression as a potential confounding factor for reduced cognitive 
assessment scores. An interim follow-up visit was completed after 21 ± 7 days, at 
which time treatment compliance was assessed with a tablet count and a self-rating 
scale [279], and enhanced CBPM and beat-to-beat BP measurements were repeated. 
Participants were asked to report any treatment side effects and those in the 
ACEI/ARB group had blood taken to check their renal function as a safety measure, as 
per routine clinical practice. The final follow-up visit was completed after 90 ± 14 days, 
at which time treatment compliance assessment, all baseline BP measurements, 
assessment of stroke severity and functional recovery, and the cognitive battery were 
repeated. 
 
The primary outcome measure for the trial was the assessment of rates of recruitment 
and retention, including reasons for exclusion. Secondary feasibility outcomes were (i) 
change in BPV from baseline to follow-up by intervention arm; (ii) rates of treatment 
compliance and discontinuation by intervention arm; (iii) completion rates of BPV 
measurements; (iv) serious adverse event rates by intervention arm. In addition, 
secondary exploratory outcomes were (i) difference in mean BP at day 21 and day 90 
by intervention arm; (ii) difference in BPV at day 21 and day 90 by intervention arm; 
(iii) mRS at day 21 and day 90 by intervention arm; (iv) difference in MoCA score at day 
90 by intervention arm. 
 
The primary objective of CAARBS was the assessment of the feasibility of recruitment, 
retention, compliance, and the safety of the trial. However, a sample size calculation 
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pre-hoc was performed to estimate the number of participants required to detect a 
potential difference in BPV between the treatment arms. Assuming a mean systolic 
BPV SD of 14.97mmHg in the CCB arm and 16.95mmHg in the ACEI/ARB arm [201], a 
sample of 150 patients (64 per group allowing for a 15% drop-out rate) was estimated 
to be required to detect an 8mmHg difference in systolic BPV with 80% power at the 
5% significance level.  
 
8.5 Statistical analysis 
 
Data were analysed using SPSS (version 25.0). Only descriptive analyses were 
undertaken, in keeping with the CONSORT recommendations for reporting pilot and 
feasibility trials [280], as the required sample size for detecting a between-group 
difference in BPV described above was not achieved. Screening and management logs 
were assessed to determine the proportion of patients screened that were eligible for 
the trial, the proportion of eligible patients that were recruited, and the proportion of 
participants that completed follow-up. Reasons for ineligibility were recorded and 
assessed. Also, when offered, reasons for eligible patients declining to participate and 
reasons for participants withdrawing from the trial were recorded and assessed. All 
exploratory variables were assessed for normality. Normally distributed variables are 
presented as mean (SD) and non-normally distributed variables are presented as 
median (IQR). For the descriptive analysis of change in BPV from baseline to follow-up 
the mean (SD) absolute change for each intervention arm is described. 
 
8.6 Results 
 
Recruitment for the trial commenced on 3rd January 2018 and continued until 31st 
December 2018, with all follow-up completed three months post-randomisation. A 
total of 2321 patients were screened across the three sites, 14 (0.6%) of whom were 
eligible and consented to participate in the trial (Figure 23). A breakdown of screening 
and recruitment by site is shown in Table 37. Of those screened, 2264 (98.1%) were 
ineligible, with 1858 (81.7%) having a single reason for exclusion recorded on the 
screening log and 463 (18.3%) having multiple reasons recorded. The most common 
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reasons for patients being deemed ineligible were recurrent stroke/TIA (N=496 
[21.4%]), non-stroke diagnosis (N=453 [19.5%]), and concurrent AF (N=431 [18.5%] 
Table 38). Patients presenting outside of the designated timeframe was also a 
prominent reason for ineligibility when screening against the initial window of <72 
hours from symptom onset (N=314 [19.4%]). However, following the substantial 
amendment to the eligibility criteria described above, late presentation became a less 
frequent reason for exclusion (N=46 [6.6%]). With a few exceptions, the main reasons 
for exclusion were similar across all three sites (Figure 24). Non-stroke diagnosis was a 
more frequent reason for exclusion at the Leicester site as medical outliers on the 
stroke ward were included in screening numbers. Presenting beyond 72 hours from 
symptom onset was a greater problem in Oxford where screening and recruitment for 
the trial was exclusively outpatient based. In Norwich a proportion of patients were 
excluded as their pre-event antihypertensive therapy was not suspended at the point 
of admission to the stroke services. 
 
In addition to those patients who were excluded, a further 43 (1.9%) met the eligibility 
criteria but did not want to participate in the trial. Patients who declined to participate 
in the trial were not obliged to provide a reason for their decision and not all offered 
an explanation for their choice. However, several patients stated that they felt unable 
to commit the time to attend trial visits (N=7) or did not wish to travel to the hospital 
for additional appointments (N=3), despite the offer of reimbursement for travel costs. 
Two patients also stated that they did not like the idea of being randomly assigned to a 
medical treatment.  
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Figure 23: CAARBS CONSORT flow diagram. CCB denotes calcium channel blocker; 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, 
blood pressure; GP, general practitioner. 
Assessed for eligibility (n=2321) 
Excluded  (n=2307) 
   Not meeting inclusion 
criteria (n=2264) 
   Declined to participate 
(n=38) 
   Discharged before 
research team could 
review (n=5) 
Analysed  (n=4) 
 Excluded from analysis (n=0) 
Lost to follow-up (participant choice) 
(n=1) 
Discontinued intervention (n=0) 
Allocated to CCB arm (n=6) 
 Received allocated intervention (n=5) 
 Did not receive allocated intervention 
as BP <130/80mmHg (n=1) 
Lost to follow-up (given CCB by GP) 
(n=1) 
Discontinued intervention (n=1) 
Allocated to ACEI/ARB arm (n=8) 
 Received allocated intervention (n=7) 
 Did not receive allocated intervention 
as BP <130/80mmHg (n=1) 
Analysed  (n=5) 
 Excluded from analysis (n=0) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=14) 
Enrollment 
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Table 37: CAARBS screening and recruitment data by participating site. 
 Norwich Leicester Oxford 
Screened 1249 803 269 
Excluded 1241 800 266 
Ineligible 1225 774 265 
Randomised 
CCB 4 1 1 
ACEI/ARB 4 2 2 
Lost or withdrawn 4 0 1 
Completed follow-up 4 3 2 
CCB denotes calcium channel blocker; ACEI, angiotensin converting enzyme inhibitor; 
ARB, angiotensin receptor blocker. 
 
 
Figure 24: Histogram showing rates of each reason for exclusion of ineligible patients 
by trial site. BP denotes blood pressure; mRS, modified Rankin scale; TIA, transient 
ischaemic attack; ICH, intracerebral haemorrhage; NIHSS, National Institutes of Health 
Stroke Scale. 
0 
5 
10 
15 
20 
25 
30 
35 
40 
P
e
rc
e
n
t 
Norwich 
Leicester 
Oxford 
 170 
 
Table 38: Reasons for exclusion of patients screened for the trial who did not meet the 
eligibility criteria. Data presented are frequency (%). 
Reason for exclusion Frequency 
Age <18 years 3 (0.1%) 
Non-stroke diagnosis 453 (19.5%) 
Late presentation >72 hours from symptom 
onset 
314 (19.4%)* 
>7 days from symptom onset 46 (6.6%)** 
BP <130/80mmHg 145 (6.2%) 
Unable to consent 120 (5.2%) 
Contraindication to the intervention 51 (2.2%) 
Unable to take oral medication 110 (4.7%) 
Clinical need for urgent antihypertensive therapy or 
treatment with specific antihypertensive class 
43 (1.9%) 
Pre-event mRS >3 67 (2.9%) 
Life expectancy <3 months 19 (0.8%) 
Atrial fibrillation 431 (18.6%) 
Participating in another investigational drug trial 40 (1.7%) 
Pregnant 1 (0.04%) 
Previous stroke/TIA 496 (21.4%) 
ICH 183 (7.9%) 
Usual antihypertensive therapy not suspended 97 (4.2%) 
NIHSS ≥10 119 (5.1%) 
Deemed inappropriate to approach for research by clinical 
team due to co-morbidities 
83 (3.6%) 
*Out of 1619 patients screened before the eligibility criteria were amended 
**Out of 702 patients screened after the eligibility criteria were amended 
BP denotes blood pressure; mRS, modified Rankin scale; TIA, transient ischaemic 
attack; ICH, intracerebral haemorrhage; NIHSS, National Institutes of Health Stroke 
Scale. 
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Randomised participants were evenly split between the two intervention groups in the 
context of the small sample size. Baseline characteristics are displayed in Table 39. 
Two participants (both from the Norwich site) were withdrawn as “screening failures” 
and provided no baseline data as their initial BP was >130/80mmHg, but repeated 
measurements at the baseline consultation were below this threshold value for 
secondary prevention treatment. Therefore, it was felt to be unethical for them to 
continue in the trial. One participant withdrew from the CCB arm of their own choice 
(they felt unable to commit the time required for follow-up visits), one participant was 
withdrawn from the ACEI/ARB arm by the trial team as they were commenced on a 
CCB by another clinical team in addition to their trial medication, and one participant 
from the ACEI/ARB arm discontinued treatment due to side effects and withdrew from 
the trial. Apart from this single treatment discontinuation there were no other major 
side effects and no serious adverse events recorded in either intervention arm. 
 
Completion rates of CBPM and beat-to-beat BP measurements were good across all 
study visits, with all completed readings judged to be valid (Table 40). However, 
completion rates of daytime ABPM measurements were lower, in part due to a 
software failure at the Leicester site meaning no ABPM recordings were possible in 
their participants, and in part due to participants refusing this method (N=2). 
Furthermore, of the completed daytime ABPM measurements, only 6/13 (46.2%) 
provided ≥14 readings and were considered valid for analysis. Compliance with trial 
treatment according to the self-rating questionnaire was good, with 8/9 (88.9%) of 
participants who completed the trial indicating compliance ≥80%. However, tablet 
count was unsuccessful at assessing compliance as participants often failed to bring 
their medication to follow-up visits, being completed in only 5/18 (27.7%) 
consultations.  
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Table 39: Baseline characteristics of randomised participants. Data presented are 
mean (SD) or frequency (%), except alcohol consumption which is median (IQR). 
 CCB ACEI/ARB 
N  5 7 
Age (years)  74.8 (4.2) 64.9 (9.1) 
Gender Male 4 (80.0%) 4 (57.1%) 
Ethnicity White-British 4 (80.0%) 6 (85.7%) 
BMI (kg/m2)  28.2 (4.6) 27.1 (5.8) 
Smoking Never smoked 2 (40.0%) 2 (28.6%) 
Ex-smoker 3 (60.0%) 2 (28.6%) 
Current smoker 0 (0.0%) 3 (42.8%) 
Alcohol (units/wk)  5 (17.5) 14 (26.5) 
Diagnosis TIA 3 (60.0%) 3 (42.9%) 
Stroke 2 (40.0%) 4 (57.1%) 
Past medical 
history 
Hypertension 3 (60.0%) 1 (14.3%) 
Diabetes 1 (20.0%) 0 (0.0%) 
IHD 0 (0.0%) 0 (0.0%) 
Mean enhanced 
CBPM (mmHg) 
SBP 163.6 (17.3) 152.7 (14.5) 
DBP 81.8 (5.9) 83.1 (6.5) 
SD enhanced CBPM 
(mmHg) 
SBP 8.4 (5.2) 6.8 (5.3) 
DBP 5.6 (3.0) 6.0 (3.4) 
CV enhanced CBPM 
(%) 
SBP 4.9 (2.6) 4.5 (3.4) 
DBP 7.0 (3.9) 7.2 (4.0) 
Mean beat-to-beat 
BP (mmHg) 
SBP 156.6 (5.7) 151.0 (11.9) 
DBP 79.8 (7.1) 82.6 (6.1) 
SD beat-to-beat BP 
(mmHg) 
SBP 9.9 (3.9) 9.2 (5.5) 
DBP 5.2 (2.2) 5.1 (2.4) 
CV beat-to-beat BP 
(%) 
SBP 6.3 (2.5) 6.0 (2.6) 
DBP 6.6 (2.6) 6.3 (3.0) 
CCB denotes calcium channel blocker; ACEI, angiotensin converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; BMI, body mass index; TIA, transient ischaemic attack; IHD, 
ischaemic heart disease; CBPM, clinic blood pressure measurement; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; SD, standard deviation; CV, coefficient of variation; BP, 
blood pressure.
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Table 40: Completion rates of each blood pressure measurement method. 
 Enhanced CBPM Beat-to-beat BP Daytime ABPM 
Baseline 12/12 (100.0%) 11/12 (91.7%) 7/12 (58.3%) 
21 days 9/10 (90.0%) 9/10 (90.0%) - 
90 days 9/9 (90.0%) 8/9 (88.9%) 6/9 (66.6%) 
CBPM denotes clinic blood pressure measurement; BP, blood pressure; ABPM, 
ambulatory blood pressure measurement. 
 
Table 41: Mean blood pressure and variability from enhanced clinic blood pressure 
measurement at day 21 and day 90 by intervention arm. Data presented are mean (SD) 
with change from baseline being the absolute difference in the mean values. 
 CCB ACEI/ARB 
SBP DBP SBP DBP 
Mean BP 
(mmHg) 
21 days 151.8 (4.1) 74.2 (2.5) 137.1 (13.0) 77.5 (9.9) 
Change from 
baseline 
-11.8 -7.6 -15.6 -5.6 
90 days 128.6 (10.1) 72.6 (4.1) 130.9 (17.9) 75.5 (8.2) 
Change from 
baseline 
-35.0 -9.2 -21.8 -7.6 
SD 
(mmHg) 
21 days 5.2 (1.5) 3.4 (1.0) 6.2 (2.9) 4.6 (2.7) 
Change from 
baseline 
-3.2 -2.2 -0.6 -1.4 
90 days 5.1 (2.1) 4.3 (2.2) 3.9 (1.7) 3.1 (1.7) 
Change from 
baseline 
-3.3 -1.3 -2.9 -2.9 
CV (%) 
21 days 3.4 (0.9) 4.5 (1.2) 4.6 (2.3) 5.8 (2.8) 
Change from 
baseline 
-1.5 -2.5 0.1 -1.4 
90 days 4.0 (1.7) 5.8 (2.7) 3.1 (1.5) 4.3 (1.6) 
Change from 
baseline 
-0.9 -1.2 -1.4 -2.9 
SD denotes standard deviation; CCB, calcium channel blocker; ACEI, angiotensin converting 
enzyme inhibitor; ARB, angiotensin receptor blocker; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; BP, blood pressure; CV, coefficient of variation.
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Table 42: Mean blood pressure and variability from beta-to-beat blood pressure 
measurement at day 21 and day 90 by intervention arm. Data presented are mean (SD) 
with change from baseline being the absolute difference in the mean values. 
 CCB ACEI/ARB 
SBP DBP SBP DBP 
Mean BP 
(mmHg) 
21 days 142.0 (7.4) 68.1 (1.3) 127.4 (14.8) 71.7 (11.4) 
Change from 
baseline 
-14.6 -11.7 -23.6 -10.9 
90 days 136.4 (3.7) 71.5 (6.2) 137.5 (27.5) 75.8 (8.9) 
Change from 
baseline 
-20.2 -8.3 -13.5 -6.8 
SD 
(mmHg) 
21 days 9.7 (4.0) 4.9 (2.5) 8.6 (4.6) 4.0 (1.7) 
Change from 
baseline 
-0.2 -0.3 -0.6 -1.1 
90 days 6.2 (3.0) 2.8 (1.4) 8.7 (5.9) 3.9 (2.7) 
Change from 
baseline 
-3.7 -2.4 -0.5 -1.2 
CV (%) 
21 days 6.7 (2.4) 7.2 (3.6) 6.6 (2.6) 5.7 (1.7) 
Change from 
baseline 
0.4 0.6 0.6 -0.6 
90 days 4.5 (2.1) 3.8 (1.8) 6.0 (2.9) 4.9 (2.9) 
Change from 
baseline 
-1.8 -2.1 0.0 -1.4 
SD denotes standard deviation; CCB, calcium channel blocker; ACEI, angiotensin converting 
enzyme inhibitor; ARB, angiotensin receptor blocker; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; BP, blood pressure; CV, coefficient of variation.
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Enhanced CBPM and beat-to-beat mean BP and BPV were reduced at 90 days 
compared to baseline in both trial arms (Tables 41-42), and the reductions seen were 
similar. There were also no apparent differences in functional or cognitive outcome 
between the intervention arms. In the CCB arm median (IQR) mRS was 0.0 (0.0) at day 
21 and 0.0 (1.0) at day 90, and mean (SD) MoCA score was 23.5 (2.7). In the ACEI/ARB 
arm mRS was 1.0 (0.8) at day 21 and 1.0 (1.0) at day 90, and MoCA score was 23.6 
(3.7). 
 
8.7 Discussion 
 
Recruitment for this trial was difficult owing to the high rate of ineligibility of patients 
who were screened (98.1%), this being an issue across all three trial sites. The trial did 
not meet its pre-specified recruitment target and consequently it must be concluded 
that in its current form it would not be feasible to scale up this study design to attempt 
a definitive RCT. The main reasons for patient ineligibility were having a previous 
stroke or TIA, having a non-stroke diagnosis, presenting outside of the window of 
eligibility, and having concurrent AF. Amending the inclusion criteria to extend the 
window of eligibility markedly reduced the number of patients excluded for this 
reason, but this did not translate into a major increase in recruitment. However, that 
the major reasons for exclusion were similar across all sites suggests that a future trial 
could be successful if the eligibility criteria were modified more comprehensively.  
 
A proportion of patients who are ultimately diagnosed with a stroke mimic must be 
accepted, but there are other criteria that could be adapted. Firstly, the findings 
suggest that retaining the extended window of eligibility could be helpful. Not only 
could it directly increase patient eligibility at the point of presentation to stroke 
services, it may also allow time for patients who would be too unwell to participate in 
the first 72 hours post event (e.g. if they are nil by mouth) to recover sufficiently for 
inclusion. Secondly, although increased BPV may persist into the chronic phase post-
stroke [256], there is the potential for large gains if patients with a previous stroke are 
included. The use of minimisation criteria to ensure equal numbers of first and 
recurrent stroke patients in each trial arm, or pre-specified analysis plans to offset 
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their inclusion, such as planned subgroup analysis of patients with first-ever stroke or 
adjustment for previous stroke in statistical testing, could be employed to ensure the 
accuracy of results. Thirdly, as it is accepted that most patients require multiple agents 
in order to achieve BP control [214-216], it may be necessary to include patients on 
additional antihypertensive medications other than the investigational medicinal 
products. Again it is likely that this would need to be accounted for with techniques 
such as pre-specified subgroup analysis or adjustment in statistical testing. A 
treatment escalation algorithm would need to be devised to minimise the risk of 
unintentional intervention group crossover during follow-up (which may need to be 
longer than in this trial), whilst allowing for treatment intensification in order to 
achieve secondary prevention BP targets. Finally, as beat-to-beat BPV is increased in 
patients with AF compared to control [281], and beta blockers are frequently used as 
part of a rate control treatment strategy for AF [282], the potential for data 
confounding by including participants with AF may outweigh any benefit of improved 
recruitment. However, automated oscillometric BP measurement devices have been 
shown to be reliable in AF provided multiple measurements are taken as per guideline 
recommendations [92, 283]. Therefore, if any future trial used BPV derived from 
enhanced CBPM or ABPM to judge the impact of the intervention, rather than beat-to-
beat BPV, it may be possible to include these patients. Further safeguarding could be 
achieved by specifying data validation criteria for patients with AF, for example by 
stating an acceptable range for HRV across BP measurements used to derive BPV that 
would minimise the impact of uncontrolled AF on the BP data. 
 
Although, owing to the findings of the primary trial outcome, the trial was considered 
not to be feasible in its current format, there were some positives amongst the 
secondary feasibility outcomes. These findings must be interpreted in the context of 
the small sample size, but they may give grounds for cautious optimism. Firstly, 
retention in the trial was reasonable, with 9/14 (64.3%) randomised participants 
completing three-month follow-up. Secondly, compliance with the intervention and 
with BP measurements was good, with the reduced rate of completed daytime ABPM 
measurements mainly due to a technical issue at one of the trial sites. Thirdly, there 
were no major safety issues in either trial arm and only one participant discontinued 
treatment due to side effects. Fourthly, although it was not possible to draw any 
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conclusions about differences between the intervention arms in terms of BPV 
reduction, functional outcomes, or cognitive outcomes, a reduction in BPV was 
demonstrated over the three-month follow-up period. This indicates that if sufficient 
numbers of participants could be recruited, it should be possible to detect a 
differential effect of different antihypertensive medication classes on BPV if one exists. 
Further work is now required to estimate the reduction in BPV that is attributable to 
each intervention as this will be required to estimate the necessary sample size in a 
future trial, and has not been adequately established in this patient group. 
 
There are no directly comparable trials for the results of this study and so, even though 
insufficient data were obtained for the secondary exploratory outcomes, its novelty 
and merits should be noted. Firstly, it should be highlighted that the primary objective 
of investigating feasibility was achieved, and this represents a strength of the study 
design and underlines the value of conducting preliminary trials such as this one. 
Secondly, the data gathered has also allowed for recommendations to be made that 
may improve recruitment if a future trial is pursued. Thirdly, the trial has proven the 
concept that it is possible to measure a change in BPV in the months following an 
ischaemic cerebrovascular event, indicating that a future trial with modified eligibility 
criteria could successfully test the hypothesis that BPV reduction will not be equal 
between groups treated with different antihypertensive medication classes. The trial 
also has limitations that are worthy of consideration. Firstly, only a small proportion of 
eligible patients who declined to take part in the trial offered a reason for their 
decision and this represents a missed opportunity for improving the trial design. 
Secondly, owing to the small sample size limited data regarding participant retention 
and reasons for withdrawal were obtained. Obtaining more data in both of these areas 
would have been useful for judging the feasibility of any similar future trial. Thirdly, it 
was not possible to demonstrate a differential effect on BPV between the two 
intervention arms. In part this was due to the small sample size, but it cannot be 
excluded that the use of antihypertensive agents in some participants prior to their 
recruitment in the trial could have influenced their BPV as recorded in the trial. 
Unfortunately, as it is accepted standard care to treat raised BP for secondary stroke 
prevention it would not be ethical to incorporate a complete washout period into the 
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trial design. Therefore, follow-up in any further trials may need to be prolonged, or 
previous antihypertensive use may need to be adjusted for in the statistical analysis. 
 
8.8 Summary 
 
 With the current design this RCT must be deemed not feasible owing to the 
large proportion of patients screened who were not eligible for inclusion. 
 However, the trial did demonstrate that it is possible to measure a change in 
BPV over three months post stroke and compliance with trial procedures by 
those recruited was good. 
 The main reasons for ineligibility were similar across trial sites, suggesting that 
modifying the eligibility criteria may allow for improved recruitment in any 
similar future trial. 
 Modifications including a longer window of eligibility following symptom onset, 
including patients with previous stroke/TIA, and allowing for patients who 
require multiple antihypertensive agents should be considered. 
 It may also be possible to include patients with AF, though this would probably 
depend on the method(s) chosen to measure BPV and would require careful 
data collection and inspection to minimise the risk of confounding. 
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9 General Discussion 
 
As summarised in chapter two of this thesis, the idea that an individual’s BP can vary 
from reading to reading, even when multiple readings are taken concurrently, is not 
new. Multiple factors can contribute to this variability, some of which are natural (e.g. 
circadian rhythm or emotional state) or situational (e.g. WCH or MH) [90], yet an 
increasing body of evidence has emerged indicating that BPV may also be pathological. 
Early suggestions that BPV may not be a benign phenomenon came from work by 
Rothwell et al. where limitations to the accepted concept of “usual BP” were noted 
[126], and secondary analyses of several major stroke trials showed that long-term 
visit-to-visit variability (after adjustment for mean BP levels) was a stronger predictor 
of recurrent stroke than mean BP [131]. Further work in the wake of these publications 
has shown that increased BPV is associated with markers of damage to multiple organ 
systems, for example microalbuminuria and proteinuria [134-136], cerebral small 
vessel disease and micro-haemorrhages [137, 138], and left ventricular hypertrophy 
[136]. Furthermore, several meta-analyses of reports on the prognostic significance of 
BPV indicate that increased long-term variability is an independent risk factor for 
mortality, coronary heart disease, and stroke [14, 128, 152, 153]. The same is probably 
also true of short-term variability, though the evidence is less robust [128]. It should be 
noted that analyses of the prognostic significance of BPV have used statistical 
adjustment for mean BP levels. This illustrates that it is not possible to consider BPV in 
isolation from mean BP. Firstly, both are measured using the same device(s) and 
(where the device is programmed to take multiple measurements) at the same time. 
Secondly, the two measurements are linked, with data indicating that BPV has a 
positive linear relationship with mean BP [130, 251]. Thirdly, although BPV is an 
independent cardiovascular risk factor, the application of this in clinical practice is 
likely to be in combination with the prognostic information provided by mean BP. In 
other words, the prognostic value of BPV is likely to be additive to that of mean BP 
rather than separate. Finally, it may be that both are altered by the same 
interventions, though the extent to which antihypertensive medications alter BPV is 
uncertain. In relation to ischaemic stroke, it has been suggested that BPV may be of 
particular relevance, with the ischaemic penumbra theoretically vulnerable to 
fluctuations in BP in the context of abnormal cerebral autoregulation and a possible 
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pathophysiological link with post stroke autonomic dysfunction [13, 181]. Compared to 
controls, BPV is increased in patients with ischaemic stroke [100]. Furthermore, 
increased BPV in this patient group is associated with adverse clinical features, such as 
secondary haemorrhagic transformation and END [185-189], and worse long-term 
functional recovery as assessed by mRS at three months [98, 197-199]. However, the 
literature on BPV is complicated by heterogeneity in terms of BPV measurement and 
calculation, a lack of understanding as to whether alternative measurement methods 
and timescales of BPV are equivalent or if any one method is superior, and a lack of 
established “normal” values for BPV.  
 
The aims of this thesis were to further the investigation of BPV in patients with 
ischaemic cerebrovascular disease with specific regard to: (i) its measurement and 
calculation, and (ii) its potential as a therapeutic target following an ischaemic 
cerebrovascular event. In summary, the experimental chapters presented in this thesis 
have indicated the following with regard to these aims. Firstly, there were significant 
differences in mean BP values as assessed by daytime ABPM and contemporaneous 
HBPM in patients with a recent ischaemic stroke or TIA, which has implications for the 
measurement of BPV using these methods. Mean daytime ABPM values were in the 
order of 7/2mmHg lower than HBPM values and this difference was consistent over 
time, but not reproducible within individuals. Secondly, there were no significant 
relationships between different timescales of BPV as assessed by comparison of BPV 
values derived from beat-to-beat BP measurements and those derived using other 
methods. This was the case even when the difference between timescales was small 
(i.e. within-hour daytime ABPM data compared with beat-to-beat BP data) and 
suggests that different BPV measurements are not interchangeable. Thirdly, there 
were significant relationships between ischaemic stroke severity, as measured by 
NIHSS or OCSP classification, and baseline short-term BPV derived from daytime 
ABPM, indicating increased BPV in patients with LACS compared to other stroke 
subtypes. However, similar relationships were not demonstrated for short-term BPV 
from enhanced CBPM or beat-to-beat BPV, and no relationship between BPV and 
affected cerebral hemisphere was demonstrated. Fourthly, there were no significant 
differences in baseline BPV for patients with a recent ischaemic stroke or TIA treated 
with a CCB or ACEI/ARB based antihypertensive regimen compared to controls. 
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However, this study did show a possible, but non-significant contrasting effect on 
short-term BPV from daytime ABPM for those treated with a CCB or ACEI/ARB. Finally, 
to test whether different classes of antihypertensive medication alter BPV to varying 
degrees, a feasibility RCT was developed to compare the effects of a CCB or ACEI/ARB 
based antihypertensive regimen on BPV following an acute ischaemic stroke or TIA. 
However, the trial design as tested was proven to be unfeasible due to the high rate of 
patient ineligibility, which resulted in poor recruitment. However, participant retention 
in the trial was acceptable and the interventions were safe. Furthermore, the trial 
demonstrated that it is possible to determine a change in BPV in the months following 
an acute ischaemic cerebrovascular event. These findings will now be discussed 
further, taking the two broad aims in turn, with consideration given to how gaps in the 
evidence have been addressed, and any implications for future research on this topic. 
 
9.1 Studies Investigating the Measurement of Blood Pressure Variability Post 
Stroke 
 
As summarised above, chapters four and five were concerned with the measurement 
of BP and BPV following a recent ischaemic stroke or TIA. Chapter four investigated 
differences in the measurement of mean BP between alternative out-of-office 
measurement methods, namely daytime ABPM and HBPM. Chapter five investigated 
the relationships between very short-term BPV from beat-to-beat BP measurements 
and variability derived over longer timescales from more commonly used BP 
measurement methods. For the adequate treatment of hypertension to be possible we 
must first understand the relevance of raised BP to future cardiovascular events, and 
second, establish the threshold value at which the benefit of intervention outweighs 
the risk/side effects of treatment. Both of these factors rely on having an accurate and 
reproducible method for measuring BP. Furthermore, these same factors apply when 
considering the clinical importance of BPV and it is unlikely that BPV can be considered 
in isolation from BP. At present there is no standardised methodology for measuring 
BPV and the threshold values of variability for increased cardiovascular risk, including 
risk of first or recurrent stroke, have not been established [90, 155, 156]. Even in the 
treatment of mean BP levels, which is widely accepted in comparison to the idea of 
targeting treatment at BPV, there remains uncertainty about the optimum target 
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value, especially for prevention of recurrent stroke and cognitive decline [55, 62, 284, 
285], and debate about which measurement method represents the gold standard 
[156]. This uncertainty is reflected in recent guideline updates, with the AHA now 
recommending treatment at a lower threshold value than European guidelines [54, 91, 
92]. Although all major guidelines agree that 135/85mmHg is the equivalent out-of-
office BP value (measured by either daytime ABPM or HBPM) for a CBPM of 
140/90mmHg, the AHA countenance that the difference is dependent on BP level, with 
no difference at a CBPM of 130/80mmHg or below and an increased difference with 
greater CBPM values [54, 91, 92]. That ABPM values tend to be lower than CBPM 
values is widely accepted [110]. However, the limited number of direct comparisons of 
ABPM and HBPM suggest that out-of-office methods may not be equivalent [112, 116, 
118, 120, 121]. Clearly these discrepancies in BP measurement, if accurate, have 
implications for the treatment and monitoring of BP for both primary and secondary 
disease prevention, and the same may be true of BPV. 
 
Evidence suggests that BPV is related to mean BP, with two studies indicating a linear 
positive relationship whereby BPV increases alongside mean BP level [130, 251]. A 
third study has suggested that the relationship may be ‘U’ shaped, with variability 
increasing either side of SBP in the range 120-140mmHg, though there was stronger 
evidence for the increase above SBP 140mmHg than below 120mmHg [286]. 
Therefore, discrepancies in the measurement of mean BP level are likely to have 
implications for the measurement of BPV, and by extension its treatment. If mean BP 
values obtained from different measurement methods are not equivalent, then we 
may expect variability derived using different methods to differ also, even before 
considering other methodological differences that may impact BPV measurement, 
such as the number of BP readings acquired and the time between readings. In 
addition, threshold values for the prognostic relevance of BPV may differ across 
measurement methods, as do threshold values for mean BP.  
 
Chapter four of this thesis established that there are discrepancies in BP measurement 
between two commonly used methods for measuring out-of-office BP, for the first 
time demonstrating that a discrepancy exists in high-risk patients with a history of 
ischaemic cerebrovascular event. The findings were that daytime ABPM values were 
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on average 7/2mmHg lower than contemporaneous HBPM values, which is at odds 
with guideline recommendations. This difference was consistent over a six-month 
period, however, there were wide limits of agreement between the two methods 
indicating a large variance in their disagreement at an individual level. Furthermore, 
the difference for individuals was not reproducible over time. Overall the findings 
suggest that daytime ABPM and HBPM are not interchangeable methods of measuring 
BP and values from one cannot be used to infer values from the other. Rather, they 
may be better considered complementary methods of BP measurement [111]. Given 
the relationship between BP and BPV, it follows that daytime ABPM and HBPM are also 
unlikely to be interchangeable methods of measuring BPV and this assertion is 
supported by reports comparing BPV derived from the two methods [118, 160]. The 
findings from chapter four add to the existing evidence base regarding the equivalence 
(or otherwise) of daytime ABPM and HBPM, and are in agreement with the majority of 
similar studies that have enrolled lower risk populations [106, 112, 116, 121, 247]. 
However, there is inconsistency in the data, with other studies reporting no 
differences [115, 119], or daytime ABPM values greater than HBPM [118, 120]. Most of 
the studies to date, including the one presented in this thesis, are limited by relatively 
small sample size and may lack the necessary statistical power to reach a definite 
conclusion. The study by Mancia et al. is larger than the others, but is limited by the 
use of an HBPM protocol that is not consistent with guideline recommendations, being 
based on just two measurements taken on consecutive days [120]. Consequently, 
additional research is likely to be necessary to clarify this issue. 
 
The study in chapter five demonstrated similar discrepancies between different 
timescales of BPV measurement in the same population. From comparison of the raw 
BPV values from different measurement methods it was clear that they were not the 
same, regardless of the technique of calculation. Further analysis demonstrated that 
there were no meaningful correlations between beat-to-beat and the other timescales 
of BPV assessed, and the agreement between methods was poor. The relationship 
between beat-to-beat and within-hour BPV was closer than for other comparisons, but 
the level of agreement remained insufficient to suggest that they could be considered 
equivalent. Beat-to-beat BPV has not previously been thoroughly compared with other 
timeframes of variability, despite evidence indicating that it may be of particular 
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prognostic significance post stroke regarding recovery and recurrent events [15, 98, 
200], perhaps because beat-to-beat BP measurement is less commonly used in clinical 
practice. The findings of this chapter were in keeping with the existing literature. 
Although limited evidence suggests that the different statistical methods used to 
calculate BPV are strongly correlated when applied to the same set of BP 
measurements [157, 259], the same is not true of different timescales of BPV [118, 
134, 160, 200]. All timescales of variability appear to be predictive of cardiovascular 
risk [128, 131, 200, 252-254], yet their prognostic value may not be equal [90, 131, 
155]. Therefore, uncertainties remain about the clinical value and application of BPV. It 
is possible that all timescales of BPV are prognostically relevant, but that threshold 
values for abnormal variability differ according to the timescale of measurement (as 
threshold values for hypertension differ according to the method of measurement). 
Alternatively, it is also possible that BPV over different timescales is not a singular 
phenomenon, representing different underlying pathophysiological processes [134, 
167, 170, 174, 256, 258], and that some timescales may be more relevant in certain 
patient groups than others. To further our understanding of this issue, additional 
research is required to establish which (if any) measurement of BPV is the most 
relevant to clinical outcomes as this will help with standardisation of BPV 
measurement and facilitate more robust research regarding therapeutic intervention 
targeted at BPV. How this might be achieved will be discussed further below. 
 
9.2 Studies Investigating the Therapeutic Intervention in Blood Pressure Variability 
Post Stroke 
 
Chapters six to eight investigated the potential of BPV as a therapeutic target following 
an ischaemic cerebrovascular event. Chapter six was primarily concerned with the 
question of who to treat, looking to see if there were relationships between BPV and 
stroke severity or affected cerebral hemisphere, whereas chapters seven and eight 
focussed on the possibility of using existing antihypertensive medications to reduce 
BPV. The findings from the previous experimental chapters indicated that different 
methods of measuring BP and BPV post stroke are not equivalent. Therefore, these 
studies incorporated multiple methods of measurement to see if any findings were 
consistent across timescales of BPV. There is currently a paucity of evidence 
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investigating the effect of treatments to reduce BPV post stroke/TIA. However, there is 
a growing body of data indicating that increased BPV in, both the acute and subacute 
periods following an ischaemic cerebrovascular event, is associated with clinical signs 
of poor prognosis, such as haemorrhagic transformation [184-187], or END [188, 189], 
and poor long-term functional outcome [98, 192, 194-199]. Importantly, it remains 
unclear whether interventions to reduce BPV would be beneficial in all patients with 
an ischaemic stroke, or what treatments would be most effective at reducing BPV. 
 
Chapter six aimed to address the question of whether all patients with a recent 
ischaemic cerebrovascular event might benefit equally from treatment to reduce BPV 
by investigating whether there are relationships between baseline BPV and stroke 
severity, or the cerebral hemisphere affected by the ischaemic event. The study found 
that there were significant relationships, independent of mean BP, between short-
term BPV from daytime ABPM and both NIHSS and OCSP classification. The 
relationships were consistent and, perhaps surprisingly, suggested that BPV was 
greater in patients with lower NIHSS and a classification of LACS. Interestingly there 
were no relationships demonstrated for BPV derived from enhanced CBPM or beat-to-
beat BP measurements. Furthermore, no relationships between BPV and the affected 
cerebral hemisphere were found. The findings regarding BPV and stroke severity were 
consistent with the only other study to have reported on BPV in relation to OCSP 
classification, which also indicated that baseline BPV was greater in patients with LACS 
than PACS, TACS, or POCS [13]. As previously discussed in section 6.7, it is not possible 
to prove a causal relationship between LACS and increased BPV based on this cross-
sectional analysis. It may be the case that having a lacunar infarct leads to increased 
BPV, but it is also possible that increased BPV may be more likely to cause lacunar as 
opposed to larger infarcts. This is possibly as a result of pulsatile haemodynamic stress 
on cerebral small vessels [269, 270], which could cause endothelial damage or 
vasospasm resulting in critically reduced CBF and/or blood-brain barrier dysfunction 
leading to stroke [266, 268]. These findings raise two interesting questions. Firstly, 
would treatment aimed at reducing BPV post stroke have the greatest potential 
benefit in patients with lacunar stroke? Secondly, would treatment aimed at reducing 
BPV for primary stroke prevention result in greater reductions in the rate of lacunar 
stroke compared to cortical stroke? The negative result in terms of affected 
 186 
 
hemisphere may be due to a methodological issue with the study. Whilst there is 
debate that central nervous system input to autonomic function may be lateralized 
[63, 179][63, 180][63, 179][63, 180][63, 180][63, 176][63, 180][63, 180][63, 180][63, 
180][63, 180][63, 179][63, 180][63, 180][63, 180][63, 180][63, 180][63, 180][63, 
180][63, 180], it is likely that specific regions within each hemisphere, for example the 
insular cortex are relevant rather than the whole hemisphere itself [265]. It was not 
possible to classify participants in this cohort based on the cerebral regions involved in 
their ischaemic stroke beyond the left or right hemisphere due to the data that was 
available. Therefore, it is possible that this study was not adequately designed to 
demonstrate relationships between BPV and stroke location and further investigation 
of this is advised. 
 
Given that the results of chapter six indicated an inverse relationship between 
increased BPV and stroke severity, and the findings from other studies demonstrating 
a link between increased BPV post stroke and adverse outcomes, the question of how 
BPV could be mitigated is pertinent. In chapter seven the possibility of differential 
effects on baseline BPV, post ischaemic stroke or TIA, of two commonly used classes of 
antihypertensive medications (CCB or ACEI/ARB) was investigated compared to 
control. This analysis was based on existing, but limited evidence of a possible 
difference in effect on BPV from different antihypertensive medication classes, with 
CCB reported to lower BPV and ACEI/ARB reported to be neutral or possibly increase 
BPV [201, 203, 211]. These two medication classes were also chosen for comparison as 
they are recommended first-line agents for the treatment of hypertension [91], and 
both have a role in secondary stroke prevention treatment. There is evidence that 
vasodilatory antihypertensives may be particularly effective for preventing recurrent 
stroke [219, 273], which supports the use of CCB (and thiazide-like diuretics) in this 
population. Similarly, there is evidence that ACEI/ARB can inhibit atherosclerotic 
processes [59], which suggests they may have benefits to stroke and cardiovascular 
disease risk in addition to BP lowering. Although this study did not show any 
differences in BPV when a CCB based regimen and an ACEI/ARB based regimen were 
separately compared to control, it did suggest a non-significant contrasting trend for 
the two groups in short-term BPV from daytime ABPM. The trend suggested that BPV 
was reduced compared to control in those participants taking a CCB whereas it was 
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increased in those taking an ACEI or ARB. This is consistent with the existing literature. 
I have already discussed that the analysis may have lacked sufficient statistical power 
to demonstrate a difference in the two comparison groups, and with beat-to-beat BPV 
only being recorded in a subgroup of participants this would have had a greater impact 
on this aspect of the study. Also, the use of a cross-sectional design, looking only at 
baseline BPV and not change in BPV over time, may have limited my ability to detect a 
difference. This design was chosen due to the constraints of the available data, with 
different follow-up periods in the trials that provided data preventing a coherent 
analysis of change in BPV over time, but pooling data from the three trials felt to be 
necessary in order to increase the sample size. Despite the overall negative findings of 
the study in chapter seven, the consistency of the findings from this and the preceding 
experimental chapter suggest that ABPM may be the most appropriate measurement 
technique for future investigations of BPV post stroke. Overall, there remains a need 
for dedicated prospective trials to investigate the use of existing antihypertensive 
medications to reduce BPV following stroke, and in other patient groups.  
 
The CAARBS feasibility trial, described in chapter eight, attempted to address this gap. 
To the best of my knowledge it is the only prospective RCT investigating interventions 
to reduce BPV following ischaemic stroke. Unfortunately, this feasibility trial 
highlighted various issues that might hinder a definitive RCT if the protocol as initially 
proposed were scaled up, the main issue being the high rate of patient ineligibility with 
the chosen inclusion/exclusion criteria. However, there was some encouragement that 
a further trial could be successful as the retention rate of successfully randomised 
participants was reasonable, compliance with the treatment interventions and BP 
measurements was generally good, and the interventions were shown to be safe. 
Furthermore, descriptive analysis of the BPV data indicated that it was possible to 
measure a change in BPV over three months following an ischaemic cerebrovascular 
event, and there did appear to be a difference in the change in BPV between the two 
trial arms (though this was not formally tested). To be viable any future trial would 
clearly need to have modified eligibility criteria, yet as this remains a significant gap in 
the evidence regarding BPV and ischaemic stroke it is my opinion that it would be 
worth pursuing. 
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9.3 Future Research Directions 
 
The findings from this thesis have advanced our understanding of the measurement of 
BP and BPV post stroke, have provided useful insights into how to further investigate 
the potential treatment of BPV, and indicate that certain subgroups of ischaemic 
stroke patients may particularly benefit from this treatment if proven to be successful. 
Uncertainties remain regarding the equivalence of out-of-office BP measurement 
methods, the optimum method for measuring BPV, and whether established 
antihypertensive medications might also be directed against BPV. Consequently, 
further research into these questions is necessary. With regard to the equivalence of 
daytime ABPM and HBPM in the assessment of mean BP, further large-scale direct 
observational comparisons taking ABPM as the reference standard may be useful. 
Likewise, further direct comparisons of different timescales of BPV may be helpful. This 
could be achieved with a large-scale cross-sectional cohort study, though without 
follow-up data over at least three months it would not be able to incorporate long-
term visit-to-visit variability, which probably requires a minimum of four visits to be 
calculated accurately [123]. Ideally the cohort would recruit participants across a range 
of ages, with a balanced mix of gender and ethnicity, a mixture of higher/lower risk 
cardiovascular profiles, and treated/untreated for hypertension as these are factors 
which may influence differences between daytime ABPM and HBPM or BPV 
measurements [106, 113, 114, 130, 238, 251, 287]. This would also improve the 
generalisability of any findings. Alternatively, an independent patient data meta-
analysis of existing studies may be another method to investigate differences between 
daytime ABPM and HBPM, though there may be insufficient studies to apply this 
method to the question of equivalence of BPV over different timescales. Whilst this 
may be quicker and more cost-effective than a de novo cohort study, it may be 
hindered by study heterogeneity. In particular, the lack of standardisation of BP 
measurement across existing studies and the use of HBPM protocols not consistent 
with current guidelines could make statistical meta-analysis difficult.  
 
Rather than further cross-sectional comparisons, it may be more meaningful to 
generate outcome driven data for mean out-of-office BP and different timescales of 
BPV. Specifically, it would be useful to establish threshold values at which the risk of 
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cardiovascular disease events begins to rise, this need being echoed by the European 
Society of Hypertension statement on BPV [156]. One study has addressed this for 
HBPM [241], but outcome driven data for both ABPM and HBPM in the same cohort 
has not been acquired. Similarly, only one study has addressed this for BPV, using 
medium-term variability derived from HBPM [118]. Whilst it is possible that 
retrospective analyses of existing cohort or registry data may be able to fulfill this 
need, they may be limited by the number of potential participants available with good 
quality baseline data from both ABPM and HBPM, and they are unlikely to provide 
data for beat-to-beat BPV. Therefore, despite the obvious difficulties of the lengthy 
required follow-up for identification of cardiovascular events and the cost of such long-
term follow-up, a prospective observational trial would probably generate more 
accurate and robust data. When reported, the primary outcomes from the BPV 
observational trial will address some of these issues in a population with stroke. Once 
it is clarified whether a particular timescale and/or statistical calculation for BPV has 
greater prognostic value, then it will be possible to provide guideline 
recommendations on the measurement of BPV for research and clinical practice, 
thereby standardising the approach. 
 
Whether the relationship between increased BPV and lacunar stroke reported in this 
thesis is genuine, and whether there is evidence that lacunar stroke is a causal factor 
for increased BPV, could also be investigated in a further large-scale cohort study, 
provided a sufficient case-mix of stroke subtypes was recruited. Alternatively, it could 
also be addressed as a secondary outcome in a future prospective RCT investigating 
the possible treatment of BPV post stroke. The latter option would provide the 
advantage that longitudinal BPV could also be assessed in addition to baseline and 
there would be standardisation of BP treatment, which would minimise the impact of 
this as a confounding factor. To investigate a possible reverse causal relationship 
between lacunar stroke and BPV it may be simplest to retrospectively review registry 
data, first identifying patients with a variety of stroke subtypes and then looking back 
to see identify any between-group differences in variability preceding the qualifying 
stroke event. This may be limited to CBPM measurements (either within-visit or visit-
to-visit variability over time), but could be sufficient to demonstrate the possibility of a 
relationship. Ultimately, this may remain a secondary question until it is proven that it 
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is possible to reduce BPV with treatment, and that this treatment has an impact on 
clinical outcomes in addition to reducing mean BP, hence pursuing the option of 
performing a secondary analysis of a future prospective RCT may be the most sensible. 
 
As previously mentioned, it is my belief that a further prospective RCT to investigate 
the effect of existing antihypertensive medications on BPV post stroke would be of 
value. The experience of CAARBS indicates that any such trial would certainly need 
modified eligibility criteria. However, if these criteria were altered to retain a longer 
window of eligibility post symptom onset, allowed the inclusion of patients with 
recurrent stroke and possibly also AF, and allowed for the inclusion of patients on 
multiple antihypertensive agents, then there is the potential to substantially improve 
patient eligibility. The employment of minimisation criteria to ensure balanced trial 
arms and statistical adjustment for factors which may confound any effect on BPV of 
the chosen intervention would be necessary, with or without the pre-specification of 
subgroups for analysis (e.g. analysing patients with first vs. recurrent stroke 
separately). Using the same intervention arms for comparison remains reasonable, as 
CCB and ACEI/ARB are the most commonly used antihypertensive drug classes and so 
this will maximise the clinical relevance of any findings. Also, until such time as it is 
proven that one particular method of measuring BPV has greater prognostic value than 
others, or the measurement of BPV is standardised, it would remain advisable to 
employ multiple BP measurement techniques in any future trial. Finally, it was a 
secondary aim of CAARBS to try and establish estimates of intervention effect size that 
could be used to calculate the necessary sample size for a future definitive trial. 
Unfortunately this was not possible due the limited number of participants recruited 
and so it remains a crucial step in planning any further trials of this nature. To that end 
a further feasibility study may be required, which would have the advantage of being 
able to test the modifications to the inclusion/exclusion criteria suggested above. 
Alternatively, if sufficient funding could be secured, it may be possible to pursue a 
definitive RCT immediately, but with an embedded pilot study to allow for further 
adjustments of the recruitment target or eligibility criteria if necessary. 
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Appendix B - National Institutes of Health Stroke Scale (NIHSS) 
 
 
Category 
 
Score/Description 
Date/Time 
Initials 
1a Level of         Consciousness 
(Alert, drowsy, etc) 
0 = Alert 
1 = Drowsy 
2 = Stuporous 
3 = Coma 
 
1b LOC Questions 
(Month, age) 
0 = Answers both correctly 
1 = Answers one correctly 
2 = Incorrect 
 
1c LOC Commands 0= Performs both correctly 
1= Performs 1 correctly 
2= Performs none correctly 
 
2  Best Gaze 
(Eyes open – patient follows examiner’s finger 
or face 
0 = Normal 
1 = Partial gaze palsy 
2 = Forced deviation 
 
3 Visual Fields 
(introduce visual stimulation/threat to pts 
visual field quandrants) 
0 = No visual loss 
1 = Partial hemianopia 
2 = Complete hemianopia 
3 = bilateral hemianopia (Blind) 
 
4 Facial Paresis 
(Show teeth, raise eyebrows and squeeze eyes 
shut) 
0 = Normal 
1 = Minor 
2 = Partial 
3 = Complete 
 
5a Motor Arm - Left 
5b Motor Arm – Right 
(elevate arm to 90º if patient is sitting, 45º if 
patient supine 
0 = No drift 
1 = drift 
2 = Can’t resist 
gravity 
3 =No effort 
against gravity 
4 = No 
movement 
 
Left 
 
 
Right 
 
6a Motor Leg - Left 
6b Motor Leg – Right 
(elevate arm to 90º if patient is sitting, 45º if 
patient supine 
0 = No drift 
1 = drift 
2 = Can’t resist 
gravity 
3 = 
4 =  
 
Left 
 
 
 
Right 
 
7 Limb Ataxia 
(finger-nose, heel down shin) 
0 = No ataxia 
1 = Present in one limb 
2 = Present in two limbs 
 
8 Sensory 
(Pinprick to face, arm, trunk and leg – 
compare side to side 
0 = Normal 
1 = Partial loss 
2= Severe loss 
 
9 Best Language 
(Name item, describe a picture & read 
sentences) 
0 = No aphasia 
1 = Mild to moderate aphasia 
2 = Severe aphasia 
3 = Mute 
 
10 Dysarthria 
(Evaluate speech clarity by patient: repeating 
listed words) 
0 =  Normal articulation 
1 =  Mild to moderate slurring of words 
2 = Near to unintelligible or worse 
X = Intubated or other physical barrier 
 
11 Extinction & Inattention 0 =  No neglect 
1 =  Partial neglect 
2 =  Complete neglect 
 
                                                                                   TOTAL SCORE  
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Appendix C – Modified Rankin Scale (mRS) 
 
 
 
Provided by the Internet Stroke Center — www.strokecenter.org 
MODIFIED Patient Name: ___________________________  
RANKIN Rater Name: ___________________________  
SCALE (MRS) Date: ___________________________  
 
Score Description 
 
0 No symptoms at all 
 
 
1 No significant disability despite symptoms; able to carry out all usual duties and activities 
 
 
2 Slight disability; unable to carry out all previous activities, but able to look after own affairs 
without assistance 
 
 
3 Moderate disability; requiring some help, but able to walk without assistance 
 
 
4 Moderately severe disability; unable to walk without assistance and unable to attend to own bodily 
needs without assistance 
 
 
5 Severe disability; bedridden, incontinent and requiring constant nursing care and attention 
 
 
6 Dead 
 
 
TOTAL (0–6): _______ 
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handicap in stroke patients.” 
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Appendix D – Consent forms for trials contributing data to this thesis 
 
 
 
 
 
Dr Phyo Kyaw Myint 
Consultant Stroke Physician 
Gunthorpe Acute Stroke Unit 
 
 
CONSENT FORM– PERSON WITH STROKE/TIA 
 
Title: TEST-BP: Trial of the Effectiveness and cost effectiveness of Self-
monitoring and Treatment of Blood Pressure in secondary prevention following 
Stroke or Transient Ischaemic Attack (TIA)  
 
Name of Chief Investigator: Dr Phyo Kyaw Myint  
                Please initial box 
 
1. I confirm that I have read and understand the information sheet  
 dated ---------------(Version …….) for the above study, have had the  
 opportunity to ask questions and had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to  
 withdraw at any time, without giving any reason, without my medical  
 care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked 
  at by responsible individuals from the Norfolk & Norwich Hospital or from  
  regulatory authorities where it is relevant to my taking part in research.     
 I give permission for these individuals to have access to my records held 
 in NHS hospital/GP surgery and/or private health provider. 
 
4. I understand that a researcher will periodically contact me, arrange to  
Participant Trial Number:  Initials:  
Date of Birth:  
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 visit at home and ask me to fill in a number of questionnaires.   
 
5. I agree to my GP being informed of my participation in the study. 
 
 
6. I understand that I may receive a number of home visits from a nurse  
 to help me to be able to use BP monitors. 
 
7. I understand that, I may be invited to take part in an interview about how  
 I have found my treatment and what impact it has had on me and  
 give my permission for this to be audio recorded. If I am interviewed agree  
 to my anonymous quotations being used for the project report and publications. 
 
8. I agree to take part in this study.     
 
________________________ ________________
 ____________________ 
Name of Participant  Date Signature 
 
 
 
 
_________________________ ________________
 ____________________ 
Researcher   Date 
 Signature 
Original stored in Central Study File; 1 copy for the patient; 1 for filing in the participant’s medical records 
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Prof John Potter 
Professor of Ageing and Stroke Medicine 
Older People’s Medicine 
Protocol reference : Version 3 
Ethics Approval Reference: 15/EE/0061 
Patient Identification Number for this trial:  
Patient Hospital Identification Number: 
 
PARTICIPANT CONSENT FORM  
 
Trial title: SERVED Memory: Feasibility study of Screening & Enhanced Risk 
  Management for Vascular Event related Decline in Memory 
Short Title:  SERVED Memory 
 
Name of Principal Investigator: Prof John Potter  
                Initial each box 
 
3. I confirm that I have read and understand the information sheet  
 dated _________ (Version …….) for the above study and have had the  
 opportunity to ask questions and had these answered satisfactorily.  
 
4. I understand that my participation is voluntary and that I am free to  
 withdraw at any time, without giving any reason, without my medical  
 care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked 
  at by responsible individuals from the Norfolk & Norwich Hospital or from  
  regulatory authorities where it is relevant. I give permission for these 
 individuals to have access to my records held in NHS hospital/GP surgery 
 and/or private health provider. 
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4. I understand that a researcher will periodically contact me to arrange 
  hospital visits and will ask me to fill in a number of questionnaires.   
 
5. I agree to my GP being informed of my participation in the study. 
 
 
6. I understand that I my GP will be informed of my cognition status and will 
 be informed of any vascular risk factors that I may have . 
 
 
7.I agree to take part in the SERVED Memory study. 
     
 
________________________ ________________
 ____________________ 
Name of Participant  Date Signature 
 
 
 
_________________________ ________________
 ____________________ 
 
Researcher   Date 
 Signature 
Original stored in Central Study File; 1 copy for the patient; 1 for filing in the participant’s medical records 
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PARTICIPANT CONSENT FORM 
VERSION 1.0, DATED 30 JANUARY 2017  
 
 
A Calcium channel or Angiotensin converting enzyme inhibitor 
/Angiotensin receptor blocker regime to reduce Blood pressure variability 
in acute ischaemic Stroke (CAARBS): A Feasibility Trial 
 
 
Participant ID:________ 
 
 
Please initial each box 
 
1. I confirm that I have read and understand the Participant Information Sheet 
Version 1.1, dated 03 May 2017 for the above study, and have had the 
opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving reason, without my medical care or legal rights 
being affected. 
 
3. I understand that my GP will be informed about my participation in this 
study, and by signing this consent form I am granting permission for this. 
 
4. I understand that relevant sections of my data collected during the study may 
be looked at by responsible individuals from the study team, the sponsor, NHS 
Trust or from regulatory authorities, where it is relevant to taking part in this 
research. I give permission for these individuals to have access to my records. 
 
5. I understand that participating in this study will involve me being prescribed 
medication with the intention of lowering my blood pressure. 
 
 
6. I understand that my data will be transferred to the University of Leicester and  
the University of East Anglia for analysis.  
 
 
 
7. I agree to take participate in this research study. 
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____________  ____________  ____________ 
Patient   Date    Signature 
 
____________  ____________  ____________ 
Researcher   Date    Signature 
 
(File: 1 copy for patient, 1 copy for researcher, 1 copy for hospital notes) 
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Appendix E – Regulatory approvals for CAARBS 
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